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   Abstract                                                              
Background:   Early identification of psychosis and intensive treatment has been the 
focus of the treatment of people with a first episode (FE) schizophrenia spectrum disorder 
(SSD). Attrition rates in studies of people in the first episode are high, which makes it 
difficult to understand the meaning of the study outcomes. High attrition rates affect the 
validity of a study by decreasing its power and the study’s ability to detect differences 
between treatment groups. Additionally, the people who leave a study may be different 
from those who stay in demographic, illness and treatment characteristics.  
Method:  This study is a secondary analysis of a group of FE SSD participants enrolled in 
one of three separate double-blind, randomized, drug trials. The variables were first 
analyzed across the three drug study data sets to determine if the patient populations are 
comparable across the three studies to allow for the merging of the data.  Exploratory and 
descriptive statistics of study participants were conducted in a comparison of the three 
studies, for the merged group, and for the attrition and non-attrition groups. Effect sizes 
(Cohen’s d) were calculated for each variable in the individual studies and in the merged 
dataset for the magnitude of difference between the attrition and non-attrition groups.  
Results:  The three studies were merged after analysis found no consistent difference in 
demographic and illness characteristics between the three studies. There was no 
significant difference between the attrition and non-attrition groups in the merged data in 
demographic and illness characteristics. Treatment characteristics consistently found lack 
of efficacy and patient withdrawal of consent to be the two most frequent reasons for 
attrition from the studies. In addition, participants receiving a typical agent were less  
likely to complete the study. Effect size calculations found attrition group to more likely 
be Caucasian, with a lower median income. The attrition group had more years of 
education, but was not in school in the year previous to hospitalization.  
Conclusion: Historically, attrition is a major problem in clinical trials of people in a first 
episode of schizophrenia spectrum disorders. People receiving typical antipsychotic 
medication are more likely to leave a study. Most common reasons for attrition include 
lack of efficacy and withdrawal of consent.                                                    
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CHAPTER 1 
First Episode Schizophrenia Spectrum Disorders  
Statement of the Problem 
In the past fifteen to twenty years there has been a refocus in the treatment of first 
episode (FE) schizophrenia spectrum disorders (SSD) to early identification of psychosis 
and intensive treatment in the hopes of sustaining remission and preventing relapse. This 
effort has lead to pre- and post-marketing clinical trials conducted with a specific focus 
on FE SSD. Attrition rates in these studies are high which makes it difficult to understand 
the meaning of the study outcomes and to generalize the results (Kane, 2005). High 
attrition rates affect the validity of a study by decreasing its power and the study’s ability 
to detect differences between study groups. Additionally, the people who leave a study 
may be different than those who stay (Streiner, 2002).  
One statistical method for handling missing data created by attrition, commonly 
used in pharmaceutical studies and accepted by the FDA, is Last Observation Carried 
Forward (LOCF). LOCF allows all participants who completed a baseline and at least one 
post randomization visit to be included in the data analysis. In this method, the 
participants’ last assessment score is entered into all missing visits. LOCF has been a key 
data analysis tool in FE SSD clinical trials where attrition rates do not allow for dropping 
cases as the cost of replacing participants is prohibitive (Leon et al., 2006).  More 
recently, questions have been raised in the literature about the lack of theoretical 
underpinnings for this statistical method. Authors wonder if this method results in bias 
and potentially contributes to a distortion of the findings (Barnes, Lindborg, & Seaman, 
2006a; Mazumdar, Liu, Houck, & Reynolds, 1999; Streiner, 2008; Wood, White, & 
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Thompson, 2004). The results from these clinical trials are used to guide practice but the 
findings, based on both a high attrition rate as well as a potentially biased statistical 
method, may be difficult to accurately interpret. 
 This chapter introduces the concept of first episode schizophrenia and describes 
the importance of early diagnosis and intervention. A review of the available literature 
regarding the clinical presentation, neurocognition, epidemiology, risk factors, treatment 
goals, and barriers to effective treatment of individuals experiencing a FE SSD is 
presented in order to lay the groundwork for a proposed study of attrition of subjects 
from clinical trials of medications used to treat FE SSD. 
Background and Significance 
  First episode SSD represents a heterogeneous collection of illnesses that includes 
schizotypal personality disorder, schizophrenia, schizoaffective disorder, and 
schizophreniform disorder. For the purpose of this study schizotypal personality disorder 
will not be discussed because it is a non-psychotic schizophrenia spectrum disorder. The 
SSDs in the psychotic end of the spectrum are defined by a period of psychosis, but 
onset, course and degree of impairment vary markedly. SSDs are characterized by 
delusional and hallucinatory symptoms and decreased levels of psychosocial functioning. 
The psychotic symptoms of SSDs often have an episodic course, with periods of 
symptomatic remission but often without attainment of functional remission. While the 
first episode may vary widely in terms of duration and illness severity, a first episode is 
typically defined as the time period beginning with the initial onset of psychosis and 
ending with the onset of a new or second psychotic episode. The first episode also 
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includes the period of symptom remission prior to the onset of a new, second episode of 
illness.  
 Psychosis onset most often exerts a disruptive impact on afflicted individuals’ 
psychosocial and adaptive functioning, and enhances risk for a variety of negative 
outcomes, including suicide and long term disability (Perkins, Lieberman, & Lewis, 
2006a). As recognition of the functional impact of SSDs matured over the past 20 years, 
burgeoning research and clinical interest in this period of illness development resulted in 
calls for intensive early intervention to reduce disability. A commonly accepted maxim is 
that early identification and treatment of FE SSD is critical to maximize an individual’s 
level of psychosocial functioning and prevent further deterioration in functioning 
(Perkins et al., 2006a).   
This viewpoint has lead to pre and post marketing clinical trials conducted with a 
specific focus on FE SSD in the hope of sustaining remission and preventing relapse. 
Attrition rates in these studies are high. What is not clear is the effect of high attrition 
rates on the results of these studies. This is unfortunate because the findings from these 
clinical trials are used to guide practice. 
Clinical Presentation 
 Schizophrenia Spectrum Disorders (SSD) is a term used to describe a 
heterogeneous disorder with marked variation in onset, course and symptom severity. 
This variability in illness onset (rapid versus slow), course (single episode to multiple 
episodes) and severity (good outcome and recovery to poor outcome with poor recovery) 
means that clinical presentation varies, but all individuals present with positive symptoms 
(psychosis) and many with negative symptoms (impaired social functioning and 
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anhedonia). Additionally, the clinical presentation can be complicated by comorbid 
substance abuse and symptoms of other Axis I disorders including depression, mania, 
post traumatic stress disorder and obsessive compulsive disorder.  
People receive a diagnosis of schizophrenia after having had two or more of the 
following symptoms, delusions, hallucinations, disorganized speech, grossly disorganized 
behavior, and negative symptoms. There must be significant social and occupational 
disability for at least six months, this may include prodromal and residual symptoms. 
When the symptoms have been evident for at least one month but no more than six 
months, then schizophreniform disorder is diagnosed. The diagnosis of schizoaffective 
disorder is given when the psychotic symptoms are prominent, but there is also a 
significant period of time when an episode of major depression or mania has occurred 
after the onset of the psychosis (American Psychiatric Association, 2000). Participants in 
two of the three studies meet DSM-IV diagnostic criteria and the participants in the third 
study meet DSM-III-R diagnostic criteria. The differences between the DSM-III-R 
(American Psychiatric Association, 1987) and DSM-IV (American Psychiatric 
Association, 1994) diagnosis of schizophrenia are minor; the duration of psychosis was 
increased from one week to one month and negative symptoms were added to the 
symptoms listed in criterion A (American Psychiatric Association, 1994). 
Positive symptoms, such as hallucinations and delusions, are perceptual 
abnormalities of the senses and are a hallmark symptom of psychosis (see Table 1) 
(Lindenmayer & Khan, 2006). Most common are auditory hallucinations of one or more 
voices that often make comments about the individual or keep up a running commentary 
(American Psychiatric Association, 2000). Delusional beliefs are another hallmark 
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symptom of SSD (American Psychiatric Association, 2000). There are many different 
types of delusions, such as delusions of being under the control or influence of another 
person or force and paranoid delusions to name two.  For example, a person has the belief 
of being controlled by radio waves coming thru the windows caused by a specific group 
of people. Moreover, hallucinations and delusions can be dangerous for the individual 
and others if an individual acts on these altered perceptions and beliefs. Positive 
symptoms and cognitive dysfunction can cause severe disruption in behavior and 
attention resulting in disorganization. This disorganization may be behavioral in nature 
and/or include grossly disorganized speech such as derailment or loose associations. 
Other criteria for schizophrenia include a significant disruption in psychosocial and 
occupational functioning (American Psychiatric Association, 2000).   
 Negative symptoms (see Table 1) are another common characteristic of SSD and 
are a distinct construct found to be separate from social cognition and neurocognitive 
deficits (Andreasen, 1982; Andreasen, Flaum, Swayze, Tyrrell, & Arndt, 1990; 
Carpenter, Heinrichs, & Wagman, 1988; Sergi et al., 2007; Stahl & Buckley, 2007). 
Alogia, affective flattening, anhedonia and avolition are the most common negative 
symptoms (Malla et al., 2002). People with negative symptoms are often quiet, non-
talkative and often keep to themselves. Family members and caregivers may see these 
behaviors as less troublesome than positive symptoms, but fail to appreciate how much 
they may interfere with social and occupational functioning (Stahl & Buckley, 2007). 
Additionally, depression, anxiety, and side effects of antipsychotic medications can serve 
as secondary causes of negative symptoms (Lindenmayer & Khan, 2006). Hence, 
treatment of these secondary influences is critical. Moreover, unlike chronic 
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schizophrenia, first episode negative symptoms may change over time suggesting they 
may be more malleable to treatment interventions (Edwards, McGorry, Waddell, & 
Harrigan, 1999; Stahl & Buckley, 2007; Subotnik, Nuechterlein, Ventura, Green, & 
Hwang, 1998). Therefore, early identification and treatment are critical for negative 
symptoms as well. 
Table 1. 
Positive and Negative Symptoms 
________________________________________________________________________          
         
Symptom     Results in: 
________________________________________________________________________ 
 
UPositive 
Hallucinations Distorted or altered perceptions 
Delusions Inferential thinking 
Disorganized speech  Difficulty in communication with disordered 
thoughts and language 
Bizarre behavior Dysinhibition of self monitoring of behavior 
UNegative 
Affective flattening or blunting         Decreased range of affect, facial expression, eye  
               contact and gestures 
 Reduced experience and perception of emotions 
Alogia               Poverty of speech and thought content 
 Increased latency of response 
Avolition and Apathy Decreased energy, interest, desire, motivation and 
drive in activities of daily living and occupational 
functioning 
Anhedonia  Decreased ability to experience pleasure in 
previously enjoyed activities 
Asociality  Decreased interest in recreational, social and sexual  
                                                           activities 
_______________________________________________________________________ 
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Early Course 
The early course of SSD can be divided into three time periods or phases: 
premorbid functioning, prodrome, and the onset of psychotic (i.e., positive) symptoms 
(Perkins, Miller-Anderson, & Lieberman, 2006b). Premorbid functioning is the time that 
the individual is engaged in usual psychosocial and academic functioning prior to 
prodrome but with a range of functioning from good to poor (Addington, van Mastrigt, & 
Addington, 2003; Lieberman et al., 2001). However, subtle motor and cognitive deficits, 
as well as difficulties in academic and social functioning, have been noted in individuals 
during their childhood prior to the onset of prodrome (Gold, 2004). Adding to the 
heterogeneity of the illness presentation is the heterogeneity associated with this 
premorbid period. In retrospective studies of those individuals with established SSDs, 
approximately 47.5% show relatively normative early levels and patterns of development, 
while 37.3% show subtle and 15.2% significant premorbid difficulties (Malla & Payne, 
2005).  
Prodrome has been defined as the time period when there is a change from 
premorbid level of functioning to the earliest signs and symptoms of the emerging 
disorder, and most often includes increasing social withdrawal, changes in or worsening 
of mood, impairment in role functioning (a decrease in school grades is common), 
blunted or inappropriate affect, poor hygiene, peculiar or odd thoughts and beliefs, and a 
decrease in interest, motivation, energy, and concentration (Tully & McGlashan, 2006). 
These changes in behavior and functioning may be non-specific and can be associated 
with a variety of other problems such as stress, depression, substance use, and post 
traumatic stress disorder (Larsen, McGlashen, & Moe, 1996). The most common co-
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morbid diagnoses for individuals in the prodrome are mood disorders, alcohol and drug 
abuse/dependence, especially cannabis, and anxiety disorders (Addington et al., 2007; 
Meyer et al., 2005; Rosen, Miller, D'Andrea, McGlashan, & Woods, 2006).  
During the prodrome phase of illness, non-specific negative symptoms also have 
been noted retrospectively to occur in up to 78% of people with a FE SSD (Rakfeldt & 
McGlashan, 2004). The prodrome phase can last from a period of weeks to 2 – 5 years 
and ends with the emergence of frank psychotic symptoms meeting criteria for a SSD. 
During the prodrome phase, individuals may experience either attenuated or brief 
intermittent psychotic symptoms that are infrequent and short lived, lasting a matter of 
minutes. These attenuated or brief psychotic symptoms lack a psychotic level of 
conviction and belief and do not cause associated avoidance or other psychotically-
motivated behavior (Addington et al., 2007). 
The prodrome phase ends when the frank psychotic symptoms emerge. This first 
episode of psychosis continues until the resolution or remission of the psychotic 
symptoms. However, the course varies markedly. A minority of people will have one 
episode of psychosis with full recovery, while others will experience a more chronic 
illness with repeated episodes without full recovery (Perkins et al., 2006b). The worst 
outcomes occur for those individuals who have a severe form of this illness and do not 
achieve symptom remission.   
Gender Differences 
 There are a number of gender differences in the occurrence, course and the type 
of symptom expression of the illness found during the time of the first episode and first 
hospital admission (Goldstein, Tsuang, & Faraone, 1989). The belief that schizophrenia 
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occurs equally between men and women has been disputed more recently, as 
approximately 65% of the first episode population is male (Bromet & Fennig, 1999) and 
data suggest males may have a 30-40% higher risk of developing schizophrenia than 
females (Eaton & Chen, 2006). On average men have an earlier onset of psychotic 
symptoms (18-25) than do women (25-35) and women have a second peak onset of the 
illness around menopause (ages 45-55) in studies of the first episode and chronic 
schizophrenia, (Eaton & Chen, 2006; Gelber et al., 2004; Shtasel, Gur, Gallacher, 
Heimberg, & Gur, 1992; Szymanski et al., 1995). However, this age at onset difference is 
not always statistically significant (Eaton & Chen, 2006; Ganguli & Brar, 1992).   
 In first episode studies, men have a lower premorbid level of functioning than do 
women, especially during late adolescence (Gelber et al., 2004; Preston, Orr, Date, 
Nolan, & Castle, 2002). Males with schizophrenia are more apt to have developmental 
problems such as learning disabilities and delays in starting school. Those with 
developmental problems have significantly more deficits in neuropsychological 
functioning (Goldstein, Seidman, Santangelo, Knapp, & Tsuang, 1994). Women tend to 
be more impulsive, with inappropriate sexual behavior and paranoid and depressive 
symptoms (Goldstein & Link, 1988). Men have more negative symptoms, with more 
isolation and withdrawal, and with lower levels of psychosocial functioning (Goldstein & 
Link, 1988; Goldstein et al., 1989; Roy, Maziade, Labbe, & Merette, 2001; Shtasel et al., 
1992).  
 In general, males with schizophrenia have more neurocognitive deficits than do 
male healthy controls and female patients on tests of attention, verbal memory and 
executive functioning. Goldstein et al. (1998) reported that women with schizophrenia 
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are less impaired in verbal processing, but are still impaired in tests of attention, 
executive functioning, visual memory, and motor functions relative to female control 
subjects. The reason for these gender differences is poorly understood but may be related 
to normal sex differences in brain physiology and cognition (Goldstein et al., 1998). 
Additionally, Hoff et al. (1998) found no gender difference in neurocognitive functioning 
in men and women experiencing a first episode SSD as compared to those with chronic 
schizophrenia. Szymanski et al. (1995) observed that women in a first episode of SSD 
had a better pharmacological treatment response with greater symptomatic improvement 
than men. 
Neurocognition 
Although the diagnosis of schizophrenia is based on the duration and severity of 
positive and negative symptoms, cognitive deficits have been recognized as a core feature 
of schizophrenia (Keefe & Eesley, 2006). Cognitive deficits remain fairly stable over the 
years from first episode on (Gold, 2004; Heaton et al., 2001; Hoff et al., 1999; Rund et 
al., 2007), and are found in a milder form in first degree relatives of people with 
schizophrenia (Green, 2006). In general, people who develop SSD score 1 to 2 standard 
deviations below normal on many tests of neurocognition (Gold, 2004; Hoff et al., 1999). 
However, there is a broad range of function in individuals with SSD as compared to 
normal control groups (Gold, 2004; Heinrichs & Zakzanis, 1998).  
 In a meta-analysis of neurocognitive deficits in schizophrenia, Heinrichs and 
Zakzanis (1998) described core deficits in seven neurocognitive domains including 
memory, motor, attention, general intelligence, spatial ability, executive function, and 
language function. These core deficits are characterized by problems with abstraction, 
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problem solving and reasoning, working memory, verbal and visual learning, spatial 
memory, attention and vigilance, speed of processing, motor speed, and social cognition 
(Green, 2006; Green, Kern, Braff, & Mintz, 2000). The areas with the largest effect sizes 
on functioning are verbal memory, performance and full scale IQ, attention as measured 
by the continuous performance tests, and word fluency. This study will focus on general 
intelligence, attention, learning, language, memory, executive function, and motor 
functioning. However, many of these domains are interrelated and deficits in one area are 
associated with deficits in another area.  
 Individuals with schizophrenia have full scale estimated IQ scores 0.5 standard 
deviations, a medium effect size, below normal control scores (Woodberry, Giuliano, & 
Seidman, 2008). Impairment in full scale IQ is associated with deficits in working 
memory, processing speed, and memory as compared to healthy controls (Dickinson, 
Iannone, Wilk, & Gold, 2004). This impairment is correlated with poor insight in 
particular, but also with negative symptoms such as affective flattening, alogia, and social 
withdrawal (Sharma & Antonova, 2003).  
 Attention and information processing reflects the ability of the brain to identify 
relevant information or stimuli in the environment, and to sustain that focus as it is 
transferred for other levels of processing. In schizophrenia, difficulty with attention and 
information processing contributes to the executive functioning and working memory 
deficits and, therefore, the ability of the brain to think through problems (Sharma & 
Antonova, 2003).   
 Working memory is the short term, temporary memory system we use to do many 
tasks over the day. The information in working memory is either used and then discarded, 
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or integrated into longer-term memory. Working memory is critically important in 
holding the information, and in the short term, understanding the meaning of that 
information. It may include active rehearsal and processing of the information to guide 
our immediate behavior (Sharma & Antonova, 2003). Working memory deficits are 
significantly correlated with formal thought disorder, an inability to stay on target when 
speaking and include loose associations, tangential and circumstantial speech in people 
with schizophrenia (Spitzer, 1993). People with SSD who have the worst learning and 
memory deficits also exhibited the largest deficits in executive functioning, and attention 
(Bilder et al., 2000) and greater global impairment in other domains as compared to 
normal controls (Fitzgerald et al., 2004).  
 Executive functioning is impaired in all people with schizophrenia but the degree 
of impairment varies greatly and is found to be associated with IQ score (Heinrichs & 
Zakzanis, 1998). Executive function includes the abilities to organize, problem solve, 
develop a plan of action and then carry out that plan, along with an ongoing assessment 
of the self and how that plan is working. This includes the ability to reassess and revise 
the problem solving strategy and plan of action. An adequate level of executive 
functioning requires the use of abstract reasoning to develop different options, to 
anticipate potential outcomes and then to choose the best plan of action. This impairment 
is significantly correlated with poor insight in particular, but also with negative 
symptoms such as affective flattening, alogia, and social withdrawal (Horan & 
Blanchard, 2003; Sharma & Antonova, 2003). 
 The language domain includes both expressive and receptive elements and has 
large effect sizes in people with schizophrenia as compared to normal controls. This 
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includes tests of vocabulary and word fluency. Word fluency may be influenced by high 
doses of antipsychotic medications resulting in lower scores as compared to healthy 
controls (Heinrichs & Zakzanis, 1998).  
 Learning deficits, ranging from medium to large effect sizes, are found in people 
with a first episode SSD (Heinrichs & Zakzanis, 1998). The learning system of the brain 
is very complicated and all parts of the system are not equally affected. Heinrichs and 
Zakzanis (1998) found more consistent deficits in verbal learning than in non-verbal 
learning in people with schizophrenia. Learning deficits are based on the ability to store 
the learning in memory and then to be able to retrieve that information. Sharma and 
Antonova (2003) describe two types of memory, declarative and procedural. Declarative 
memory is the ability to learn from experience and then recall that learning. This deficit 
in declarative memory in people with schizophrenia is not due to forgetting, but to errors 
in encoding, retrieval, and impairments in working memory. This longer term memory is 
known as declarative memory and reflects the ability to learn information and be able to 
remember or recall it at a later time. On the other hand, the ability to learn new skills and 
motor activities, called procedural learning, is characterized by only mild deficits.   
 Motor performance is often included under executive functioning since it is the 
end stage of processing and planning behavior. Motor function is assessed by tests of 
finger tapping or grooved pegboard (Spreen & Strauss, 1998b). Effects sizes of these 
deficits in people with schizophrenia are moderately large and males are less affected 
than females (Heinrichs & Zakzanis, 1998). 
 Cognitive deficits are thought to be relatively independent of clinical symptoms in 
SSD (Gold, 2004; Nieuwenstein, 2001; Velligan et al., 1997), particularly positive 
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symptoms (Keefe et al., 2006b; Stirling et al., 2003) but the data regarding this 
relationship are mixed. Bilder and colleagues (2000) reported that the severity of 
generalized cognitive deficits was weakly associated with severity of psychotic 
symptoms, but only after patients were clinically stable (6 months after hospitalization 
and either in remission or with stable residual symptoms) after a first episode of SSD. 
Stirling et al. (2003) found poor performance on neurocognitive tests predicted higher 
levels of negative symptoms at follow-up in first episode patients. Better premorbid 
functioning has been associated with milder working memory deficits, while the worst 
working memory deficits have been associated with more relapses in the first year (Rund 
et al., 2007). Neurocognitive deficits, particularly the worst attention and executive 
function deficits are associated with more severe psychosocial and functional (work 
related behavior) impairment of people with schizophrenia (Bilder et al., 2000). Stirling 
et al. (2000; Stirling et al., 2003) found treatment outcome to not be associated with 
baseline deficits but instead associated with a decline in neurocognitive functioning from 
baseline to follow-up (on average 10 years later).  
 Disentangling the association between cognitive impairment and social functioning 
is complicated, and is influenced by negative symptoms (Keefe & Eesley, 2006). The 
association between negative symptoms and neurocognitive deficits in learning and 
memory may represent a common set of symptoms that is assessed by two different 
methods (e.g., neurocognitive testing and clinical rating of symptoms) (Fitzgerald et al., 
2004; Keefe & Eesley, 2006). The type of antipsychotic medication may also play a role 
in cognitive and social functioning impairments. Patients switched from typical to 
atypical antipsychotic medications tend to show improved cognition, quality of life and 
  
15
 
  
social problem solving (Keefe & Eesley, 2006). Social functioning deficits (e.g., poor 
social problem solving) have been shown to be most highly associated with poor verbal 
ability and poor verbal memory (Addington & Addington, 2000). 
 Overall, executive function deficits along with problems in attention, memory, and 
learning cause the most impairment in individuals with a FE SSD. These deficits 
contribute to increased difficulty in solving problems, expressing and evaluating 
thoughts, integrating information, detecting inconsistencies between verbal and 
perceptual information, paying attention, and learning new information, along with a 
decrease in mental flexibility (Hoff et al., 1999).  
Epidemiology 
 Currently, researchers have focused only on SSDs in general, and there are no 
published epidemiological studies of first episodes of psychosis. Jablensky (1997) 
emphasized that incidence rates of SSDs vary based on country, region of birth and 
gender in contrast to prior assertions that the incidence rates were homogeneous. 
McGrath (2006) in a review of the literature noted different incidence patterns in the 
Northern Hemisphere as compared to the Southern Hemisphere.  For example, the 
Northern Hemisphere has higher incidence rates in urban areas and among migrant 
workers, and higher latitudes are often associated with season of birth and males  
(McGrath, 2006; Saha, Chant, Welham, & McGrath, 2006), but this is not true in the 
Southern Hemisphere (McGrath & Welham, 1999).  Most researchers have focused on 
the incidence and point and lifetime prevalence of these disorders in different countries. 
Incidence (0.11 to 0.70 per 1,000) and lifetime prevalence (2.7 to 8.3 per 1,000) vary 
depending on the country (Eaton & Chen, 2006). McGrath also noted variance in 
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incidence for different countries depending on which diagnostic criteria were used. For 
example, cities in countries that use the World Health Association CATEGO S+ 
computer generated diagnosis based on a psychiatric rating scale, a narrow diagnostic 
criteria (Aarhus, Denmark to Nottingham, England) reported incidences that range from 7 
to 14 per 100,000 while those that use the ICD-10, a broader criteria (Honolulu, Hawaii 
to Chandigarh, India) reported incidences that range from 16 to 42 per 100,000  
(McGrath, 2005). Even within the US, the prevalence ranged from 6 to 11 per 1,000 
(Faraone, Glatt, & Taylor, 2004).  
 At the individual level, recent data support the notion that there are gender 
differences in rates of SSD (McGrath, 2005). As previously described, males have a 
higher risk (Eaton & Chen, 2006) and an earlier age of onset (Bromet & Fennig, 1999) 
than females as demonstrated by several investigators (Eaton & Chen, 2006; Gelber et al., 
2004; Shtasel et al., 1992; Szymanski et al., 1995). However, gender differences in age at 
onset were not always statistically significant (Eaton & Chen, 2006; Ganguli & Brar, 
1992).  
Risk Factors 
The risk factors associated with vulnerability to SSDs is complicated and likely 
additive. The range of factors broadly implicated in illness development includes genetic 
risk factors/family history, gestational and obstetric-perinatal complications, substance 
abuse and stressful events. Each of these will be reviewed in turn.   
Genetic Risk 
A family history of schizophrenia is one of several risk factors that can result in 
an increased vulnerability to a SSD. The risk of developing schizophrenia varies with the 
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relationship when a relative has a diagnosis of schizophrenia. The lifetime risk for first-
degree family members of people with schizophrenia is 9% for a sibling, 13% for 
children with one parent with schizophrenia, and 46% if both parents have a diagnosis of 
schizophrenia (Tsuang, Stone, & Faraone, 1999). Faraone and colleagues (2004) in twin 
studies showed that the rate of concordance for schizophrenia in monozygotic twins was 
approximately 45% - 75%, while it was 4 - 15% for dizygotic twins and varied depending 
on the specific diagnostic criteria used.  
Researchers studying non-psychotic first-degree relatives of people with 
schizophrenia demonstrated a genetic linkage. Abnormalities similar to those observed in 
individuals with schizophrenia, have been observed to be less severe in the non-psychotic 
first-degree relatives. These non-psychotic first-degree relatives do not have any of the 
clinical symptoms of schizophrenia (Turetsky et al., 2007). These abnormalities have 
been found in brain functioning through magnetic resonance imaging (MRI) (Seidman et 
al., 2007; Seidman et al., 2006; Thermenos et al., 2007), in electrophysiology through the 
use of a specialized functional electroencephalogram (Turetsky et al., 2008) and in 
neurocognition through the use of cognitive test batteries (Bove, 2008; Horan et al., 2008; 
Tsuang et al., 2006). In addition, the degree of abnormality in structural MRI increases in 
the non-psychotic relative as the number of relatives with schizophrenia increases 
(Faraone et al., 2003; Faraone et al., 2000; Seidman et al., 2002). These findings have led 
to a change in the focus of genetic studies from attempts to identify genes associated with 
schizophrenia (phenotypes) to identifying markers of vulnerability (endophenotypes). 
Given that the abnormalities exist, current efforts are focused on identifying the 
endophenotypal genes that control the neurodevelopment of brain structure, function, 
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electrophysiology and cognition found in both affected and non affected family members 
(Seidman & Wencel, 2003; Turetsky et al., 2007). The hope is that identification of 
endophenotypes and phenotype will allow us to better understand the genetic basis of 
schizophrenia (Braff, Freedman, Schork, & Gottesman, 2007). It is important to note 
these markers are not sufficient to cause schizophrenia (Kremen & Hoff, 2004). 
Clinically, identification of the genetic basis of schizophrenia may lead to better ways to 
identify young people at genetic high risk and to provide treatment at the earliest signs 
and symptoms of psychosis.  
Gestational and Perinatal Complications 
 Gestational and perinatal events, such as maternal influenza, starvation, pre-
eclampsia, pregnancy induced hypertension, anoxic birth injuries, prematurity and other 
obstetric complications increase the risk of schizophrenia, with an overall odds ratio of 
2.0 (Clarke, Harley, & Cannon, 2006; Gilmore & Murray, 2006; McClure & Lieberman, 
2003). Other factors include exposure to genital and reproductive tract infections 
(Babulas, Factor-Litvak, Goetz, Schaefer, & Brown, 2006) and other perinatal infections 
such as toxoplasmosis (Dickerson, Boronow, Stallings, Origoni, & Yolken, 2007; 
Mortensen et al., 2007) and meningitis, as well as advanced paternal age (Eaton & Chen, 
2006). These obstetric and perinatal complications do not cause schizophrenia, but 
comprise another set of factors contributing to a vulnerability to SSDs.  
The genetic and perinatal factors may give rise to both structural and functional 
brain and developmental abnormalities in vulnerable individuals. The presence of 
neurological abnormalities contributes another set of factors that lead to a vulnerability to 
SSDs. Neurological abnormalities include hard and soft signs of impairment in sensory 
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functioning, motor coordination (such as difficulty in balance and coordination), reflexes, 
language and cognition, and sequencing problems including difficulty with rhythmic 
behaviors such as finger and toe tapping (Rosso et al., 2000).  Children may exhibit right 
left confusion, and difficulty in audiovisual integration (Bachmann, Bottmer, & Schroder, 
2005).  Signs of neurological dysfunction are found in 50 – 65% of individuals with 
schizophrenia as compared to 5% of normal controls (Heinrichs & Buchanan, 1988) with 
individuals with other psychiatric disorders having fewer of these signs, but more than a 
normal control group (Bombin, Arango, & Buchanan, 2005).  
In schizophrenia, these neurological abnormalities are associated with negative 
symptoms (decreased affect, interest and motivation) and cognitive deficits (impairment 
in memory, attention, reasoning, and problem solving) (Bombin et al., 2005; McClure & 
Lieberman, 2003). Many of these impairments, tied to developmental stages, first arise in 
early childhood through adolescence (Niemi, Suvisaari, Tuulio-Henriksson, & Lonnqvist, 
2003). Several researchers and clinicians have suggested that cognitive deficits, delays in 
speech and motor milestones, and poor academic and social adjustment found in 
childhood may be markers for risk and, as such, contribute or indicate vulnerability to 
later development of schizophrenia (Gold, 2004; Niemi et al., 2003). For example, in a 
follow-back study of individuals with a first episode of schizophrenia, Bilder and 
colleagues (2006) found these patients had significantly lower scores on academic 
achievement tests as compared to matched controls as early as first grade. The gap 
between the two groups (those with schizophrenia and those without) continued to grow 
through 12th grade (Bilder et al., 2006).  
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Substance Abuse 
 Substance use and abuse is both a risk factor and an important barrier to effective 
treatment (the latter will be discussed in a subsequent section of this chapter). In a review 
of substance abuse in FE SSD, Larsen and colleagues (2006) found prevalence rates of  
6% to 44% for those who abused drugs and 3% to 35% for those who abused alcohol. 
Across studies, cannabis appears to be the most commonly used drug, followed by 
alcohol (Buhler, Hambrecht, Loffler, Van der Heiden, & Hafner, 2002; Cantwell et al., 
1999; Green et al., 2004). Substance abuse, in particular cannabis, has been found to 
increase the risk of developing schizophrenia by up to 6 times (Andreasson, Allebeck, & 
Rydberg, 1989). In two recent reviews of large population-based, longitudinal studies, 
cannabis use was noted to double the risk of developing schizophrenia, with the risk 
increasing in proportion to amount of use (Odds Ratio 2.1-21.7) (Zammit, Allebeck, 
Andreasson, Lundberg, & Lewis, 2002), particularly in vulnerable individuals, such as 
those with a family history of psychosis (Henquet, Murray, Linszen, & van Os, 2005; 
Smit, Bolier, & Cuijpers, 2004). A number of investigators have postulated that use for 
several years before the onset of schizophrenia may result in cannabis-induced 
neurobiological changes and an increased vulnerability to schizophrenia. Meanwhile, 
cannabis use may trigger or precipitate illness onset in people who have a preexisting 
vulnerability from genetic, perinatal and environmental factors (Hambrecht & Hafner, 
2000; Henquet et al., 2005).   
 Individuals with SSD who use drugs have been characterized as male and younger 
as compared to those who do not use drugs (Cantwell et al., 1999; Hambrecht & Hafner, 
2000; Larsen et al., 2006; Linszen, Dingemans, & Lenior, 1994), and in particular, those 
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with a premorbid cannabis use disorder have a lower age at onset of SSD (Addington & 
Addington, 1998; Buhler et al., 2002; Green et al., 2004; Linszen et al., 1994). However, 
not all studies have found an association of substance abuse with a younger age at onset 
(Green et al., 2004; Wade, Harrigan, McGorry, Burgess, & Whelan, 2007).   
Stressful Events 
 At the individual level, a sensitivity or vulnerability to stress is often regarded as 
an important risk factor, one that is at the intersection of biological and social influences 
on the disorder onset and/or progression. Stress vulnerability has been documented prior 
to illness onset, during relapse, and in the context of normative daily life events or hassles 
(Goldman & Mitchell, 2004). Goldstein’s (2006) review of the affective arousal system 
in schizophrenia implicates structural and functional neural abnormalities that are 
exacerbated by specific endocrine dysfunction, namely, overactivity of the hypothalamic 
pituitary adrenal (HPA) axis. HPA axis dysfunction may result in neuronal dysfunction 
and hypersensitivity to stress, as seen in schizophrenia.  
Adolescence is a time of endocrine changes and other developmental as well as 
environmental stresses, (e.g. increased social demands, and the use of alcohol and drugs 
of abuse). Taken together, an interaction among genetic, developmental  and environment 
risk factors during the perinatal and peri-adolescent period may result in a vulnerability to 
psychosis and the actual development of psychosis in some individuals (Csernansky & 
Bardgett, 1998; Keshavan, 1999; Keshavan, Gilbert, & Diwadkar, 2006; McClure & 
Lieberman, 2003; O'Donnell & Grace, 1998). This model of vulnerability to psychosis 
suggests that it may be possible to intervene during these early phases to prevent the  
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progression to psychosis as well as the progression and downward course of the illness 
(Keshavan, 1999). 
Goals of Treatment  
 The treatment of people in a first episode of schizophrenia is multifaceted and 
complex, requiring an understanding of many different factors that may influence 
treatment outcomes. The hope of intensive early treatment in the FE is to increase the 
number of people who have only one psychotic episode and achieve both symptomatic 
and functional recovery (about 12%) and decrease relapse rates in those who have 
multiple episodes (Perkins et al., 2006a). First episode SSD has high rates (approximately 
85%) of symptom recovery during the first year after the psychotic episode, but of these 
patients only 56.7% achieve a second year of symptomatic recovery (Lieberman et al., 
1993; Robinson et al., 1999b). This means almost half of the individuals with SSD 
continue to be afflicted with significant symptoms. Moreover, the functional recovery 
rate is much lower (37.9%) in the first episode (Robinson, Woerner, McMeniman, 
Mendelowitz, & Bilder, 2004), with only 10% - 20% of people returning to a level of 
work at which they can support themselves (McGlashen, 1988). Goals essential to 
effective, early treatment include reduction of duration of untreated psychosis, 
maximization of symptomatic and functional recovery through effective treatment, and 
prevention of relapse (Spencer, Birchwood, & McGovern, 2001). Investigators have 
demonstrated better outcomes for people in a first episode SSD when treatment is 
provided within specialized, intensive, treatment programs.  
The President’s New Freedom Commission on Mental Health (New Freedom 
Commission on Mental Health, 2003) emphasized the importance of recovery and the 
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development of resilience as the goal of treatment. Canada, England, Australia and parts 
of Europe have intensive psychosocial treatment in specialized or integrated clinics for 
teens and young adults in the FE (Addington & Gleeson, 2005; Lewis, Tarrier, & Drake, 
2005; Mullen, Murray, & Happell, 2002; Spencer et al., 2001). Thus far, positive 
outcomes at these comprehensive specialized clinics have included better medication 
adherence and increased satisfaction with treatment, and less substance misuse (Penn, 
Waldheter, Perkins, Mueser, & Lieberman, 2005; Petersen et al., 2005), fewer inpatient 
days (Cullberg, Levander, Holmqvist, Mattsson, & Wieselgren, 2002), a decrease in the 
frequency of psychotic episodes (Falloon et al., 1998b) and a decrease in positive and 
negative symptoms (Sanbrook, Harris, Parada, & Young, 2003). It is clear that 
specialized treatment programs can improve treatment outcome, but there remain many 
barriers to effective treatment.  
Barriers to Effective Treatment 
 Clinicians and researchers have identified and discussed numerous barriers to 
effective treatment in the literature. However, the scope of this review will be limited to 
those that have received the most attention and appear to have the greatest impact. Thus, 
this review will exclude system barriers such as the relative absence of specialized 
treatment services in most areas of the US, and the inaccessibility of psychosocial 
treatments such as cognitive behavioral therapy due to lack of trained personnel in mental 
health clinics.  
 Barriers to effective treatment can be viewed as falling into one of three categories: 
(1) those that result in a delay in diagnosis and treatment; (2) those inherent to the illness 
and its treatment; and (3) those that may be related to psychosocial factors. Taken 
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together, these three types of barriers affect the ability of people in FE SSD to achieve 
symptomatic and functional recovery.   
Barrier to Early Diagnosis and Treatment 
 Duration of untreated psychosis (DUP) is a concept used to define a time period 
beginning with the appearance of frank psychotic symptoms and ending with the 
initiation of antipsychotic medication. DUP itself is not a barrier to early diagnosis and 
treatment, but constitutes a way of representing a multitude of issues that prevent an 
individual from seeking treatment, such as delusional beliefs, lack of insight, stigma, and 
mental health literacy, which are harder to measure. DUP is an important, measurable 
concept in the field and a shorter DUP is associated with a better response to 
antipsychotic medication, and improved functional outcome (Perkins, Gu, Boteva, & 
Lieberman, 2005). The DUP for people with SSD ranges anywhere from 4 weeks to 5 
years of untreated psychosis before they start treatment (Eaton & Chen, 2006; Gelber et 
al., 2004; Perkins et al., 2005). A shorter DUP is associated with an acute onset of 
psychosis, greater family involvement (Morgan et al., 2006), pre-psychosis employment, 
and living with a partner (Wunderink, Nienhuis, Sytema, & Wiersma, 2006).   
 In general, many authors have reported outcomes to be worse (as defined by more 
symptoms and decreased functioning) in people with a longer DUP (Black et al., 2001; 
Marshall et al., 2005; Norman, Lewis, & Marshall, 2005). A long DUP has been 
associated with multiple episodes (Altamura, Bassetti, Sassella, Salvadori, & Mundo, 
2001), longer time to remission, poor symptom remission (Loebel et al., 1992; 
Wunderink et al., 2006), greater severity of negative symptoms (Black et al., 2001; 
Perkins et al., 2005; Scully, Coakley, Kinsella, & Waddington, 1997), generalized 
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cognitive impairment (Scully et al., 1997), and severity of positive symptoms (Black et 
al., 2001).  In contrast, investigators have also found that DUP is not associated with 
remission (Ho, Andreasen, Flaum, Nopoulos, & Miller, 2000), substance abuse (Larsen et 
al., 2006), neurocognitive functioning (Hoff et al., 2000; Perkins et al., 2005; Rund et al., 
2007), or positive symptom severity (Ho et al., 2000; Loebel et al., 1992; Perkins et al., 
2005). However, in a critical review, Norman and colleagues (2005) found DUP to be an 
independent predictor of remission of positive symptoms during the first year of 
treatment.  
 Despite all of the studies using DUP as a predictor and a factor associated with 
treatment response and outcome, very little is known about the actual individual reasons 
and/or barriers that prevent individuals from seeking treatment at the onset of a first 
psychotic episode. Psychopathology and psychosocial issues may influence when and 
how an individual seeks and enters treatment and are issues requiring further study. 
Barriers Inherent to Illness and Its Treatment 
 Barriers inherent to the illness and its treatment include individual differences in 
positive and negative symptoms, the phenomenon of relapse, and medication side effects.  
Severe positive symptoms are associated with a decrease in treatment response (Robinson 
et al., 1999b) and a significant correlation between negative symptoms and impaired 
occupational and social functioning, increased financial dependence, and decreased 
global level of functioning in FE SSD (Ho, Nopoulos, Flaum, Arndt, & Andreasen, 
1998). Meanwhile, each relapse episode requires a longer time to recovery (Lieberman et 
al., 1993; Szymanski et al., 1995), and higher doses of antipsychotic medication than the 
previous episode (Lieberman et al., 1993). Moreover, despite the good symptomatic 
  
26
 
  
recovery rates, relapse rates are high in people who have recovered from a first episode of 
SSD. Robinson and colleagues (1999a) reported a cumulative 5 year first relapse rate of 
81.9% and for those who recovered from this first relapse, 78% went on to a second 
relapse.  
Intolerability of antipsychotic medications due to side effects can lead to 
medication non-adherence (Hudson et al., 2004; Perkins, 2002), particularly with respect 
to side effects that mimic Parkinsonian symptoms (Robinson et al., 2002), akathisia 
(Hudson et al., 2004), or cause weight gain, dyslipidemia or diabetes secondary to 
metabolic syndrome (Lieberman et al., 2005a). Other side effects, such as antipsychotic 
drug induced dysphoria, sedation, and sexual side effects also play a role in patients 
choosing to stop their medications (Perkins, 1999, 2002).  
Psychosocial Barriers to Treatment 
In FE SSD barriers to effective treatment and medication adherence includes a 
lack of insight and understanding of the risks of this chronic illness, difficulty getting to 
appointments, and a lack of family support (Perkins, 1999, 2002). Patient self-reports of 
barriers to medication adherence include the stigma of taking medication, forgetfulness, 
and a lack of social supports (Hudson et al., 2004).  
Negative Attitudes Toward Medication 
Medication non-adherence has also been associated with a negative attitude 
toward taking medication. For example, Lacro and colleagues (2002) found in their 
review of studies on medication adherence, that a negative attitude toward medication did 
predict non-adherence. Predictors of a negative attitude toward medication include less 
insight about symptoms, primary negative symptoms, and employment (Freudenreich, 
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Cather, Evins, Henderson, & Goff, 2004). Freudenreich et al. (2004) theorize that the 
relationship between employment and negative attitude reflects either an increased 
awareness of side effects and their effect on functioning, or an awareness of the stigma 
associated with antipsychotic medication as the cause for this negative attitude. Similarly, 
Hudson et al. (2004) found patients identified the stigma of taking medication as a barrier 
to medication adherence.   
Other Barriers 
 Substance abuse.  The use of alcohol and drugs in the time period before and after 
the onset of psychosis presents major challenges to treatment of the first episode. Several 
investigators who collected follow-up data of first episode substance abusers at the 
beginning of the psychotic illness found a significant association with poor medication 
adherence (Buhler et al., 2002; Green et al., 2004; Wade et al., 2007), more severe 
positive symptoms and poorer social functioning (Hambrecht & Hafner, 2000; Wade et 
al., 2007). The ongoing use of cannabis is a barrier to effective treatment because it is 
associated with significantly more relapses (Linszen et al., 1994) and with more re-
hospitalizations, inpatient days, and psychopathology (Caspari, 1999). Moreover, 
medication non-adherence and co-morbid substance abuse caused the highest rates of 
readmission (57%) over a 4 year period (Hunt, Bergen, & Bashir, 2002). 
The Problem of Medication and Treatment Non-Adherence 
Medication adherence sets the stage for a return to age appropriate tasks, and an 
improvement in psychosocial and occupational functioning. Hence, reducing medication 
non-adherence is an essential treatment goal. Medication non-adherence causes 
disruption in the process of symptomatic and functional recovery because after a first 
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episode, each subsequent relapse has been found to require a longer time to recovery than 
the previous episode (Lieberman et al., 1993; Szymanski et al., 1995), and to require 
higher doses of antipsychotic medication in subsequent episodes (Lieberman et al., 1993).  
During the first year of treatment there is a high rate of medication non-adherence 
(39%) and inadequate (irregular use of medication) adherence (20%), with only 41% of 
this population medication-and treatment-adherent (Coldham, Addington, & Addington, 
2002).  One study of FE SSD and atypical antipsychotic medications found people who 
stopped antipsychotic medication against medical advice were more likely to be 
depressed, with ongoing substance abuse and a poor treatment response (Perkins et al., 
2008). Additionally, in studies of the typical antipsychotic medications, approximately 
40% of patients have stopped taking medication by the end of the first year, and this 
proportion increases to 75% by two years. However, it is important to note that there is 
wide variation in how adherence is defined and measured in the literature, from missing 
one dose to stopping antipsychotic medication (Gray, Wykes, & Gournay, 2002; Lacro et 
al., 2002; Velligan et al., 2006; Zygmunt, Offson, Boyer, & Mechanic, 2002). 
Additionally, self report, with questionable reliability, is the most commonly used 
method to determine adherence as reported in the literature (Velligan et al., 2006). 
Moreover, the lack of consistent definition and data collection methods are 
methodological problems that limit generalization across studies of non-adherence. 
After stopping medication, approximately 75% of individuals will relapse over 
one year as compared to a 25% relapse rate for those who continue their medication 
(Perkins, 1999). The high relapse rates highlight the critical importance of medication 
adherence. One year later those with non-adherence had significantly more positive 
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symptoms, higher rates of relapse, more alcohol and cannabis use, less insight into 
illness/symptoms, and a poorer quality of life (Coldham et al., 2002). Low levels of 
cognitive functioning during the pre-morbid phase (Robinson et al., 2002) and high levels 
cognitive disorganization (Perkins, 1999, 2002) may also contribute to failure to take 
medication as scheduled in the first episode. People with medication non-adherence had 
an earlier age of onset, poorer pre-morbid functioning, and less family involvement. 
Compounding the problem of non-adherence, co-morbid substance abuse causes the 
highest rates of readmission (57%) over a 4 year period (Hunt et al., 2002).  
Frequently, individuals in a FE view psychosis as an acute illness and want to 
stop medication once they have achieved remission of positive symptoms. However, 
discontinuing antipsychotic medication is not always a realistic or desirable goal even 
when medication discontinuation is a treatment goal. Wunderink and colleagues (2007) 
compared two groups (i.e., gradual medication discontinuation versus maintenance 
treatment) in first-episode patients in remission and found that 43% of the people in the 
discontinuation group relapsed as compared to 21% of those who received maintenance 
medication. Overall, only 20% were able to successfully discontinue their medication 
during the follow-up period of 2 years.  
A related barrier is treatment non-adherence such as missed office visits, and 
failure to follow through with referrals to psychosocial treatment and substance abuse 
programs. The range of treatment non-adherence varies from refusal to engage in 
treatment to missed visits resulting in premature termination of treatment (Perkins, 2002). 
As with medication non-adherence, treatment non-adherence is associated with relapse 
and re-hospitalization (Perkins, 2002). 
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Overall, individuals in a FE SSD fail to seek and/or remain in treatment. 
Regardless of the cause, such as paranoia or other symptom-motivated avoidant behavior, 
the result is often medication non-adherence and potential relapse. Clearly, adherence to 
medication is critical for treatment and relapse prevention.  
Clinical Trials: Relevance to Problem of Medication and Treatment Non-Adherence 
What happens in a clinical trial has relevance to the problem of medication and 
treatment non-adherence in four respects. First, the goal of clinical trials of individuals in 
a FE SSD has been to identify a more effective antipsychotic medication with fewer side 
effects. Second, clinical trials of antipsychotic medication provide the knowledge upon 
which clinicians base their medication and treatment decisions. Third, non-adherence in 
clinical trials is an under-investigated phenomenon. For example, understanding why 
patients decide to stop medications is important in preventing medication non-adherence, 
but understanding the patient’s point of view has not traditionally been a clinical priority.  
In the largest study to date of the effectiveness of post marketed antipsychotic 
medications, the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) 
study, investigators found at the end of the 18 month treatment period that 74% of 
patients were no longer taking the antipsychotic medication assigned at the start of the 
study (Lieberman et al., 2005a). The reasons for discontinuation were only collected 
when the patient and clinician agreed on the reason, but not when the clinician and 
patient disagreed on the reason. When the clinician and patient disagreed, no reasons 
were listed other than “patient decision.”  This is unfortunate as patient decision is by far 
the most common reason for drug discontinuation (Weiden, 2007).  
What happened in the CATIE study is all too common: complete data on reasons 
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for discontinuation are not collected in clinical trials. Thus, clinical trials drive treatment 
decisions but provide few or no insights into reasons for non-adherence to these 
recommendations. Attrition rates from randomized controlled trials (RCT) of 
antipsychotic medication in young people in a first episode of SSD range from 4% at 6 
weeks to 87.9% at 2 years (Crespo-Facorro et al., 2006; Green et al., 2006). These high 
attrition rates occur despite more frequent study visits than found in usual care, and a 
proactive approach to the follow-up of missed visits and missed doses of medication. 
Most commonly, the statistical method of Last Observation Carried Forward (LOCF) is 
used to replace missing data related to attrition (Leon et al., 2006; Mazumdar et al., 2007; 
Streiner, 2002; Streiner, 2008; Wood et al., 2004). Attrition rates in clinical trials can be 
high and the use of statistical methods to replace missing data related to this attrition can 
create bias in the results (Barnes et al., 2006a). 
Investigators have often described the treatment groups in a study as equivalent 
based on a comparison of baseline scores of severity of psychosis and demographic 
characteristics. However, we do not know very much about two different groups, those 
who remained in a study and those who either withdrew or were withdrawn. Thus, it is 
unclear whether the results of clinical trials are generalizable to all patients with SSD, or 
only to those who remain in the clinical trial.   
Conclusions 
In the past fifteen to twenty years, a new focus on the treatment of first episode 
schizophrenia spectrum disorders has emerged to include an emphasis on early 
identification of psychosis and intensive treatment in the hope of preventing symptom 
exacerbation, chronicity and a downward course in psychosocial functioning. The goal of 
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FE treatment is to decrease the number and frequency of relapses from those rates 
exhibited by persons diagnosed with chronic schizophrenia, in which 60% of patients 
have an episodic relapsing course with a decrease in functioning, and 30% have a severe 
chronic course with unremitting psychosis (Bromet & Fennig, 1999; Huber, Gross, & 
Schutter, 1975).  
The International Early Psychosis Association Writing Group (2005) and Spencer 
et al (2005; Spencer et al., 2001) identify achieving and maintaining the highest possible 
level of symptomatic remission and functional recovery as the goal of treatment. In 
addition to psychosocial treatment strategies, antipsychotic medication use during an 
acute episode of psychosis as well as during remission to prevent relapse is essential. As 
such, medication remains the cornerstone of treatment. Symptomatic and functional 
recovery requires an understanding of the many factors that influence the willingness of a 
person in a FE SSD to take antipsychotic medication and remain in treatment. Without 
ongoing effective antipsychotic drug treatment, individuals are often unable to engage in 
the intensive psychosocial rehabilitation necessary for functional recovery. 
One strategy of researchers has been to compare currently available antipsychotic 
medications in the hope that one will be better tolerated, have fewer side effects and be 
more efficacious. Moreover, pre-and post-marketing studies attempt to influence the view 
of which antipsychotic medications are considered first line or the advantages of one 
medication over another (Green et al., 2006; Lieberman et al., 2003b; Robinson et al., 
2006; Sanger et al., 1999; Schooler et al., 2005; Tollefson et al., 1997). However, these 
studies have high rates of patient attrition and do not identify the differences between 
those who stay in the clinical trial and those who leave. It is important to move beyond 
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baseline demographic and psychosis severity and explore the ways that patients who 
remain in clinical trials differ from those who leave in regards to clinical presentation, 
risk factors, and barriers to effective treatment.  
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CHAPTER 2 
Attrition and its Significance to FE SSD Treatment and Adherence 
In the past fifteen to twenty years there has been a refocus in the treatment of first 
episode (FE) schizophrenia spectrum disorders (SSD) to early identification of psychosis 
and intensive treatment in the hopes of sustaining remission and preventing relapse. This 
effort has lead to pre-and post-marketing clinical trials conducted with a specific focus on 
FE SSD. Attrition rates in these studies are high which makes it difficult to understand 
the meaning of the study outcomes and to generalize the results (Kane, 2005). This is 
unfortunate because the results from these clinical trials are used to guide practice.  
Attrition 
 Attrition has been defined as a reduction in numbers (Berube, 1985). In the 
context of clinical trials, the term attrition has been used to refer to a reduction in 
numbers due to participant drops outs, including side effects, lack of efficacy, 
administrative withdrawal, discontinuation, and all cause discontinuation (Holroyd, 
Powers, & Andrasik, 2005; Leon et al., 2006; Perkins et al., 2008). These descriptors 
represent the various reasons that researchers might give for participants leaving a 
clinical trial. Many, but not all, researchers describe the reasons for attrition in their 
reports, some in detail, some only in broad categories. For example, for the CATIE study, 
the investigators collected information on all causes of discontinuation, but did not 
collect the patient’s reason for discontinuation if the physician disagreed with patient’s 
reason for stopping medication (Weiden, 2007).  
 Attrition from a clinical trial can happen at any time during the study, from 
screening to the double blind treatment phase (see Figure 1). Attrition during screening 
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can result from poor medication adherence, an inability to comply with study procedures 
(e.g., too psychotic to follow directions or procedures), or a withdrawal of consent to 
participate. Some studies include a washout phase that may also result in attrition. Post-
randomization attrition may be due to adverse events or a failure to improve (lack of 
efficacy), medication non-adherence and consent withdrawal.  Another form of attrition 
includes participants who are lost to follow-up, such as those who fail to keep clinic 
appointments and are non-responsive to phone calls and letters.   
 
 
Figure 1.  Common Causes of Attrition from Clinical Trials at Different Phases 
______________________________________________________________________ 
 
Attrition and Randomized Clinical Trials  
There are multiple factors that might contribute to high attrition rates in clinical 
trials which can occur at any time during a study (see Figure 1). Additional factors 
include the length of the clinical trial, variability in protocol design, differences between 
diagnostic groups, participant characteristics and cultural issues. Attrition rates from 
Phase I 
Screening    Washout 
 Phase II 
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*Too Psychotic      
*Withdrawn    
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*Too Psychotic      
*Withdrawn    
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*Lack of Efficacy 
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randomized controlled trials (RCT) of antipsychotic medication in young people in a first 
episode of SSD are high, but vary depending on the length of the clinical trial (see Table 
2), ranging from 4% at 6 weeks to 82.3% at 2 years (Crespo-Facorro et al., 2006; Emsley, 
1999; Green et al., 2006; Lieberman et al., 2003a; Lieberman et al., 2003b; McEvoy et 
al., 2007; Robinson et al., 2006; Sanger et al., 1999; Schooler et al., 2005). 
The most common reported causes of attrition from these FE studies (see Table 3) 
is patient withdrawal (mean 18.4%), lack of efficacy (mean 11%), and other causes 
(mean 9.1%) while the lowest was lost to follow-up (3.7%). However, other causes of 
attrition are under-reported or rarely addressed.  For example, only one study (Lieberman 
et al., 2003a) reported the number of participants who had signed consent forms as well 
as those who were randomized to a condition. Most investigators report only the number 
of participants who are randomized (see Table 4). Consequently, it is not possible to 
estimate how many individuals signed the consent form but dropped out before they 
could be randomized. Some of the studies have a washout phase, potentially a time of 
high risk for attrition, but the researchers do not report on the number of patients who left 
the study during either the screening or washout phases.  The lack of information about 
attrition rate during washout is unfortunate. This information is important for patient 
safety among other reasons.  
A high attrition rate is not unique to clinical trials involving individuals diagnosed 
with FE SSD. Other randomized trials of antipsychotic medications for the treatment of 
schizophrenia also have high attrition rates. Wahlbeck, Tuunainen, Ahokas, and Leucht 
(2001) examined the dropout rates from 163 drug trials for the treatment of schizophrenia 
from 1955 to 2000 and found a pooled dropout rate of 33%, with a range of 18.6% 
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(chlorpromazine) to 44.3% (haloperidol). As in the trials for FE SSD, the dropout rate 
increased as the length of the trial increased. Investigators have reported similar rates for 
both typical (41.2% range 9.7% - 65.4%) and atypical antipsychotics (35.5% range 0% - 
69.1%) in clinical trials of antipsychotic medications lasting 12 weeks or fewer 
(Kemmler, Hummer, Widschwendter, & Fleischhacker, 2005).  
Attrition rates for schizophrenia treatment trials are generally higher than those 
observed for trials of other Axis I psychiatric disorders. Khan, Schwartz, Redding, Kolts, 
and Brown (2007) found the schizophrenia group had the largest attrition rate (51%) of 
five diagnostic groups (see Table 5). They identified lack of efficacy, adverse events, and 
loss to follow-up and other causes as the three main reasons for termination for all 
diagnostic groups. Attrition in the schizophrenia group was more likely due to a lack of 
efficacy (29%), loss to follow-up and other reasons (21.8%) than it was for the other 
disorders, but less likely due to adverse events (5.7%). Consistent with the Wahlbeck et 
al. (2001) analysis, Khan et al. (2007) found a significant (p<.001) relationship between 
the length of the clinical trial and completion rates for the schizophrenia group only, but 
not the other psychiatric diagnostic groups. Thus, the literature regarding attrition in 
clinical trials involving patients with schizophrenia argues for length of clinical trial, lack 
of efficacy, and loss to follow-up being critical factors for attrition in FE SSD.
  
38
 
  
1 These two reports are based on the same subsample at different time periods      *p<.05, **p<.001 
 
 
 
Table 2.  
Attrition Rates for First Episode SSD Clinical Trials                                                                                      
 
UAuthorU                               UStudy SiteU           UStudy Design U                              UTime U        UDiscontinued (Range)U              UImputation 
Method 
Crespo-Facorro et al., 2006 Spain                Randomized                              6 weeks         4.0% (1.8 - 6.6%)                          LOCF 
Emsley, 1999                    International       Double-Blind, Randomized      6 weeks      25.6% (20.2 - 30.9%)*                not reported 
Lieberman et al., 2003a    China                  Double-Blind, Randomized     12 weeks     10.5% (10 - 11%)              
                                                                                                                       52 weeks     18.75% (15 - 22.5%)                       LOCF   
Lieberman et al., 2003b1  International        Double-Blind, Randomized     12 weeks     39.0% (32 - 46%)*                          LOCF 
          Green et al., 20061                                                                                26 weeks    47.5% (40.5 - 54.5%)* 
                                                                                                                         2 years      82.3% (76.6 - 87.9%)*                    LOCF 
McEvoy et al., 2007         US & Canada      Double-Blind, Randomized    52 weeks      70.3% (68.4 – 71.4%)  LOCF and Mixed Models 
Robinson et al., 2006       United States       Open-label Randomized           4 months     28.0%                Survival analysis and ANCOVA 
Sanger et al., 1999            International       Double-Blind, Randomized      6 weeks      44.8% (27.1 - 62.5%)**               LOCF                  
Schooler et al., 2005         International       Double-Blind, Randomized      2 years       39.3% (36.5 - 42.1%)                   not reported  
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Table 3.  
Reasons Reported for Attrition from First Episode SSD Clinical Trials                                                                                       
 
                                                                                                                  Reason Reported for Discontinuation                                             
                                                                                         ______________________________________________________________      
                                                                                         Lack of        Adverse        Non-                  Patient             Lost to            Other* 
Author                              Weeks   Discontinued (%)      efficacy       events           adherence          withdrawal       follow-up 
___________________________________________________________________________________________________________ 
 
Crespo-Facorro et al., 2006  6            4.0%                                                                                         2.0%                1.0%              1.0% 
Emsley, 1999                         6           25.6%                                        14.5%                                                                                   11.1% 
Lieberman et al.,  2003a     12          10.5%                                                                                            
                                            52          18.8%                     1.9%             5.0%                                      11.9%                                      
Lieberman  et al., 2003b1    12         39.0%                      9.1%            4.5%                                         8.7%                                  16.7% 
         Green et al., 20061      26         47.5%      
                                           104         82.2%                   18.3%            9.9%                 12.6%           22.8%               5.3%            13.3%    
McEvoy et al., 2007             52        70.3%                    10.8%          10.0%                                      41.5%                                     8.0% 
Robinson et al., 2006           17         28.0%                     6.0%                                       8.0%             4.0%               2.0%              8.0% 
Sanger et al., 1999                 6         44.8%                   23.5%            9.4%                   
Schooler et al., 2005          104         39.3%                     7.4%            5.8%                   2.3%           11.9%               6.5%              5.4% 
1 These two reports are based on the same sample at different time periods * Ineligible to continue, other causes, or not 
reported 
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Table 4.  
Study Methods for First Episode SSD                                                                                      
 
UAuthor U                              UConsented (N) U     URandomized (N) U      UWashout PhaseU                             UStudy PhasesU  
Crespo-Facorro et al., 2006                                  172              3-5 days (for 3 subjects)       Screening, DB* randomization 
Emsley, 1999                                                        183                            No                           Screening, DB randomization 
Lieberman et al., 2003a          164                        160                            No                           Screening, DB randomization  
Lieberman et al., 2003b1                                       263                      2 -14 days                     Screening, DB randomization 
          Green et al., 20061     
McEvoy et al., 2007                                              400                           No                            Screening, DB randomization          
Robinson et al., 2006                                            120                           No                            Screening,  
                                                                                                                                                Open-Label randomization 
 
Sanger et al., 1999                                                  83                       2 - 9 days                      Screening, DB randomization 
Schooler et al., 2005                                             555                       3 - 7 days                     Screening, DB randomization  
* Double-Blind 
1 These two reports are based on the same sample at different time periods 
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Table 5.  
Reasons Reported for Attrition from Other Psychiatric Studies1                                                          
 
                                                                                                          Reason Reported for Discontinuation                                  
                                                                                                                                                                      
                                                                       _______________________________________________________________ 
                                                        
                                                                                Lack of                                 Adverse                           Lost to follow-up 
                                                                                efficacy                                 events                              and other reasons 
                                                                         UPlaceboU       UDrug U                  UPlaceboU        UDrug U                  UPlaceboU        UDrug 
Schizophrenia                                                   35.0%        23.0%***            5.7%             5.7%                19.1%          21.8% 
Depression                                                        14.4%         6.8%***             4.5%           11.8%***          17.5%          16.2% 
Generalized Anxiety Disorder                            7.5%         3.7%*                8.5%           19.9%***          11.4%        10.6%    
Obsessive-Compulsive Disorder                         7.4%         3.7%***             2.5%            9.0%***            8.1%            9.3% 
Panic Disorder                                                   16.5%         3.9%***             6.3%          12.9%**              7.7%            7.2% 
1Table adapted from Kahn et al., (2007)   
*p=<.05  **p=<.01  ***p=<.001 
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Attrition from Non-Psychiatric Clinical Trials 
Six pharmacology clinical trials (see Table 6) (Arnold et al., 2005; Brili et al., 
2008; Leung et al., 2007; Mark et al., 2007; Retsch-Bogart et al., 2008; Schreiber et al., 
2007) were selected for a comparison with the psychiatric clinical trials because the 
participants in these trials have a chronic illness that may cause a decrease in level of 
functioning. Attrition rates from the randomized controlled trials of non-psychiatric 
medications are lower (22.9%) than from the FE SSD clinical trials (39.1%). The most 
common cause of attrition from the non-psychiatric studies (see Table 7) is adverse 
events (mean 12.9%), other causes (mean 10.3%), and patient withdrawal (mean 6.9%), 
while the lowest was non adherence (2.0%). However, the mean rate for attrition for 
other causes was inflated by one study in which the study sponsor terminated the study 
early due to lack of efficacy.   
Unfortunately, it is difficult to use information regarding these non-psychiatric 
clinical trials to inform understanding of attrition in FE SSD group for at least two 
reasons. First, the FE SSD group and the non-psychiatric group participants differ with 
respect to mean age (27.4 versus 35.7 respectively). Second, the drug side effect profiles 
and nature of the illnesses are quite different. Ideally, one would like to compare similar 
age groups that vary in nature of illness such as participants in clinical trials of 
medication for Type II diabetes treatment, but such trials have not been conducted. 
Consequently, it is not possible to disentangle the influences of development and illness 
characteristics. Thus without additional research, it remains important to consider both 
age of participant and nature and severity of illness symptoms as potential contributors to 
the high attrition rates observed in FE SSD.  
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Table 6.  
Attrition Rates for Non-Psychiatric Clinical Trials                                                                                 
UAuthorU                            UIllnessU                     UMean AgeU      UStudy DesignU         UTime U        UDiscontinued (Range)U    UImputation Method 
Arnold et al., 2005       Fibromyalgia                46.9         DB1, Randomized    12 weeks        38.9% (35 - 43%)                  LOCF 
Brili et al., 2008           Inflammatory                27.3            Randomized,        12 weeks          0%                                        None                   
                                   process s/p repair                             Crossover with  
                                   coarctation of aorta                          4 week washout       
Leung et al., 2007        Dyspepsia                     30.8            DB, Randomized   12 weeks        19.7% (19.2 - 20.3%)       Intent to Treat        
Mark et al., 2007          Genital Herpes             39.0            DB, Randomized   65 weeks      SP1* 14.9% (10.3 - 19.4%)  Left missing 
                                     Simplex Virus Type 2                                                      2 years       SP2* 61.3% (58.3 - 64.1%)  Left missing          
Retsch-Bogart et al., 2008 Cystic Fibrosis        26.0            DB, Randomized     4 weeks         6.7%                                  Not included  
                                     Pseudomonas                                                                                                                                in efficacy data 
Schreiber et al., 2007   Ulcerative Colitis         43.9             DB, Randomized    8 weeks     34.4% (22.6%-43.5%)             LOCF 
* SP1 = Sampling Period 1, SP2 = Sampling Period 2 
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Table 7.  
Reasons Reported for Attrition from Non-Psychiatric Clinical Trials                                                                                      
 
                                                                                                               Reason Reported for Discontinuation                                
                                                                                  __________________________________________________________   
                                                        
                                                                                  Lack of        Adverse       Non-             Patient           Lost to        Other 
Author                              Weeks   Discontinued     efficacy       events       adherence      withdrawal     follow-up 
                                                              (%) 
____________________________________________________________________________________________________ 
Arnold et al., 2005              12            38.9%              8.2%          18.6%          1.4%              7.3%             2.8%          0.6%* 
Brili et al., 2008                  12              0%                     
Leung et al., 2007               12            19.7%                                                                            8.9%            10.8% 
Mark et al., 2007                 65           13.3%               5.3%                              1.3%               4.0%              2.7% 
                                          104           47.1%               2.7%                                                      3.0%              2.7%       34.7%** 
Retsch-Bogart et al., 2008    4             6.7%                                    2.9%                                                                        3.8%*** 
Schreiber et al., 2007            8           34.4%                                  17.2%         3.2%             11.3%              0.5%         2.2%* 
*Protocol Violation   **Early termination of study by sponsor   ***Reason not report
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Handling Missing Data --Last Observation Carried Forward 
Last Observation Carried Forward (LOCF) is a statistical method commonly used 
in pharmaceutical studies and accepted by the FDA as a method for handling missing 
data created by attrition. LOCF allows all participants who completed a baseline and at 
least one post randomization visit to be included in the data analysis (Barnes et al., 
2006a; Mazumdar et al., 2007; Streiner, 2002; Streiner, 2008; Wood et al., 2004). In this 
method, the participants’ last assessment score is entered into all missing visits. LOCF 
has been a key data analysis tool in FE SSD clinical trials where attrition rates are too 
high to allow for dropping cases and the cost of replacing participants is prohibitive.   
LOCF assumes that no further change in a participant’s response will take place 
once they have dropped from a study, regardless of when they drop. However, this 
assumption is hard to defend because in real life change is to be expected (Mazumdar et 
al., 2007; Streiner, 2008; Wood et al., 2004).  Moreover, using the last data point fails to 
make use of all prior data points that could be used to show the direction of change 
(getting better, worse or no change; (Streiner, 2002).  
Most importantly, Barnes, Lindborg and Seaman (2006a) argue that LOCF’s use 
should be limited because its initial intent was meant to introduce bias in the analysis of 
safety data. When LOCF is used in the analysis of safety data, early drops due to adverse 
events bias statistical results against a drug, creating a bias in the direction toward safety. 
Applying this same technique to efficacy data analysis can introduce bias in an unknown 
direction, affecting validity of study findings (Barnes et al., 2006a). This bias is more 
pronounced if the attrition rates are different for each drug treatment group and if the 
drops occur at different times during the study (Mazumdar et al., 1999). In FE SSD 
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clinical trials there can be significant differences in post randomization attrition rates for 
each drug treatment group. For example, Sanger (1999) and Emsley (1999) found a 
statistically significant difference in attrition rates between the study drugs. Lieberman et 
al. (2003b) report a statistically significant difference in attrition between the two study 
drugs at 12 weeks. In the long- term continuation phase of that study, Green et al. (2006) 
report the differences in attrition rates due to adverse events and lost to follow-up. It 
should be noted here that two researchers (Green et al., 2006; McEvoy et al., 2007) used 
observed case analysis, a mixed models technique, and LOCF.  Green et al., (2006) only 
reported the results from the mixed models because the results were not “substantially 
different” from the LOCF analysis. McEvoy et al., (2007) report comparing the results of 
mixed models and LOCF methods but the results of this comparison are not noted. 
Finally, most FE SSD clinical trials do not provide data as to the attrition rate prior to 
randomization creating the possibility of undetectable differences in attrition rates (see 
Table 3).  
It is important to note attrition from psychiatric studies is usually not random but 
related to the medication, such as side effects and lack of efficacy, or to the study 
procedures such as subject burden (Mazumdar et al., 2007). Non-random missing data, 
often referred to as ‘nonignorable missingness’, differs from data missing at random in 
that the latter can be ignored whereas the former cannot (Mazumdar et al., 2007; Streiner, 
2008). Imputation of missing data using LOCF implies that all data are missing at 
random regardless of whether or not such data meet the criteria for being missing at 
random (Leon et al., 2006; Mazumdar et al., 2007; Sheiner, 2002).  
In the literature, there are different models for operationalizing LOCF. In a 
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reanalysis of several large clinical trials of atypical antipsychotic medication as compared 
to a typical antipsychotic, Leucht, Engel, Bauml, and Davis (2007) compared three 
different models of LOCF, and a fourth non LOCF method which analyzed only those 
participants who had completed the study. The first LOCF method included all 
randomized participants in the data analysis. This model is the closest to the more 
common practice of including only those participants who completed at least one post 
randomization visit, a method thought to bias against a drug with very early attrition due 
to early onset side effects. Haloperidol is one example of an antipsychotic with early 
onset side effects where this bias could be seen. The second LOCF model excluded only 
the adverse events attrition group from the data analysis. The third LOCF model excluded 
the whole attrition group except for those with a lack of efficacy.  
Leucht et al. (2007) compared results for their four models for handling missing 
data under two different conditions: (a) data pooled across multiple studies; and (b) data 
analyzed separately for each study. When data were pooled across studies, the researchers 
did not find a difference in effect size between the various models. However, when they 
analyzed the data separately, the use of the first LOCF model (similar to the approach 
most frequently used in FE SSD research) resulted in higher effect sizes in favor of the 
atypical antipsychotic medications in 50% of the study data sets. The authors concluded 
further study comparing results using other statistical methods was needed.  
In summary, although LOCF has been a key data analysis tool in FE SSD clinical 
trials where attrition rates are high, its use may result in biased results where the  
direction of the bias is variable (Leon et al., 2006).  Potentially more problematic is that 
LOCF ignores other variables that may impact attrition. Furthermore LOCF keeps the 
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focus on the potentially biased outcome rather than on the individuals in the completion 
and attrition groups of clinical trials. Changing the focus to understanding the differences 
between those participants who stay and those who leave the study may help to inform 
clinicians of the demographic, illness and treatment characteristics of persons most likely 
to tolerate and perhaps benefit from an antipsychotic medication.   
Overview of Proposed Study 
The aim of this study is to: (1) evaluate the differences between those FE SSD 
participants who remain in a study and those who leave with respect to their 
demographic, illness and treatment characteristics; (2) evaluate the effect size for all of 
the variables and independently for each of the three studies. The attrition and non-
attrition groups will be evaluated for differences in factors that effect outcomes such as 
cognitive deficits, substance use, and severity of positive and negative symptoms.  
This study is a secondary analysis of a group of FE SSD participants enrolled in 
one of three separate double-blind, randomized, drug trials. These studies are typical and 
representative of other studies of FE SSD found in the literature. Two of the studies used 
in this analysis were investigator-initiated pharmaceutical-sponsored (Eli Lilly and 
AstraZeneca) multi-site studies of people in a first episode of SSD. The third study, 
funded by the National Institute of Mental Health (RO1 MH52376), studied the efficacy 
and safety of clozapine versus haloperidol in first episode schizophrenia.   
Research Questions 
 The following research questions will be addressed: 
1. What are the demographic profiles, illness and treatment characteristics of the 
participants in the three double-blind randomized drug trials? 
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2. To what extent do patients’ demographic profiles, illness and treatment 
characteristics differ in those who withdraw for any reason and those who 
remain in the three double-blind randomized drug trials? 
3. What is the effect size in analyses comparing those who withdraw and those 
who remain in terms of their demographic profiles, illness and treatment 
characteristics in: (a) each of the three double-blind randomized drug trials; 
and, (b) a merged data set combining all three double-blind randomized drug 
trials?   
For the purposes of this study, demographic characteristics are defined as age, 
gender, race, marital status, education, employment, median household income and 
functional health. Illness characteristics are defined as diagnosis, severity of psychiatric 
symptoms, severity of positive and negative symptoms, substance use, duration of 
untreated psychosis, number of previous hospitalizations, and cognitive functioning. 
Treatment characteristics are defined as medication, number of days in a washout phase, 
and medication adherence. 
Summary 
Historically, the problem of attrition from clinical trials has not received much, if 
any attention. There has been a tendency to use LOCF to compensate for the 
phenomenon of attrition, but questions about the limitations of LOCF have been raised in 
the statistics literature suggesting its use can be problematic. A secondary data analysis of 
data from three separate double-blind, randomized drug trials for FE SSD is proposed as 
a means to shift the focus to the differences between participants who complete a clinical 
trial and those in the attrition group. A better understanding of the demographic, illness, 
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and treatment characteristics related to attrition is critical for clinicians and researchers to 
understand which treatment works best for which people and may lead to more effective 
early intervention for patients in first episode schizophrenia spectrum disorders.  
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CHAPTER 3 
Methods 
Study Design and Procedures 
 
Sample 
 
For this secondary analysis, data will be integrated from three different 
randomized, double-blind treatment studies of first episode schizophrenia spectrum 
disorders (FE SSD) and analyzed using SPSS 16 (Statistical Programs for Social Science) 
(SPSS, 2008).  The studies took place at an academic clinical research unit based in a 
community mental health center. Studies with an inpatient component occurred on a 
dedicated inpatient research unit and outpatient visits at offices in the same facility. 
Appendix A contains written documentation of permission to work with study data and 
institutional review board approvals. Appendix B contains a description of the study 
phases and attrition rates for all three studies. For the purpose of this study consented 
includes everyone who signed a consent form and evaluable refers to people who 
completed diagnostic workup and were included in this analysis if they met criteria for 
FE SSD. Between screening and randomization two studies had a taper and washout 
phase (see description of each individual study).  
Participants in all three studies met criteria for DSM-III-R (American Psychiatric 
Association, 1987) or DSM-IV (American Psychiatric Association, 1994) diagnosis of 
schizophrenia, schizoaffective disorder or schizophreniform disorder, and were 
comprised of men and women between the ages 18 and 45.  All participants had 
psychotic symptoms that had persisted for at least one month and no longer than five 
years without entering a second psychotic episode. Women of childbearing potential 
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agreed to the use of a medically accepted means of contraception. All participants were 
able to give written informed consent or assent in the case of a legal guardian who then 
gave the written informed consent.  
Exclusion criteria included: (a) past history of psychosis with recovery; (b) 
substance induced psychotic disorder; (c) non-English speaking; (d) serious and unstable 
medical illness; and (e) serious suicide risk. The lower age restriction of 18 was, on a 
case-by-case basis, waived by the Massachusetts Department of Mental Health, and the 
upper age limit of 45 was designed to exclude the confounding effects of age on the 
neurocognitive tests. Participants who did not meet inclusion criteria (a) no longer in a 
first episode, (b) diagnosed with a brief reactive psychosis, an affective psychosis or 
substance induced psychosis or (c) at randomization did not met severity criteria were not 
randomized to study medication. Participants were removed from the study by the 
principal investigator if found to be too psychotic to follow study procedures, and were 
then treated clinically and discharged to standard clinical care when appropriate.  
 Clozapine or Haloperidol in first episode schizophrenia (ClozHal) Funded by the 
National Institute of Mental Health (NIMH) (Grant No. R01 MH52376), the “Clozapine 
and Haloperidol in First Episode Schizophrenia” (no publications as currently in data 
analysis) is a double-blind, randomized controlled trial of Clozapine and Haloperidol in 
people with a first episode of schizophrenia.  Entry criteria included less than twelve 
weeks of prior antipsychotic drug exposure and a DSM-III-R (American Psychiatric 
Association, 1987) diagnosis of schizophrenia. Participants were admitted to an inpatient 
research unit, gave written informed consent, and entered the screening phase for 
evaluation of inclusion and exclusion criteria. Once participants met all inclusion and 
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exclusion criteria, they entered an antipsychotic drug-free washout period for up to two 
weeks after a taper and discontinuation of antipsychotic medication. Participants were 
randomized to either clozapine or haloperidol if they met minimal severity criteria. The 
study medication was started at a cardiac telemetry unit (for 48 hours) to observe for any 
untoward cardiac effects. Participants were then followed for an acute, double-blind, 
twelve week treatment phase followed by a two to five year long-term double-blind 
treatment phase.  
 The acute and long-term efficacy of Olanzapine in first episode psychotic 
disorders: A randomized double-blind comparison with haloperidol (OlzHal). Funded by 
Eli Lilly, “The Acute and Long-term Efficacy of Olanzapine in First Episode Psychotic 
Disorders” (Green et al., 2006; Keefe et al., 2006a; Lieberman et al., 2003b) is a double-
blind, randomized controlled trial conducted at fourteen academic medical centers in the 
United States and Western Europe for up to two years. Olanzapine was compared with 
haloperidol in people with a first episode of schizophrenia, schizoaffective disorder or 
schizophreniform disorder (American Psychiatric Association, 1994) with less than 
sixteen weeks of prior antipsychotic drug exposure. Participants were admitted to the 
inpatient research unit, gave informed consent, and entered the screening phase. If 
screening criteria were met, antipsychotic medication was tapered and discontinued for a 
drug-free washout period of two days to two weeks. Only those persons who met a 
minimum severity score at baseline were randomized to study drug (olanzapine or 
haloperidol). A twelve week acute treatment phase was followed by a long-term, double-
blind treatment phase for a total of two years. Participants could be followed on an open 
label medication phase for up to six months if their symptoms met the severity criteria 
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(greater than or equal to their baseline score at two consecutive visits at visit 11 (week 
12) or anytime in the long term phase.   
Efficacy and tolerability of Olanzapine, Quetiapine and Risperidone in the 
treatment of first episode psychosis: A randomized double blind 52-week comparison 
(OlzQueRis). Funded by AstraZeneca, this investigator-initiated study entitled “Efficacy 
and tolerability of Olanzapine, Quetiapine and Risperidone in the treatment of first 
episode psychosis: A randomized double-blind 52-week comparison” (Keefe et al., 2007; 
McEvoy et al., 2007; Perkins et al., 2008) was designed for people in a first episode of 
schizophrenia, schizoaffective disorder or schizophreniform disorder (American 
Psychiatric Association, 1994), with less than 26 weeks of prior antipsychotic drug 
exposure. This study had twenty six sites in the US and Canada with a double-blind 
assessment period of one year. Participants giving informed consent entered the screening 
phase. This study did not have a drug taper or washout period because it was conducted 
on an outpatient basis. Baseline evaluations were completed and participants were 
randomized to study drug (quetiapine, olanzapine or risperidone) for a 52-weeks double-
blind, treatment phase. 
Protection of Human Subjects 
All data to be used in this secondary analysis came from patients who signed a 
written informed consent form for one of the three studies. If found to be incompetent 
and their inpatient treatment team agreed to the need for a guardian, then legal 
guardianship was obtained with approval to treat with the study medications.  Patients 
between the ages of 17 to 18 provided written assent and their parents/guardians signed 
the written consent form. All staff have received training and are in compliance with 
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good clinical practices as described by the United States Food and Drug Administration 
(FDA). Approval was obtained by the Boston College and Beth Israel Deaconess Medical 
Center institutional review boards for protection of human subjects for this secondary 
analysis of previously collected data (see Appendix A).  
Data Protection 
 The research records used in this study are the property of Alan I. Green, MD of 
the Commonwealth Research Center of Beth Israel Deaconess Medical Center and kept 
in secure, limited access offices. The database for this analysis is deidentified, does not 
contain date of birth or zip code information, and is maintained on a password protected 
computer (PC). The database will be kept on a password protected computer at the 
Commonwealth Research Center of Beth Israel Deaconess Medical Center at the 
completion of this dissertation. 
Study Variables 
 
 Appendices C, D and E describe how each variable was measured in the three 
data sets, and how each is defined for the proposed analyses. If a particular variable was 
not entered into the data file, it was constructed through a review of the research source 
documents (e.g., admission and discharge summaries and progress notes) and a data 
collection form was developed by the researcher to facilitate chart review for, and 
construction of, these variables (see Appendix F). 
Operational Definitions (see Appendices C, D, and E for coding) 
Independent (or Grouping) Variables 
Attrition was defined as those who left or did not complete the study for any 
reason (0 or No), and those who completed 24 weeks of the double-blind phase (1 or 
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Yes). It was a dichotomous grouping variable for questions 2 and 3. 
Research studies are defined as the three double-blind randomized studies that 
were combined for this study ClozHal (1), OlzHal (2), OlzQueRis (3) and were used as a 
grouping variable for questions 1 and 3. 
Dependent Variables 
A. Demographic characteristics. (see Appendix C for demographics form)   
Demographic information was reported by participant and documented in the 
study records. Categories were collapsed as appropriate to the data. The name of the 
variable used in the tables is noted in parentheses. For purposes of this study, the 
following operational definitions and/or measures of the demographic variables of 
interest were used:  
 Age (Age) is the number of years living.  
 Gender (Gender) is the sex of the participant. It is coded as 0 for male and 1 for 
female. 
 Race and/or ethnicity (Race) is based on the participant’s self report and uses the 
following categories: Caucasian (1), African American (2), Asian (3), or Hispanic (4). 
 Marital Status (Marital Status) is the participants’ self-reported current marital 
status.  It is coded as single/never married (1), married/common law (2), separated (3), 
divorced (4). In study analyses used to address the study questions, these categories are 
collapsed into (0) never married and (1) ever married. 
 Education is measured in three ways.  First, an ordinal measure for school 
attendance (School Attendance) is used for the 12 months prior to baseline. Values are 
assigned as follows: not in school (0); in GED/HS classes (1); in college/graduate school 
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(2). Second, a continuous measure, the total number of years of education completed 
(Education [years]). The third measure of education, left school, is dichotomous (Left 
School). Participants are coded as a 1 if they left school due to symptoms under study and 
a 0 if they did not.  
 Living situation (Living Situation [past year]) is defined as the place where a 
person is living. It is measured on an ordinal scale. Values are assigned as follows: 
independent living (1); dormitory (2); family (3); homeless living in a shelter or on the 
street (4) as the highest level in the year prior to baseline and in the month prior to 
baseline.   
 Employment is defined as the type of work (including working for wages, or as a 
volunteer, or attending school) and measured in two different ways. Data for both 
measures were collected from demographic, admission history forms and weekly 
assessments. Two levels of employment, first a dichotomous measure (Employment 
Status [past year]), unemployed due to study disease disability (0) or working for 
pay/student (1) was collected for the year prior to baseline and one month prior to 
baseline. The second variable for employment is measured as a continuous variable in 
terms of the number of hours worked (Hours Employed) for the highest level in the year 
prior to baseline. 
 Functional Level (Functional Level [past year]) is defined as the percentage of 
time spent in any educational, occupational, social or productive activity and is measured 
at the highest level during the year prior to baseline and one month prior to baseline. 
Educational, occupational, and social activities include time spent working, going to 
school, housekeeping/activities of daily living and volunteer work. Data for this measure 
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are obtained from the demographic and history forms. These data are recorded on an 
ordinal scale as: no useful functioning (1); >0 to <25% of time (2); >25% to <50% (3); 
>50% to <75% (4); >75% to 100% (5).  
 Median Household Income (Median Household Income) is identified based on US 
government census data on zip code and street name (United States Census Bureau, 
2000). If a street crosses several income categories the average of those income 
categories were used. The actual zip code number was not entered into the data base. The 
median income level, associated with the zip code was entered. 
 B.  Illness Characteristics (see Appendix D). For purposes of this study, the 
following definitions were used to describe participants’ in relation to the characteristics 
of their psychiatric illnesses: 
Psychiatric Axis I Diagnosis is defined as a DSM-III-R (American Psychiatric 
Association, 1987) or DSM-IV (American Psychiatric Association, 1994) diagnosis of 
Schizophrenia, Schizophreniform, or Schizoaffective Disorder. This diagnosis was 
determined by the use of the Structured Clinical Interview for DSM-IV (SCID) (First, 
Spitzer, Gibbon, & Williams, 1997), a semi-structured clinical interview for Axis I 
disorders in all of the studies except for the ClozHal, for which investigators used the 
Schedule of Affective and Schizophrenia Disorders (SADS) (Spitzer, Endicott, & Robins, 
1975). The SADS resulted in a DSM-III-R (American Psychiatric Association, 1987) 
diagnosis of schizophrenia.  
 Age at onset of psychosis (Age at Onset) is the number of years living at onset of 
psychosis.  
Severity of Psychiatric Symptoms is measured by one continuous variable at two 
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time points: screening and baseline by the Clinical Global Impression – Severity for all 
three studies (Clinical Global Impression - Screening) (Clinical Global Impression - 
Baseline).  
The Clinical Global Impression (CGI) (Guy, 1976) is a single rating of severity of 
illness coded on a 7-point scale (1 = normal, not at all ill to 7 = among the most 
extremely ill patients) where the overall severity of symptoms is measured within the 
context of other people with a diagnosis of a SSD during the previous week. The CGI is 
completed during the clinical rater’s interview. The CGI severity, a single item scale, is 
reliably correlated with the BPRS and the PANSS (Leucht et al., 2006; Leucht et al., 
2005; Mortimer, 2007), frequently used measures of severity. Validity was .71 and the 
CGI has been shown to be a valid measure of clinical effectiveness and appropriate for 
clinical use (Berk et al., 2008).  
Duration of Untreated Psychosis (DUP) (Duration of Untreated Psychosis) is 
measured in weeks based on the difference in dates between the onset of the first 
psychotic symptom and the first use of an antipsychotic medication in all three studies. 
DUP was identified using a consensus rating by senior clinical staff members of the 
Commonwealth Research Center based on definitions of illness onset as defined by 
Keshavan and Schooler (1992) and Larsen, McGlashen and Moe (1996). Information was 
obtained from clinical interviews, medical record review, and interviews with parents and 
family members whenever possible. DUP is an interval level variable coded from 0 to 
208 weeks. 
Number of previous psychiatric hospitalizations (Psychiatric Hospitalizations) is 
defined as the number of inpatient psychiatric hospitalizations prior to entry into the 
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study. It is collected from a review of research records.  
Substance Use is assessed separately for alcohol, marijuana, cocaine, opiates, 
PCP, LSD and amphetamines. Use of each substance was measured in three different 
ways. First, lifetime use coded as absent (0), use (1), abuse (2), or dependence (3) was 
determined using information from the SCID in the OlzHal and OlzQueRis studies and 
the SADS in the ClozHal. Both the SCID and SADS have comparable substance use 
sections that allow collection of lifetime substance use (Lifetime Alcohol) (Lifetime 
Marijuana) (Lifetime Other Drugs). Second, the Alcohol Use Scale/Drug Use Scale 
(AUS/DUS) (Drake et al., 1990) was used to retrospectively measure substance use in the 
month prior to study and during the double-blind phase. The AUS/DUS consists of one-
item using a five-item response scale ranging from and coded as 1 (abstinent) to 5 
(dependence with hospitalization).  The AUS/DUS was only used in the OlzQueRis 
study. However, it can be used to generate a rating from the participant’s research records 
for the month prior to baseline. Third, two continuous variables, age at first alcohol use 
(Age Alcohol) and age at first marijuana use (Age Marijuana) will be measured in years. 
The drug groups (other than alcohol and marijuana) may be combined if use frequencies 
are too low (e.g. less than 10%) for any individual drug. Inter-rater reliability was .85 for 
current and .72 for lifetime substance use disorders (Drake et al., 1990). 
Cognitive Functioning is defined by the domains of intellectual, attention, 
executive, language, memory, and motor functioning and was measured using standard 
neuropsychological tests. All tests were conducted prior to baseline and start of 
randomized medication. These tests provide/generate a composite score for each domain. 
In two of the domains (executive functioning and language) each study used the same 
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neuropsychological test, but in each of the remaining domains two different tests were 
used. In neuropsychological testing there are many different tests to measure individual 
domain functioning and it is not unusual for different tests to be combined under a 
domain. Between the three studies, there was no more than two tests used within a 
domain. The two tests, within a domain, are considered comparable because they 
measure the same domain functioning and results are coded as standardized scores and 
percentile rank which are comparable across studies (Lezak, 1995; Spreen & Strauss, 
1998d). The neuropsychological tests used in each domain are described below and the 
individual study noted. 
Intellectual Functioning (Intellectual Functioning) is based on an estimated 
premorbid IQ obtained using two different neuropsychological tests: 
1. Wide Range Achievement Test, Third Edition (WRAT 3) (Spreen & Strauss, 1998e)  
reading subscale, standardized scores and percentile rank (ClozHal, OlzQueRis). The 
test-retest reliability of the WRAT 3 was .97 and construct validity for WRAT 3 total 
reading score was .69 (Wilkinson, 1993). 
2. North American Adult Reading Test (NAART) Second Edition (Spreen & Strauss, 
1998c), number of errors was used to derive a Wechsler Adult Intelligence Test - Revised 
(WAIS-R) estimated premorbid IQ score (OlzHal) (Nelson & Willison, 1991) using 
standardized scores and percentile rank. Test-retest reliability was above .98 (Crawford, 
Stewart, Besson, Parker, & De Lacey, 1989) and validity (.85) was high for general 
intelligence (Crawford, Stewart, Cochrane, Parker, & Besson, 1989). The WRAT-R and 
the NAART estimated premorbid IQ is highly correlated (.80) (Johnstone, Callahan, 
Kapila, & Bouman, 1996). 
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Executive Functioning is based on the Wisconsin Card Sort, 64 card version 
(WCST-   64) (Heaton, Chelune, Talley, Key, & Curtiss, 1993; Lezak, 1995) using 
percentile rank of perseverative responses (Executive Functioning – Perseverative) and 
total number of categories completed (Executive Functioning – Total Categories) in all 
three studies (ClozHal, OlzHal, OlzQueRis). Test re-test reliability was .94 (Heaton, 
1981) and found the WCST to be a valid measure of executive functioning in 
schizophrenia (.70) (Sullivan et al., 1993). 
Language Functioning (Language Functioning) is based on the Controlled Word 
Association Test (COWAT - FAS) the total number of correct words and percentile score 
for the letters F, A, S using education, age and gender adjusted norms (Spreen & Strauss, 
1998a) in all three studies (ClozHal, OlzHal, OlzQueRis). Test-retest reliability was .74 
(Ruff, Light, Parker, & Levin, 1996) and .84 (Ross et al., 2007) with construct validity. 
Memory Functioning (Memory Functioning) is based on two different 
neuropsychological tests that have been found to be highly correlated: 
1. Wechsler Memory Scale – Revised (WMS-R)  (Wechsler, 1987) Logical Memory 
(LM1) subtest standardized scores and percentile rank of immediate recall (ClozHal, 
OlzHal). Immediate recall was used from the LM1 test because the Hopkins Verbal 
Learning Test (HVLT) only involved immediate recall. Additionally, only the A (1) form 
of LM was used at baseline so the immediate recall score was prorated by multiplying by 
two and then standardized scores and percentile rank were obtained from the WMS-R 
manual (Wechsler, 1987). Inter-rater reliability for LM1 are .74 and .99 (Wechsler, 
1987). Validity for a standardization sample was .52 and .76 for a mixed clinical sample 
(Russell, 1982). 
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2. Hopkins Verbal Learning Test (Brandt & Benedict, 2001), sum of the number of 
items recalled on each trial (OlzQueRis) using standardized T-scores and percentile rank 
score. The T- score was obtained from the raw score using the manual (Brandt & 
Benedict, 2001). The T-scores were converted to percentile rank (Spreen & Strauss, 
1998d). Validity between the HVLT-R and LM1 immediate total recall found significant 
correlations (Pearson .75 p<.001) (Shapiro, Benedict, Schretlen, & Brandt, 1999) and 
test-retest reliability for total recall at .74, p<.001 (Benedict, Schretlen, Groninger, & 
Brandt, 1998). 
Motor Functioning (Motor Functioning) is based on two highly correlated 
measures of motor speed for the dominant hand in the three studies:  
1. Finger Tapping (Heaton, Grant, & Matthews, 1992), standardized T scores and 
percentile rank for dominant hand only (ClozHal, OlzHal). Test-retest evaluation found 
reliability coefficients for dominant hand .64 and non-dominant hand .87 (Goldstein & 
Watson, 1989). Finger tapping test has been shown to be correlated (.78) with a pegboard 
task (Triggs, Calvanio, Levin, Heaton, & Heilman, 2000) even though they load on 
different dimensions of manual proficiency (Stanford & Barratt, 1996). 
2. Grooved Pegboard version used in the OlzQueRis study involved inserting pegs for 
two minutes using the dominant hand only. The resultant score is based on the average 
number of pegs inserted in two minutes for two trials for dominant hand (OlzQueRis).  
Z-scores were calculated based on data for patients with schizophrenia and normative 
data (patient score minus the control mean/control standard deviation) (Keefe et al., 
2006b).  The calculated Z-scores were converted to percentile rank (Spreen & Strauss, 
1998d). Test-retest reliability was .82 (Kelland, Lewis, & Gurevitch, 1992). Schear & 
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Sato (1989) found a modest relationship (-.35) with finger tapping. It has been found to 
be more closely related to finger tapping than to grip strength (Corey, Hurley, & 
Foundas, 2001). 
Visual Attention Functioning (Visual Attention Functioning) is based on two 
different neuropsychological tests:  
1. Cancellation Test (Mesulam, 1985) (ClozHal) does not have standardized normative 
data. Instead the scoring is based on two components of the test, the organization score 
and the time it takes to complete the task. There are standardized rules for scoring the 
organization of the search on two different forms (letters or symbols). A normal search 
organization is systematic and mostly systematic, and an abnormal search organization is 
mostly unsystematic and unsystematic. A normal time to completion should be < 120 
seconds, scores above that are labeled as abnormal (Weintraub, 2000). This result in four 
scores, two for organization (one for letter cancellation and one for symbol cancellation) 
and the time to completion for each of the forms of the test. The following rule was 
applied, any abnormal score or time resulted in a final score of abnormal and no 
abnormal score or time was rated as normal.  Reliability and validity data are not 
available for this test of spatial scanning ability but it has been widely used in neurology  
(Mesulam, 1985). 
2. The Visual Continuous Performance Test (CPT), identical pairs (IP) version, d’ prime 
(CPT-IP response sensitivity) for each of three conditions (2, 3 and 4 digit numbers) 
(OlzHal, OlzQueRis) (Cornblatt, Risch, Faris, Friedman, & Erlenmeyer-Kimling, 1988) 
does not have published normative data. Instead, normative guidelines for people in a FE 
SSD were provided by Dr. Cornblatt (personal communication November 24, 2008). Dr 
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Cornblatt did not report reliability and validity data for this earlier version of the test. The 
average d’prime score was rated as normal (>2.5), and mild to moderate impairment (1.8-
2.4) and severe impairment (<1.7) as abnormal.  
 C.  Treatment Characteristics for the participants are based on the following: (see 
Appendix E) 
Participation is defined as the length of time participants remained in the study 
and is measured by one dichotomous variable and one continuous variable. The 
dichotomous variable (Termination Phase) describes the phase when participant left the 
study: early withdrawal (1) and double-blind (2). Early withdrawal is defined as 
occurring during the screening, washout and baseline study visit prior to taking the first 
dose of study medication. Double-blind withdrawal is defined as leaving the study during 
the 24 weeks of double blind medication treatment excluding the baseline visit. The 
second measure, completion weeks creates a continuous variable. It measures the number 
of weeks the participant completed in the double-blind phase (Double-Blind [weeks]).  
Study termination is defined as the reason for leaving a study and is measured as a 
categorical variable (Termination Reason). The value labels for this variable are: 0 = 
completed study; 1 = adverse event; 2 = lack of efficacy (LOE) - MD perception; 3 = 
LOE  patient & MD agree;  4 = patient withdrew consent; 5 = lost to follow-up; 6 = 
patient moved; 7 = inclusion/exclusion criteria not met; 8 = too psychotic for study 
procedures; 9 = requires disallowed medication; 10 = patient stopped study medication; 
11 = severity criteria not met. Study termination (Termination [collapsed]) was collapsed 
into three groups: (1) patient related issues (e.g. patient withdrew consent, lost to follow-
up and patient moved), (2) medication related issues (e.g. adverse events, lack of 
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efficacy), and (3) research design related issues (e.g. inclusion criteria, requires 
disallowed medication, severity criteria not met).       
Washout is defined as a period of time during which the patient is taken off of 
his/her antipsychotic medication. Washout was dichotomized as either having 
experienced a washout (1) or not having this (0). The continuous variable, number of 
days without antipsychotic drug treatment, was used to describe the sample (Washout 
[days]).  
Antipsychotic medication is defined as two categorical variables. The categories 
coded for the first variable include not randomized (0), clozapine (1), olanzapine (2), 
haloperidol (3), quetiapine (4), or risperidone (5). Second, the medication was 
dichotomized into typical (0 - haloperidol) or atypical (1 - clozapine, olanzapine, 
quetiapine, and risperidone) medication (Randomized Medication).   
Data Analysis  
 Prior to answering the research questions frequencies and percents were 
calculated for all categorical study variables and mean, standard deviation, median and 
range for continuous variables. Next, variables with continuous data were checked for the 
presence of skewness using the Pearson’s coefficient of skewness with marked skewness 
identified if the value is U>|U1.0|. Two methods of handling skewed continuous data include 
the use of a median split or dividing the data into three categories (low, medium and 
high). The categorical variables were checked to ensure there is a minimum of 10% of the 
data within a category (Burns & Grove 2001).  If there was less than 10% in any 
category, then categories were collapsed in a manner consistent with and appropriate to 
the variable. 
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The variables were first analyzed across the three drug study data sets to 
determine if the patient populations are comparable across the three studies.  If minor or 
non-statistically significant differences are found, dummy variables were created to 
capture the effect of variable differences and these variables were entered into all major 
study analyses. Exploration of the effects of these differences was conducted.  
Question 1: “What are the demographic profiles, illness, and treatment 
characteristics of the participants in the three double-blind randomized drug 
trials?” and  
Question 2: “To what extent do patients’ demographic profiles, illness, and 
treatment characteristics differ in those who withdraw for any reason and those 
who remain in the three double-blind randomized drug trials?” 
Exploratory and descriptive statistics of study participants were conducted in a 
comparison of the three studies, for the merged group, and for the attrition group and 
non-attrition group (see Appendix G). For the continuous variables, t-tests (2 groups) or 
ANOVA (more than 2 groups) were used unless the variables did not meet the 
assumptions for a t-test. The Welch test was used when the data was not robust to 
violations of the assumptions (e.g., heterogeneity of variance with unequal group sizes 
and less than 20 in a group). Mann Whitney U was used when there were small but equal 
sized groups (less than 20). Levene’s statistic was evaluated for unequal variance 
between the groups. As this is a pilot study there will be some leeway on identifying 
factors that may be related to attrition. Because this is an exploratory analysis of data a 
post hoc power analysis was done to evaluate if there is sufficient power to reject the null 
hypotheses (Huck, 2008). 
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Question 3: “What is the effect size in analyses comparing those who withdraw 
and those who remain in terms of their demographic profiles, illness and 
treatment characteristics in: (a) each of the three double-blind randomized drug 
trials; and, (b) a merged data set combining all three double-blind randomized 
drug trials?”   
Effect sizes (Cohen’s d) were calculated for each variable in the merged data for 
the attrition and non-attrition groups, and independently for the attrition and non-attrition 
groups for each of the three double-blind randomized drug trials. Because there were five 
different drugs under study and the sample size is small differences between the 
individual drugs and the attrition and non-attrition groups were not done. Instead, effect 
sizes were used to evaluate the magnitude of change between the two groups and to 
evaluate for variation in effect size between the three studies as compared to the merged 
sample. The criteria used for the effect size was small (> .20), medium (> .50), and large 
(> .80) (Huck, 2008).  
The effect size (Cohen’s d) for the continuous variables was calculated using an 
online effect size calculator (see appendix H) (Becker, 2000). The formula    
                            was used for the calculation of Cohen’s d from categorical 
 
 variables (Chi Square 2x2 only and Fisher’s Exact) (Lipsey & Wilson, 2001). In this 
formula ES= effect size; X2=Pearson’s Chi Square; and N = the sample size.  
It is recommended that Chi Square analysis for > 2 x 2 contingency table not be 
calculated.  Even with two dichotomous variables there is an attenuation of the 
correlation coefficient. This attenuation is increased when there is increased skew, greater 
2
2
2 

 NES
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than a 50/50 split. This attenuation restricts the correlation coefficient (<.80) and the 
attenuation worsens when the two variables have more than two values (> 2 x 2 
contingency table) to the point of being unreliable (Lipsey & Wilson, 2001). Effect size 
calculation for the variables analyzed using the median (e.g., Mann-Whitney U) will use 
the mean instead as there is not a formula for effect size with the median (R. Mesholam-
Gately, PhD, verbal communication, January 17, 2009).  
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CHAPTER 4 
 
Results 
 
 This chapter will first present an explanation of how the data was prepared for 
analysis. Next is a description of the merged three studies to provide an overview of the 
study population. Each research question is answered in turn with a presentation of the 
results for the demographic profiles, and illness and treatment characteristics. For the 
results of the individual studies each study is presented in turn (ClozHal, OlzHal, 
OlzQueRis).  
Data preparation 
 
 In preparation for data analysis, the continuous variables were evaluated for 
skewness and the categorical variables for cell size. In the merged database marked 
skewness was found and the use of a median split was employed for: (1) duration of 
untreated psychosis (skewness = 2.139) divided into <13 and >13 weeks; (2) number of 
prior psychiatric hospitalizations (skewness = 1.678) divided into <2 or >2 
hospitalizations; and (3) number of days in washout (skewness = 1.968) divided into < 3 
and > 3 days. 
 When small cell size was found the cells were collapsed in a manner consistent 
with the data. The following demographic categorical variables were collapsed into 
dichotomous variables. Race/Ethnicity became non-Caucasian (0) or Caucasian (1). 
School attendance in past year became in school (0) or not in school (1). Highest work 
level became not working (0) or working/student (1). Highest useful functioning became 
no useful functioning to 25% (0) or 25 – 100% (1).  
In the illness characteristics, the lifetime substance use categorical variables were 
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collapsed into dichotomous variables, no use and use (0) or abuse and dependence (1) 
and were used in the analysis. Another set of lifetime substance use categorical variables 
were developed for descriptive purposes to retain the distinction between those with no 
use and use: no use (0); use (1); and abuse and dependence (2). For the 
neuropsychological test scores with percentile rank, the scores were converted into the 
Barona scale which defines below average as < 25th percentile and above average as >74th 
percentile. (Strauss, Sherman, & Spreen, 2006). This division provides a way to 
categorize the results as below average, average or above average, a more understandable 
way to interpret the results.  
Reason for termination had three different values to describe who made the 
decision to terminate the study for a lack of efficacy (by MD, by patient, or by agreement 
between patient and MD). These were combined into one value, lack of efficacy. This 
variable was not used in the analysis but was retained for descriptive purposes.  
Independent or Grouping Variables 
 The independent variable attrition was used with the merged database and with 
each of the studies individually. In the merged database there were 54 (65.8%) people in 
the attrition group and 28 (34.2%) who completed the twenty four weeks of the study. 
For complete details on the attrition and non-attrition groups in the merged database see 
Appendix J, Tables 14 – 16.  
Each of the three double-blind randomized studies were analyzed separately. 
There were 36 participants in the ClozHal with 25 (69.4%) in the attrition group; 29 
participants in the OlzHal study with 20 (69%) in the attrition group; and 17 participants 
in the OlzQueRis study with 9 (52.9%) in the attrition group. For details on the attrition 
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and non-attrition groups for the ClozHal study see Appendix K, Tables 17 – 19; OlzHal 
study Appendix L Tables 20 – 22; OlzQueRis study Appendix M Tables 23 – 25.  
Description of the Merged Sample 
Demographic Characteristics 
 
 This section provides a description of the demographic characteristics for the 
whole or merged database prior to answering the research questions. A total of 82 people 
in a first episode (FE) of a schizophrenia spectrum disorder (SSD) participated in one of 
the three clinical trials. On average the participants were 22.8 years old, predominately 
male (89%), and never married (96%). The majority were Caucasian (52%) followed by 
African Americans (28%), Hispanic (15%) and Asian (5%). At baseline the majority 
were not in school (61%), and the whole group had an average of 12.1 years of completed 
education. The highest level of school completed included high school diploma or GED 
(35%), some college (30%) and graduate school (7%) but 27% of this sample never 
completed high school. Of those who attended college (37%) only 7% graduated. In the 
group of those in school, 40% had to leave school due to psychiatric symptoms. This 
sample reflects a wide range of socioeconomic groups with a median household income 
of $41,186 (in 1999 dollars), based on US census zip code track, with a range of $11,400 
to $98,000 (homeless were excluded). 
Change in the level of functioning is common in the year prior to hospitalization 
(see Table 8). During the past year the majority (64%) of the participants reported they 
were living with family, followed by living independently or in a dormitory (30%) and 5 
(6%) were homeless due to psychiatric symptoms. However, in the month prior to 
baseline there was a decrease in the participants ability to maintain functional role 
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responsibilities with only 18% living independently and the number of homeless people 
doubled. Likewise, the number of people working and/or students in the prior 12 months 
(77%) dropped to 43% in the month prior to hospitalization. Consistent with a 
deterioration in functional roles prior to entering the study, twice as many participants 
reported no useful functioning (53%), than in the previous year (22%). 
 
Table 8.  
Demographic Characteristics at 1 Year and 1 Month Prior to Entry to Study 
 
Functional Role 
 
1 year  
prior to study 
(N)  % 
 
1 month  
prior to study  
(N)  % 
Living level 
     Independent/Dormitory 
     Family 
     Homeless, shelter 
 
         (23) 30% 
         (49) 64% 
           (5)   6% 
 
           (14)  18% 
           (54)  69% 
           (10)  13% 
 
Occupational 
     Student 
     Working for pay 
     Unemployed 
 
 
        (23)  30% 
        (37)  47% 
        (18)  23% 
 
           (10)  13% 
           (23)  30% 
           (44)  57% 
Overall level of functioning   
     No useful functioning to 25%         (16)  22%            (40)  53% 
     25% to 75%           (9)  12%            (17)  22% 
     75% to 100%         (48)  66%            (19)  25% 
   
   
 
Illness Characteristics 
This section provides a detailed description of the illness characteristics for the 
whole group prior to answering the research questions. At the time of admission to the 
study 65% were diagnosed with schizophrenia, 20% schizophreniform and 15% with 
schizoaffective disorder, with the average onset of psychosis at 21 years of age. At both 
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screening and baseline the participant’s severity of illness was between moderately and 
markedly ill (mean 4.7 and 4.4 respectively) as measured by the Clinical Global 
Impression – Severity (CGI). The average duration of untreated psychosis (DUP) was 30 
weeks but was skewed (range from 0 to 208 weeks) resulting in the use of a median split 
(13 weeks) for the analysis. The majority of the participants had one (53%) or two (26%) 
prior psychiatric hospitalizations (mean 1.75, range 0 to 6).  
 
Table 9. 
Lifetime Substance Use 
 
Substance 
 
No Use 
(N) % 
 
Use 
(N) % 
 
Abuse 
(N) % 
 
Dependence 
(N) % 
 
Alcohol 
 
(10) 13.2% 
 
(30) 39.5% 
 
(18) 23.7% 
 
(18) 23.7 
 
Marijuana 
 
(17) 22.1% 
 
(17) 22.1% 
 
(23) 29.9% 
 
   (20) 26.0% 
 
LSD 
 
(43) 57.3% 
 
(28) 37.3% 
 
(4) 5.3% 
 
- 
 
Cocaine 
 
(51) 68.0% 
 
(21) 28.0% 
 
(2) 2.7% 
 
   (1) 1.3% 
 
Opiates 
 
(67) 89.3% 
 
(7) 9.3% 
 
- 
 
   (1) 1.3% 
 
Amphetamines 
 
(65) 86.7% 
 
(9) 12.0% 
 
(1) 1.3% 
 
- 
 
PCP 
 
(66) 88.0% 
 
(8) 10.7% 
 
(1) 1.3% 
 
- 
     
 
The analysis of the merged data on substance use found a similar mean age at first 
use for alcohol and marijuana (14.5 and 15.1 respectively). Rates of lifetime abuse or 
dependence (see Table 9) were highest for marijuana (56%), followed by alcohol (47%). 
Substance use at any level found LSD (43%) and cocaine (32%) to also be high, while 
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use of opiates (11%), amphetamines (13%) and PCP (12%) was low. Only 22% reported 
no use of marijuana and 13% stated they had never used alcohol. Use of substances 
sharply declined in the month prior to entering the study with 74% reporting no use of 
alcohol or marijuana. During the 24 weeks of the double-blind phase of the study twenty-
one participants (34%) resumed use of alcohol and fourteen participants (24%) resumed 
marijuana use. Despite the heavy lifetime use of other drugs (LSD and cocaine) only one 
person reported using any other drug during the double-blind phase. 
Neurocognitive functioning was divided into six domains: estimated premorbid 
IQ; visual attention (Cancellation Test or Continuous Performance Test – Identical Pairs); 
executive functioning (Wisconsin Card Sorting Test, perseverative errors and categories 
achieved); language (Controlled Word Association Test - letters FAS; verbal memory 
(Wechsler Memory Scale – Revised, Logical Memory I or Hopkins Verbal Learning 
Test); and motor speed (Finger Tapping or Grooved Pegboard). The average estimated 
premorbid IQ for the merged data was 102.8, well within the normal range. The tests with 
percentile rank scores were converted into the Barona scale which defines below average 
as < 25th percentile and above average as >74th percentile (see Table 10). The Wisconsin 
Card Sorting Test of executive functioning for the whole group averaged 15.94 
perseverative errors, over twice as high as the normal mean norm of 6.92 (SD 5.04) . The 
average number of categories achieved (2.39) was well below the average norm of 5.58 
(SD 1.10) (Strauss et al., 2006).  
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Treatment Characteristics 
The treatment characteristics are described in this section for the merged group 
without any comparisons. Of the original 82 participants, 63 were randomized to study 
medication: 35% haloperidol (n = 22); 27% olanzapine (n = 17); 25% clozapine (n = 16); 
8% risperidone (n = 5); and 5% seroquel (n = 3). For data analysis purposes the 
randomized drugs were divided into atypical (n = 41, 64.5%) and typical (haloperidol n = 
22, 35.5%).  
A total of 66% (54) did not complete the study, 23% (19) left before 
randomization to study medication and 43% (35) left during the double-blind phase. The 
Table 10.  
 
Selected Neuropsychological Categorical Test Domains   
   
 
Domain  
 
Below 
Average 
(N)  % 
 
Average 
(N) % 
 
Above 
Average 
(N) % 
 
 
Between  
 3 Studies 
p 
 
 
Executive functioning 
   Perseverative response 
 
 
(16) 24.6% 
 
(31) 47.7% 
 
(18) 27.7% 
 
ns 
 
Language (20) 31.7% (33) 52.4% (10) 15.9% ns  
Verbal Memory (48) 73.8% (11) 16.9%    (6)   9.2% ns  
Motor speed (36) 55.4% (24) 36.9%    (5)   7.7% ns  
      
 Abnormal 
(N)  % 
Normal 
(N)  % 
 
   
 
Visual Attention 
 
(39) 68.4% 
 
(18) 32.6% 
  
.007 
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mean number of weeks completed in the double-blind phase was 15.7 weeks. Lack of 
efficacy (31.5%) was the most common medication related reason for leaving the study 
followed by withdrawal of consent by the participant (22.2%). 
Summary of Merged Sample 
Demographic Profiles 
 On average 22.8 years old, predominately male and never married 
 Wide range of socioeconomic groups 
 Decreasing level of role functioning as participants approached study entry 
Illness Characteristics 
 Average onset of psychosis at 21 years of age 
 Severity of illness was rated as moderately to markedly ill 
 History of high use of marijuana, alcohol and other drugs which sharply 
decreased in month prior to study 
 Neuropsychological functioning varied widely from well below average to above 
average 
Treatment Characteristics 
 The majority of participants were randomized to atypical agents (64%) 
 Attrition rates were high (66%) 
 Lack of efficacy and withdrawal of consent were the two most common reasons 
for attrition
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Question 1: What are the demographic profiles, illness and treatment characteristics of 
the participants in the three double-blind, randomized drug trials? 
 Comparison of the three double-blind, randomized drug trials found statistically 
significant differences between the three studies in demographic characteristics (see 
Appendix I, Table 11), illness characteristics (see Appendix I, Table 12), and one 
treatment characteristic (see Appendix I, Table 13). The significant results will be 
described in this section. Operational definitions and coding criteria are listed in 
Appendix C for demographic characteristics. Illness characteristics in Appendix D and 
treatment characteristics in Appendix E. Results with and without Bonferroni correction 
will be described for continuous variables when findings are statistically significant.  
Statistically Significant Differences Between the Three Studies 
Demographic characteristics 
Median income and highest functioning level in the past year were statistically 
different between the three studies. The median income was highest in the ClozHal group 
(M = $49,722) and lowest in the OlzHal group (M = $36,362), Welch  
(F = 3.838, df = 2,35.325, p = .031) without Bonferroni correction. Post hoc tests with 
Bonferroni correction found the difference between these two groups to be not significant 
(p=.055), but there is a trend.  
Two measures of functioning were found to be significantly different between the 
three studies. First, employment status, “not working due to disease disability” and 
“working and/or student”, during the year prior to baseline had the vast majority of the 
OlzHal study participants working or in school (93%) (X2 (2, n = 78) = 9.200, p = .01) as 
compared to the OlzQueRis study which had the lowest number of people working or a 
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student (53.3%). Similarly, the second functional measure, the “percent of time spent in 
useful activities” (0 to 25% or >25 to 100%) (X2 (2, n = 73) = 6.819, p = .033) found the 
OlzHal participants to be functioning at the higher level (93.1%) as compared to the 
OlzQueRis study (61.5%).  
Illness Characteristics 
The significant illness characteristics between the three studies include severity of 
illness and three of the neurocognitive domains, estimated premorbid IQ, memory 
functioning and visual attention. There was a significant difference between the three 
studies in the severity of illness Welch (F = 6.148, df = 2,34.993, p = .005); post hoc tests 
with Bonferroni correction found the severity of illness at screening was highest (m = 
5.36 markedly ill) for the OlzQueRis than in the ClozHal group (M = 4.62 moderately ill) 
(F = 5.970, df = 2,69, p = .009) and the OlzHal groups (M = 4.39 moderately ill) (F = 
5.970, d.f. = 2,69, p = .006). These findings suggest that the OlzQueRis group was more 
severely ill at screening than the other two studies. Of note, the mean clinical assessment 
for the baseline CGI was moderately ill and there was no significant difference between 
the three studies Welch (F = .282, df = 2,65, p = .761).  
The significant findings for the neuropsychological tests will describe each 
domain separately. The first domain, estimated premorbid IQ, was significantly higher in 
the OlzQueRis group (M = 107) than in the ClozHal group (M = 101.5), Welch (F = 
3.878, df = 2,26.345, p = .033) but post hoc tests with Bonferroni correction found no 
significant difference between the groups (p = .09).  
The second domain, memory functioning (Wechsler Memory Scale – Revised, 
Logical Memory I or Hopkins Verbal Learning Test) results showed the percentile score 
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to be strikingly lower in the OlzQueRis group (Hopkins Verbal Learning Test) and 
significantly different from the other two groups (Logical Memory I) Welch (F = 23.074, 
df = 2,33.398, p < .001). The homogeneity of variance (Levene) was significant at a .000 
level. In post hoc tests with Bonferroni correction, the  memory functioning score for the 
OlzQueRis study was lower than the ClozHal study (p = .004) but not significantly 
different from the OlzHal study (p =  .077). It is unclear why there is such a difference in 
scores.  
The third significant domain was visual attention (Cancellation Test or 
Continuous Performance Test – Identical Pairs).  The OlzHal group had more participants 
in the abnormal group (94.4%) (X2 (2, n = 57) = 9.922, p =.007), compared to both the 
ClozHal (62.1%) and the OlzQueRis groups (40%).  
The treatment characteristic, number of days in washout, a dichotomous variable 
due to skewness in the continuous variable, was significantly different between the 
ClozHal and the OlzHal groups (Fisher’s Exact  p = .008). The majority of the 
participants in the ClozHal study (n = 21, 70%) had fewer days in washout (<3) and the 
OlzHal study had the highest percentage of participants (n = 18, 66.7%) in the higher 
washout group (>4). Prior to the washout period, the current antipsychotic medication 
was tapered and stopped in a manner consistent with good clinical practices. In all cases, 
if someone had a rapid increase in symptoms, the washout period was terminated and 
randomization to study medication occurred.  
 
Summary of significant differences between the three studies: 
 
Demographic Profiles 
 
 The median income was highest in the ClozHal group and lowest in the OlzHal  
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group 
 
 The OlzHal group had the highest employment status and functional level   
 
 The OlzQueRis group had the lowest employment status and functional level 
 
Illness Characteristics 
 
 The OlzQueRis group had the highest severity of illness at screening 
 
 The OlzQueRis group had the highest premorbid IQ 
 
 Memory functioning was lowest in the OlzQueRis group 
 
 The majority of OlzHal group had abnormal scores in visual attention while the   
 
OlzQueRis group had the least number of abnormal scores 
 
Treatment Characteristics 
 
 The ClozHal group had fewer days in washout 
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Question 2: To what extent do patients’ demographic profiles, illness, and treatment 
characteristics differ in those who withdraw for any reason and those who remain in each 
of the three double-blind randomized drug trials? 
Each of the three double-blind, randomized drug trials were analyzed separately for 
differences in the attrition and non-attrition groups. Findings for the merged sample and 
then each of the drug trials are described.  
Attrition vs. Non-attrition Groups 
Merged Data (all three studies) 
The sample characteristics for the attrition and non-attrition group for 
demographic, illness and treatment characteristics can be found in Appendix J Tables  
14 – 16 respectively.  There were no statistically significant differences between the 
attrition and non-attrition groups in demographic and illness characteristics in the merged 
data. There was a significant different between the attrition and non-attrition groups in 
whether the participant was randomized to typical (haloperidol) or atypical (olanzapine, 
quetiapine, risperidone, clozapine) antipsychotic medication. One study (OlzQueRis) did 
not contain a typical antipsychotic medication. The data was analyzed for typical and 
atypical agents without the OlzQueRis study.  Significantly fewer participants on typical 
antipsychotic medication completed the study (25% n = 22), compared to those receiving 
an atypical medication (75% n = 41) (p < .05) (excluding the OlzQueRis study). 
ClozHal 
ClozHal Demographic Profile 
In the demographic profile of the ClozHal study (see Appendix K, Table 17), 
there were two significant findings, age at study entry and years of education. The 
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attrition group was modestly but significantly older (M = 23.88) than the non-attrition 
group (M = 20.09), Levene’s test was significant (.006), (t = -3.409, df = 33.307, p = 
.002). The attrition group also had significantly more years of education (M = 12.68) than 
the non-attrition group (M=10.81) (t = -2.268, df = 34, p = .03).  
ClozHal Illness Characteristics 
One illness characteristic (see Appendix K, Table 18), age at onset of psychosis, 
was significant, with the attrition group older at the onset of psychosis (M = 22.56) than 
the non-attrition group (M = 18.91) (t = -3.345, df = 33.007, p=.002). Levene’s test was 
significant (.011). There was no significant difference between the attrition and non-
attrition groups in any of the other illness characteristics. 
ClozHal Treatment Characteristics 
Analyses of the treatment characteristics (see Appendix K, Table 19) showed no 
significant difference between the attrition and non-attrition groups.  In the ClozHal study 
69.4% (n = 25) did not complete the study with 36% (n = 9) leaving the study before 
entering the double-blind phase. In the attrition group, participants completed, on 
average, 8.5 weeks of double-blind treatment (range 1 – 21 weeks). Two reasons for 
termination, including lack of efficacy and patient withdrawal of consent, occurred most 
frequently (24% each); the next two most frequent reasons for leaving were adverse 
events and patients moving away (16% each). Even though it did not reach a level of 
significance, the majority (81.8%) of the participants who completed the study were 
taking the atypical agent clozapine (Fisher’s Exact = .109). Those who did not complete 
the study were divided between the typical and atypical agents (56.2% and 43.8% 
respectively).   
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ClozHal Summary 
The ClozHal attrition group was:  
 significantly older at study entry with more years of education 
 older at age of onset of psychosis 
OlzHal 
OlzHal Demographic Profile   
The demographic profile (see Appendix L, Table 20) showed significant 
differences between the attrition and non-attrition groups in three variables. Two 
measures involved education. The first variable measured school attendance in the past 
year.  The second variable measured if the participant left school due to psychiatric 
illness in the past year. The third variable measured the participants living situation in the 
past year. In a comparison of the attrition and non-attrition groups, 37.9% (n = 11) were 
in school in the past year, and all eleven people were in the attrition group (Fisher’s Exact 
p =.005). Likewise, all of the people who left school due to psychiatric illness were in the 
attrition group (n = 8, 29.6%) (Fisher’s Exact p=.026). There was a significant different 
between the attrition and non-attrition groups and living situation in the past year (X2 (2, 
n = 29) = 8.112, p = .017). The majority of the people in the attrition group were living 
with family (70%). Two other demographic characteristics, number of years of education 
and median household income, approached significance. The majority of the participants 
were in the attrition group (n = 20, 69%) and had a higher number of years of education 
(M = 12.9) than those who completed the study (M = 11.6) (p = .066). The attrition group 
had a lower household income (M = $31,613) than the non-attrition group (M = $45,066) 
(p = .065).  
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OlzHal Illness and Treatment Characteristics 
 There were no significant differences between the attrition and non-attrition 
groups and illness and treatment characteristics (see Appendix L, Table 21, 22). In the 
OlzHal study, 62.5% (n = 15) did not complete the study, with 17% (n = 5) leaving the 
study before entering the double-blind phase. In the attrition group, participants 
completed an average of 9.3 weeks of double-blind treatment (range 1 – 20 weeks). The 
most frequent reason for termination from the study was lack of efficacy (n = 10, 50%). 
The next most frequent reason was patient withdrawal of consent (n = 3, 15%). There 
was no difference between the attrition and non-attrition groups in type of medication, 
but 66.7% of the non-attrition group received the atypical agent, olanzapine (p = .423).  
OlzHal Summary 
The OlzHal attrition group was: 
 More likely to be in school in the previous year and to have left school due to 
psychiatric illness 
 More likely to be living with family 
OlzQueRis 
 It is important to note this group was small (n = 17), with very small cell sizes. 
Therefore, these results should be treated tentatively. They are underpowered and the 
small sample size also limits robustness for violations of statistical assumptions of 
normality and homogeneity of group variances. Mann-Whitney U was used for the 
analysis of the continuous variables when they were skewed, the groups were equal in 
size and if Levene’s test of equality of variance was significant. This study had more 
skewed variables than the other two studies. Data were skewed in age at the onset of the 
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study (2.048), highest number of hours worked in the past year (4.0), age at onset of 
psychosis (1.869), and memory functioning (3.182). Levene’s test for equality of 
variance was significant for the baseline CGI (.030) only.  
OlzQueRis Demographic Profile and Illness Characteristics 
There were no demographic or illness variables (see Appendix M, Table 23 and 
24 respectively) on which the two groups differed. There was a trend in the baseline CGI, 
with the attrition group’s mean rank (9.58) higher than the non-attrition group’s mean 
rank (5.94) z = -1.799, p = .072.  
OlzQueRis Treatment Characteristics 
There were no significant differences in treatment characteristics between the 
attrition and non-attrition groups (see Appendix M, Table 25). In the OlzQueRis study, 
52.9% (n = 9) did not complete the study with 29.4% (n = 5) leaving the study before 
entering the double-blind phase. In the attrition group, participants completed an average 
of 10 weeks of double-blind treatment (range 6 – 12 weeks). The two most frequent 
reasons for termination from the study were patient withdrawal of consent and lost to 
follow-up (n = 3, 33.3% each). There were no significant differences between the three 
atypical medications and the attrition and non-attrition groups.  
 
OlzQueRis Summary 
There was no significant difference in the OlzQueRis group between the attrition and 
non-attrition groups.        
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Question 2 Summary 
In two of the three groups, educational variables (school attendance in the past year, left 
school due to psychiatric illness and more years of education) were significantly 
associated with the attrition group, although the significant variables differed between the 
studies.                                                                      
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Question 3: What is the effect size in analyses comparing those who withdraw and those 
who remain in terms of their demographic profiles, illness and treatment characteristics 
in: (a) each of the three double-blind randomized drug trials; and, (b) a merged data set 
combining all three double-blind randomized drug trials?   
Question 3a:  
Description of Methods 
Effect sizes (Cohen’s d) were calculated for each variable as described in the 
methods section. The criteria used for the effect size was small (>.20 to <.50), medium 
(>.50 to <.80), and large (>.80) (Huck, 2008). Table 26 presents the effect size for the 
variables in rank order. Effect sizes meeting criteria for small, medium or large are in 
bold to facilitate ease in reading the table. Effect sizes are not reported for Chi Square 
analysis with greater than a 2 x 2 contingency table. Significant differences between the 
attrition and non-attrition groups are noted (e.g., * p < .05  ** p < .01  *** p < .001). 
Several of the variables did not meet statistical significance but did show a trend, which 
was noted as well (e.g., 1 p < .066 and 2 p < .089). 
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Table 26.   
 
Effect Size for the Comparison of the Attrition and Non-attrition GroupsA 
 
 
UDependent Variable 
 
 
UEffect Size Cohen’s d 
 
Large > .80 
UMerged data 
(N = 82) 
UClozHal 
(N = 36) 
UOlzHa Ul 
(N = 29) 
UOlzQueRis 
(N = 17) 
Motor functioning   .33 .18 .59 1.661 
School Attendance .10 .38 1.23** .73 
Severity of illness 
baseline 
 
.17 .05 .16 1.131 
Number of years 
completed education 
 
.34 .70* .65 1.121 
Age at start of study .28 1.08** .63 .02 
Age at onset of psychosis .16 1.06** .49 .04 
Left school (past year) .10 .09 1.03* .72 
Median household 
income 
 
.36 .15 1.021 .45 
Functional Level 
 
  .32 .12 .892 .05 
Employment level   
(past year) 
.20 .02 .892 .40 
 
Intellectual functioning 
 
 
.17 
 
.27 
 
.11 
 
.86 
Typical versus atypical 
medication (ClozHal & 
OlzHal only) 
 
  .62* .82 .48 - 
   1 p < .066 
   2 p < .089 
   * p < .05  ** p < .01  *** p < .001  
A Effect sizes equal to or exceeding the cut off for small (.20), medium (.50) and large 
(.80) are in bold. 
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Table 26 (continued). 
 
Effect Size for the Comparison of the Attrition and Non-attrition GroupsA 
 
 
Medium > .50 - < .80 
 
UMerged data 
 
(N = 82) 
 
UClozHal 
 
(N = 36) 
 
UOlzHa Ul 
 
(N = 29) 
 
UOlzQueRis 
 
(N = 17) 
     
Previous hospitalizations 
 
.17 .51 .41 .72 
Executive functioning –  
categories achieved 
 
.34 .05 .68 .11 
Alcohol (Age 1st use)         .06 .37 .30 .68 
 
Lifetime Marijuana  
 
.26 .62 .10 .27 
Language functioning .08 .32 .58 .11 
Marijuana (Age 1st use)      
 
.10 .41 .08 .58 
Executive functioning –  
perseverative  
 
.19 .06 .53 .12 
Employment 
(hours/week) 
.08   .003 .51 .29 
 
Memory functioning  
 
.31 
 
.02 
 
.50 
 
.14 
     
 
A Effect sizes equal to or exceeding the cut off for small (.20), medium (.50) and large 
(.80) are in bold. 
 
 
 
 
 
 
 
 
 
 
 
  
91
 
  
 
Table 26 (continued). 
 
Effect Size for the Comparison of the Attrition and Non-attrition GroupsA 
 
 
 
Small > .20 - < .50 
 
UMerged data 
 
(N = 82) 
 
UClozHal 
 
(N = 36) 
 
UOlzHa Ul 
 
(N = 29) 
 
UOlzQueRis 
 
(N = 17) 
 
Gender 
 
.18 
 
.18 
 
.03 
 
.48 
 
Screening severity of 
illness 
 
.05 
 
.13 
 
.45 
 
.05 
 
Race 
 
 
.29 
 
.12 
 
.39 
 
.37 
Lifetime alcohol  .19 .13 .29 .39 
Visual Attention 
functioning 
.11 .06 .39 .34 
 
Duration of untreated 
psychosis 
 
 
.15 
 
.06 
 
.37 
 
.27 
Lifetime use of other 
drugs 
 
.27 .17 .22 .20 
     
 
A Effect sizes equal to or exceeding the cut off for small (.20), medium (.50) and large 
(.80) are in bold. 
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Question 3a: ClozHal  
ClozHal Effect Size - Large  
In the demographic profile of the ClozHal study (see Appendix K, Table 17), 
there were two significant findings, age at study entry and years of education (see Table 
26 effect size). The difference in age at study entry showed a large effect size (d = 1.08) 
with an older attrition group (M = 22.6 as compared to M = 18.9 in non-attrition group).  
In the illness characteristics (see Appendix K, Table 18), the attrition group was 
older at the onset of psychosis (M = 22.56) than the non-attrition group (M = 18.91) with 
a large effect size (d = 1.06). The treatment characteristic, type of medication, showed a 
large effect size (d = .82) between the two groups, with the majority of the attrition group 
receiving a typical antipsychotic (56%) as compared to the non-attrition group (18%).  
ClozHal Effect Size - Medium 
The demographic profile of the attrition group found significantly more years of 
education (M = 12.7) with a moderately large effect size (d = .70) as compared to the 
non-attrition group (M = 10.8).  Illness characteristics did not reach statistical 
significance but did have a medium effect size. Lifetime use of marijuana (p = .141) had 
a medium effect size (d = .62), with 41% of the attrition group diagnosed with marijuana 
abuse or dependence as compared to 73% of the non-attrition group. The number of 
previous hospitalizations did not differ significantly between the groups (p = .137) but 
had a medium effect size (d = .51), with 56% of the attrition group having one previous 
hospitalizations as compared to 82% of the non-attrition group. The attrition group had 2 
or more previous hospitalization (44%) as compared to the non-attrition group (18%).  
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ClozHal Effect Size - Small 
A non significant demographic variable, school attendance had a small effect size 
(d = .38) with the majority of the attrition group (65%) not in school in the past year as 
compared to 46% in the non-attrition group. There was a small effect size (d = .41) for 
the age at first marijuana use with the attrition group older (M = 15.4, d = 41) as 
compared to the non-attrition group (M = 14.5). The effect size (d = .37) for mean age at 
first use of alcohol found the attrition group was older (M = 14.75) as compared to (M = 
14) the non-attrition group. The effect size of two neuropsychological tests, language 
functioning (d = .32) and estimated premorbid IQ (d = .27), were small. Language 
functioning in the attrition group had a higher percentile score (48.8) than in the non-
attrition group (41.5). The estimated premorbid IQ was higher (100.47) in the attrition 
group as compared to non-attrition group (97). 
 
Summary – ClozHal Effect Size Attrition vs. Non-attrition Groups 
With a large effect size, the attrition group: 
 was older at study entry (d = 1.08)  
 was older at onset of psychosis (d = 1.06) 
 was more likely to have received a typical antipsychotic medication (d = .82) 
With a medium effect size, the attrition group was: 
 was more likely to have more years of education (d = .70) 
 was less likely to be diagnosed with marijuana abuse or dependence (d = .62) 
 was more likely to have fewer previous psychiatric hospitalizations (d = .51) 
With a small effect size, the attrition group: 
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 was less likely to be in school in the previous year (d = .38) 
 was older at first use of marijuana (d = .41) and alcohol (d = .37) 
 was more likely to have a higher scores in language function (d = .32) and a 
higher estimated premorbid IQ (d = .27) 
Question 3a: OlzHal 
OlzHal Effect Size - Large 
 In the demographic characteristics (see Appendix L, Table 20), there was a 
significant difference between the attrition and non-attrition groups in three variables (see 
Table 26 for effect size). Both educational variables had a large effect size, attendance in 
school in the past year (d = 1.23), and did the participant leave school due to psychiatric 
illness in the past year (d = 1.03).  In the attrition group, 55% were in school in the 
previous year while 100% of the non-attrition group was not in school. In the attrition 
group, 56% did not leave school due to psychiatric symptoms as compared to 100% of 
the non-attrition group. The third variable, living situation in the past year, was not 
calculated for effect size because it was not a dichotomous variable. Two other 
demographic characteristics, median household income and years of education 
approached significance. There was a large effect size for income (d = 1.02), with a lower 
median income ($29,072) in the attrition group than in the non-attrition group ($43,751). 
Despite not achieving a significant difference between the groups other demographic 
variables, functional level and employment status each had a large effect size (d = .89). 
The majority of both groups were employed or a student functioning at the higher level in 
both groups (attrition 100%; non-attrition 77.8%).  
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OlzHal Effect Size - Medium 
The demographic profile found years of education to have a medium effect size 
 (d = .65), with more years of education (12.9) in the attrition group than in the non-
attrition group (11.6). A medium effect size was found with age at the start of the study 
(d = .63) and number of hours employed per week (d = .51). The attrition group was 
younger (M = 22.3) than the non-attrition group (M = 25.4) and working less hours (M = 
20.5) than the non-attrition group (M = 30). Medium effect sizes were found for the 
neuropsychological tests, including executive functioning categories achieved (d = .68), 
motor functioning (d = .59), language functioning (d = .58), executive functioning 
perseverative errors (d = .53), and memory functioning (d = .50). The attrition group had 
lower percentile scores in executive functioning but higher scores in language, memory 
and motor functioning.  
OlzHal Effect Size - Small 
It is important to note that the following results reflect small effect sizes and non 
significant differences. The majority of the attrition group was Caucasian (65% vs 
44.4%) with a small effect size (d = .39). For the illness characteristics, age at onset of 
psychosis (d = .49), and screening severity of illness approached a medium effect size  
(d = .45).  A small effect size was found for duration of untreated psychosis (d = .37), age 
at first alcohol (d = .30), lifetime use of alcohol (d = .29) and lifetime use of other drugs 
(d = .22). The attrition group was younger (M = 21.5 vs 23.89) at onset of illness, with a 
higher screening severity of illness (M = 4.6 vs 4.3) and fewer hospitalizations (d = .41), 
with 55% of the attrition group with one or no previous hospitalizations versus 33% of 
the non-attrition group. The attrition group was split between longer (47.2%) and shorter 
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(52.6%) DUP, while the majority of the non-attrition group had a longer (66.7%) DUP. 
For the substance use variables the attrition group was slightly older at first alcohol use 
(M= 14.88 vs 14) and 60% did not meet criteria for alcohol abuse or dependence as 
compared to 44.4% of the non-attrition group. Only 5% of the attrition group meets 
criteria for abuse or dependence of other drugs of abuse as compared to 11% in the non-
attrition group. In the visual attention domain the vast majority of participants were in the 
abnormal group for both the attrition (91%) and non-attrition (100%) groups (d = .39). 
There was no significant difference between the attrition and non-attrition groups in type 
of medication, but 53.3% of the attrition group were receiving the typical agent, 
haloperidol (p = .423), while only 33.3% of the non-attrition group were receiving 
haloperidol, almost reaching a medium effect size (d = .48). 
 
Summary – OlzHal Effect Size Attrition vs. Non-attrition Groups 
With a large effect size, the attrition group: 
 was less likely to be in school in the past year (d = 1.23) 
 was more likely to have left school due to psychiatric symptoms (d = 1.03) 
 had a lower income level (d = 1.02) 
 was employed or a student (d = .89) 
With a medium effect size, the attrition group: 
 had more years of education (d = .65) 
 was younger at the start of the study (d = .63) 
 was more likely to not be working or a student (d = .51) 
 had lower scores in executive functioning (categories) (d = .68) and perseverative 
  
97
 
  
errors (d = .53) 
 had higher scores in motor (d = .59), language (d = .58), and memory functioning 
(d = .50) 
With a small to medium effect size, the attrition group: 
 was more likely to be receiving typical antipsychotic medication (d = .48) 
 was younger at the onset of psychosis (d = 49) 
With a small effect size, the attrition group: 
 was more severely ill at screening (d = .45) 
 had fewer previous hospitalizations (d = .41) 
 was more likely to be Caucasian (d = .39) 
 had fewer abnormal scores in visual attention (d = .39) 
 had a shorter DUP (d = .37) 
 was older at age of first alcohol use (d = .30) 
 had less participants diagnosed with alcohol abuse or dependence (d = .29) 
 had more participants with no diagnosis of abuse or dependence of other drugs   
(d = .22) 
 
Question 3a: OlzQueRis  
OlzQueRis Effect Size - Large 
 It is important to remember this group was small (n=17) with very small cell 
sizes; therefore, these results should be treated tentatively. There were no demographic or 
illness variables (see Appendix M, Table 23 and 24 respectively) on which the two 
groups differed. There were several variables with a large effect size including motor 
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functioning (d = 1.66), baseline severity of illness (d = 1.13), number of years of 
completed education (d = 1.12) and intellectual functioning (d = .86). The motor 
functioning percentile score was higher in the attrition group (M = 70.67 vs 35.75). The 
baseline severity of illness was higher in the attrition group (M = 4.83 vs 3.88). The 
attrition group had fewer years of completed education (M = 10 vs 12.5). The attrition 
group had a lower estimated premorbid IQ (M = 101 vs 109.75).  
OlzQueRis Effect Size - Medium 
There was a medium effect size in two measures of education, school attendance 
(d = .73) and left school in past year due to psychiatric illness (d = .72). The majority of 
the participants in the attrition group were not in school (83.3% vs 50%) and did not 
leave due to illness (71.4% vs 37.5%). Previous psychiatric hospitalizations had a 
medium effect size (d = .72) with the vast majority of the participants in the attrition 
group having two or more prior hospitalizations (87.5%) as compared to the non-attrition 
group (37.5%). Age at first use of alcohol (d = .68) and marijuana (d = .58) showed a 
medium effect size. Age at first alcohol use was younger in the attrition group (13.3 
years) than in the non-attrition group (14.88 years). Similarly, age at first marijuana use 
was younger (14 years) for the attrition group than the non-attrition group (15.12 years).  
OlzQueRis Effect Size - Small 
Close to a medium effect size was found for gender (d = .48); but the female 
sample size is too small for valid comparison purposes and race (d = .37), in which more 
Caucasian participants were in the attrition group (55.6%) than in the non-attrition group 
(37.5%).  Median household income approached a medium effect size (d = .45), while 
employment status (d = .40) and number of hours working per week (d = .29) were 
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smaller. The median household income was lower in the attrition group ($35,874) as 
compared to the non-attrition group ($43,751). Participants in the attrition group were 
less likely to be working or students (42.9% vs 62.5%), but the attrition group was 
working more hours per week (M = 18 vs 11.4). A small effect size was found for 
lifetime alcohol use (d = .39), lifetime marijuana use (d = .27) and use of other drugs (d = 
.20). The attrition group had more participants with a diagnosis of marijuana (87.5%) 
abuse or dependence than the non-attrition group (75%).  Alcohol abuse or dependence 
was also high in both groups, but lower in the attrition group (57.1%) than in the non-
attrition group (75%). Similarly, the attrition group was less likely to be diagnosed with 
abuse or dependence of other drugs (16.7%) than in the non-attrition group (25%).  Other 
variables with a small effect size include visual attention (d = .34) and DUP (d = .27). In 
the attrition group an equal number of participants (50% each) had normal or abnormal 
scores on visual attention, and the attrition group had more participants (50%) with an 
abnormal score when compared to the non-attrition group (33.3%). The majority of the 
attrition participants were in the shorter DUP group (75%) as compared to the non-
attrition group (66.7%).  
 
Summary – OlzQueRis Effect Size Attrition vs. Non-attrition Groups 
With a large effect size, the attrition group: 
 had a higher motor functioning percentile score (d = 1.66) 
 was more severely ill at baseline (d = 1.13) 
 had fewer years of completed education (d = 1.12) 
 had a lower estimated premorbid IQ (d = .86) 
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With a medium effect size, the attrition group: 
 was less likely to be in school (d = .73) 
 did not leave school due to psychiatric illness (d = .72) 
 was more likely to have had 2 or more previous hospitalizations (d = .72) 
 was more likely to be younger at first use of alcohol (d = .68) and marijuana (d = 
.58) 
With a small effect size, the attrition group: 
 had more Caucasian participants (d = .37) 
 had a lower median income (d = .45) 
 was less likely to be working or students (d = .40) but worked more hours per 
week (d = .29) 
 had more participants with a diagnosis of marijuana abuse or dependence            
(d = .27) 
 was less likely to be diagnosed with alcohol (d = .39) and other drug (d = .20) 
abuse or dependence  
 was more likely to have an abnormal score in visual attention (d = .34) 
 was more likely to have a shorter DUP (d = .27) 
 
Question 3b: Three Combined Studies 
Combined Studies Effect Size - Large 
 For the combined study there was no significant difference between the attrition 
and non-attrition groups in demographic or illness characteristics and no large effect size 
(see Table 26 for effect sizes).  
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Combined Studies Effect Size - Medium  
The one significant difference in treatment characteristics, typical versus atypical 
antipsychotic medication (p = .034) showed a medium effect size (d = .62) in the 
combined ClozHal and OlzHal studies only. The majority of the participants in the 
attrition group were receiving a typical antipsychotic medication (55%) rather than an 
atypical antipsychotic medication (45%). In the non-attrition group, the majority (75%) 
were receiving atypical antipsychotic medication.  
Combined Studies Effect Size - Small 
There were several small effect sizes although most were very small (d = .05 to 
.19). The attrition group was slightly older at the start of the study (d = .28) (M = 22.9 vs 
22.36), had more Caucasians (d = .29) (57% vs 42.9%), and a slightly higher number of 
years of completed education (d = .34) (M = 12.36 vs 11.54). The functional level (d = 
.32) of the attrition group was higher (83%) than the non-attrition group (69%) with the 
attrition group more likely to be working or a student (80%) than the non-attrition group 
(71%) (d = .20). The median household income was lower (d = .36) (M = $39,507) in the 
attrition group than in the non-attrition group ($44,260).  
Small effect sizes were found with three of the neuropsychological domains: 
executive functioning categories achieved (d = .34), memory functioning (d =.31) and 
motor functioning (d = .33). Executive functioning categories achieved was lower (M = 
2.16) in the attrition group as compared to the non-attrition group (M = 2.7). Memory 
functioning (M = 22.9) and motor functioning (M = 34) were higher in the attrition group 
as compared to memory functioning (M = 15.3) and motor functioning (M = 25) in the 
non-attrition group. Lifetime marijuana (d = .26) had a small effect size with fewer 
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participants in the attrition group with a diagnosis of marijuana abuse or dependence 
(51%) as compared to the non-attrition group (64.3%). Similarly, in the attrition group 
fewer participants had a diagnosis of abuse or dependence (6.4%) for lifetime use of 
other drugs (d = .27) as compared to the non-attrition group (14.3%).  
 
Summary – Three Combined Studies Effect Size Attrition vs. Non-attrition Groups 
There were no large effect sizes in the three combined studies.  
With a medium effect size, the attrition group: 
 was more likely to be receiving a typical antipsychotic medication (d = .62) 
With a small effect size, the attrition group: 
 was slightly older (d = .28) and more likely to be Caucasian (d = .29) 
 had more years of education (d = .34)  
 had a higher level of functioning (d = .32) 
 was more likely to be working or a student (d = .20) 
 had a lower median household income (d = .36) 
 had lower executive functioning (categories achieved) (d = .34) 
 had higher memory (d = .31) and motor functioning (d = .33) 
 was less likely to have a diagnosis of marijuana (d = .26) and other drug (d = .27) 
abuse or dependence  
Summary 
Comparison of three studies 
 There were minor differences in demographic and illness characteristics between 
the three studies but no consistent pattern of differences. 
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 Overall, there were no serious differences between the three studies which 
allowed, therefore, for the use of the merged database. 
Attrition and Non-attrition in the three studies and merged database 
 No significant difference between the attrition and non-attrition groups in the 
merged data in demographic and illness characteristics. 
 No consistent pattern in demographic and illness characteristics between the three 
studies and the attrition and non-attrition groups. 
 Treatment characteristics consistently found lack of efficacy and patient 
withdrawal of consent to be the two most frequent reasons for attrition from the 
studies. 
 Participants receiving a typical agent were less likely to complete the study. 
Effect size 
 Each individual study had a range from small to large effect sizes. 
 The following variables were identified in three out of four of the studies and 
merged data (ClozHal, OlzHal, OlzQueRis, and merged) based on effect size.      
The attrition group: 
o was more likely to be Caucasian (range d = .29 - .39) 
o had more years of education (range d = .34 – 1.12) 
o was less likely to be in school in the year prior to the study (range d = .38 
– 1.23) 
o was less likely to have a diagnosis of abuse or dependence for other drugs 
(range d = .20 - .27) 
o had a lower median income (range d = .36 – 1.02) 
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o had higher scores on motor functioning (range d = .33 - 1.66) 
o was receiving typical antipsychotic medication (range d = .48 - .82) 
 In the merged database effect sizes were mostly small. 
 The only consistent effect size across the studies that included a typical agent was 
the higher use of typical agents in the attrition group (d = .62).  
The direction of the effect size was not consistent between the studies and the merged 
data. The attrition group: 
 was older at the start of the study in two (merged and ClozHal) of the three 
(OlzHal) 
 was more likely to be working in two (merged and OlzHal) of the three 
(OlzQueRis) 
 had fewer hospitalizations in two (ClozHal and OlzHal) of the three (OlzQueRis) 
 was older at first use of alcohol in two (ClozHal and OlzHal) of the three 
(OlzQueRis) 
 was less likely to have a lifetime diagnosis of marijuana abuse or dependence in 
the merged data and the ClozHal group, and much more likely in OlzQueRis 
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CHAPTER 5 
Discussion 
Question 1:  
What are the demographic profiles, illness and treatment characteristics of the 
participants in the three double-blind, randomized drug trials? 
 
 This study provides a snapshot in time of a group of participants in a first episode 
of a schizophrenia spectrum disorder who participated in one of three double-blind, 
randomized drug trials. The study participants are more similar than different based on 
the lack of significant differences between the three studies. The differences identified 
may actually be a reflection of the range of characteristics found in larger first episode 
samples and in the natural course of the illness (Perkins et al., 2006b).  
 Overall, the data paints a picture of the devastating effects of psychosis on the 
lives of these young participants. The effect on educational and occupational role 
functioning is great, as exemplified by an inability to complete high school (27%, n = 22) 
as compared to the Massachusetts 2000 - 2001 statewide annual high school dropout rate 
of 3.5% (Massachusetts Department of Education, 2002). In this study, 64% (n = 14) of 
those who did not complete high school came from cities with the highest dropout rates 
in Massachusetts (up to 50% in some schools). Of those who completed high school 38% 
(n = 31) entered college, but only 19% (n = 6) completed college resulting in an 81% 
dropout rate, a much higher than the current college dropout rate of more than 50%  
(Barefoot, 2004; The Associated Press, 2005). The inability to graduate high school or 
college may be a consequence of the onset of psychosis. Specifically, 27% had an onset 
of psychosis between 16 to 18 years of age, and 37% had an onset during the college 
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years.  Occupational functioning (see Table 8) was also adversely affected, with 22% (n = 
16) functioning at a level of less than 25% during the year prior to the study, suggesting a 
long period of very poor functioning for almost one quarter of the sample.  
 Substance use is a critical health and mental health problem in this age group of 
young adults. The Centers for Disease Control provide data on substance use in 
secondary education students using the Youth Risk Behavior Survey (YRBS) (Centers 
for Disease Control and Prevention (CDC), 2007) and on adults using the Behavioral 
Risk Factor Surveillance System (BRFSS) (Centers for Disease Control and Prevention 
(CDC), 2001). The Substance Abuse and Mental Health Services Administration 
(SAMHSA) also collects data using a National Survey on Drug Use and Health 
(NSDUH) (Substance Abuse and Mental Health Services Administration, 2007). The 
National Institute on Alcohol Abuse and Alcoholism (NIAAA) provides data on 
adolescent alcohol use based on the YRBS, NSDUH and MTF (Monitoring the Future) 
for ages 12 - 20 from 1991 to 2007 (Chen, Yi, Williams, & Faden, 2009). Another source 
for information on substance use is the Healthy People 2010, which provides information 
on a 1998 (baseline) and 2010 target goals for decreased use (Office of Disease 
Prevention and Health Promotion, 2005). The Healthy People 2010 obtains its data from 
the SAMHSA national survey (NSDUH).  
Higher Marijuana and Hallucinogen and Cocaine Use in FE SSD 
 The three studies were conducted from 1996 to 2004 (ClozHal (1996 – 2003), 
OlzHal (1997 – 2001) and OlzQueRis (2002 – 2004)), with the majority of the 
participants entering one of the studies between 1997 and 2000. Although there was 
overlap in the studies, data for substance use is drawn from several different sources as 
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noted above. Whenever possible, the comparison data noted in this section used data 
from years closest to the collection of this study data to ensure a similar cohort 
comparison. The data reported in this study used age at first use and lifetime use.  
 The average age of first use of alcohol (14.5) and marijuana (15.1) observed in 
these studies is older than that found in the 1998 NSDUH survey’s average age at first 
use of 13.1 for alcohol and 13.7 for marijuana. (The NSDUH reports very little difference 
in age at first use for males and females.) While the age at first use is slightly older in this 
study, never using alcohol and marijuana is much higher in both the national and 
Massachusetts population based surveys. In the 1998 national survey of high school 
seniors, the percentage of people who never used alcohol (19%) is higher than in this 
study (13%). There is a striking difference between the data in this study and the national 
data in which more than twice as many adolescents (46%) reported never using marijuana 
than in this study (22%) (Office of Disease Prevention and Health Promotion, 2005). 
Also in 1999, half of all Massachusetts adolescents reported lifetime marijuana use as 
compared to three-quarters (78%) in the FE SSD studies. Likewise, in 1999, the rate of 
lifetime alcohol use as reported by Massachusetts adolescents (80%) was only slightly 
lower than reported by study subjects (87%) (Governor's Adolescent Health Council and 
Massachusetts Department of Public Health, 2003). Overall, lifetime alcohol use is 
consistent with the national and state surveys but the higher rate of marijuana use in 
young people in a first episode SSD is notable. 
 In this sample the rates of marijuana misuse (56%) were higher than alcohol 
misuse (47%). This high rate of marijuana misuse in the first episode sample is consistent 
with the literature (Barnes, Mutsatsa, Hutton, Watt, & Joyce, 2006b; Barnett et al., 2007; 
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Van Mastrigt, Addington, & Addington, 2004) and a new meta-analysis (Koskinen, 
Lohonen, Koponen, Isohanni, & Miettunen, 2009) reports the highest rates of marijuana 
use (45%) to be in young males. It is unclear why there is such a high use of marijuana in 
schizophrenia, requiring further study beyond the scope of this study.  
 The higher rate of marijuana use relative to alcohol use in this sample is 
consistent with new thinking regarding the relationship between marijuana use and the 
risk of developing schizophrenia. Currently, it has been hypothesized that marijuana is an 
environmental factor that increases risk in participants with a genetic vulnerability and 
possibly in participants without genetic risk (Hambrecht & Hafner, 2000; Henquet et al., 
2005; Hickman, Vickerman, Macleod, Kirkbride, & Jones, 2007; Smit et al., 2004). 
Several studies have shown a dose response relationship between increased use of 
cannabis and increased risk for psychosis with odds ratios ranging from 2.3 to 3.5 
(Andreasson, Allebeck, Engstrom, & Rydberg, 1987; Arseneault et al., 2002; Fergusson, 
Poulton, Smith, & Boden, 2006; Henquet et al., 2005; van Os et al., 2002). Arseneault 
(Arseneault et al., 2002) found 10% of those using cannabis before age 15 developed 
schizophreniform disorder by age 26 as compared to 3% for the group who initiated 
cannabis use by age 18. An association between cannabis use and an earlier age at onset 
of psychosis has been suggested (Arendt, Rosenberg, Foldager, Perto, & Munk-
Jorgensen, 2005; Barnes et al., 2006b). 
 The use of other drugs follows the same pattern of being higher in this sample of 
participants in a first episode of SSD than those reported in the national and state surveys. 
In this FE SSD study, subjects report of PCP use was five times higher (12%) than in 
national surveys (2.7%). Subjects reported twice as much use of LSD (43%), and cocaine 
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(32%) than in the 2002 national survey (LSD 24% and cocaine 15%) (Substance Abuse 
and Mental Health Services Administration, 2005). Stimulant use was only slightly 
higher in the FE SSD sample (13% vs. 10.8%), while opiate use was only half (11%) that 
of the national sample (22.1%) (Substance Abuse and Mental Health Services 
Administration, 2005).  
 These findings regarding high rates of marijuana and some illicit drugs 
underscore the treatment challenges facing young adults in the first episode of 
schizophrenia. Ongoing misuse of marijuana and some illicit drugs amplifies the 
challenges of treating a new onset of psychosis. Often, use of marijuana and some illicit 
drugs is associated with poor treatment adherence (Coldham et al., 2002; Green et al., 
2004; Wade et al., 2007), poor symptomatic remission (Hambrecht & Hafner, 2000; 
Wade et al., 2007) and a high relapse rate (Caspari, 1999; Linszen et al., 1994). People in 
a first episode have a poor understanding of the nature and course of a SSD, the effect of 
marijuana on symptoms and outcome, and the need for medication adherence and 
abstinence from substances of abuse. Psychoeducational approaches are complicated by 
poor insight, which is associated with both use of substance use and psychosis (Drake, 
2008; Drake et al., 2007; McEvoy et al., 2006; Perkins et al., 2008). Treatment programs 
that include the building of insight through psychoeducation on the nature of the illness, 
and the effects of marijuana and other substances, improve motivation for treatment 
adherence and abstinence of substances (Archie et al., 2007).   
Neurocognition FE SSD Variability 
 The results of the neurocognitive tests in this study vary widely from below 
average to above average, consistent with the literature as noted in a recent meta-analysis 
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of neurocognition in first episode (Mesholam-Gately, Giuliano, & Seidman, 2009). This 
meta-analytic comparison of healthy controls and people in a first episode of 
schizophrenia found the magnitude of deficits to vary widely within and between 
domains. Analysis of the cognitive tests in this study suggests a similar picture of wide 
variation within domains as those found in the literature on schizophrenia. 
Neurocognitive functioning, in people with schizophrenia, is often impaired and is 
closely tied to functional impairment (Heinrichs & Zakzanis, 1998; Keefe & Eesley, 
2006; Mesholam-Gately et al., 2009).  The young people in this study of the first episode 
showed clear cognitive deficits at the onset of psychosis along with functional 
impairment. Three of the domains had a majority of participants in the below average 
range: verbal memory (73.8%); visual attention (68.4%); and motor speed (55.4%). 
Similarly, the executive functioning domain for the whole group had a much higher rate 
of perseverative errors than controls and were well below the average norm for number of 
categories achieved (Strauss et al., 2006). As expected, premorbid estimates of IQ were 
found to be in the normal range (M = 102.8) in this study. 
Conclusions 
 Similar to findings in the literature, high rates of marijuana, hallucinogens and 
cocaine use were associated with cognitive deficits, impaired educational and 
occupational functioning.  
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Question 2:  
To what extent do patients’ demographic profiles, illness, and treatment characteristics 
differ in those who withdraw for any reason and those who remain in the three double-
blind randomized drug trials? 
 
 There are few differences in demographic, illness and treatment characteristics 
between the attrition and non-attrition groups in this study, but it is critical to note that 
this small exploratory study is underpowered. In this study, no consistent significant 
differences were found between the attrition and non-attrition groups in the merged data 
except for the type of antipsychotic medication. Typical antipsychotic medication, 
specifically haloperidol, was most often associated with attrition from the studies. 
Practice guidelines today suggest starting with an atypical agent and avoiding 
extrapyramidal side effects, commonly associated with the use of haloperidol (American 
Psychiatric Association, 2006). The two studies with haloperidol took place at a time 
before many of the atypical agents were on the market and their use reflected standard of 
care at that time. It remains important to not forget the one key point of this study; 
attrition rates are very high in studies of first episode SSD, even in those studies that do 
not include a typical agent. A better understanding of the reasons for attrition is still 
needed. 
 Unfortunately, this small sample limited the ability to use the detailed data on 
dropouts. Detailed analysis of the reasons for attrition and analysis of differences 
between the attrition and non-attrition groups in demographic profiles and illness and 
treatment characteristics of larger studies is still needed. The importance of a more 
careful and complete analysis of the reasons for attrition is recommended in the literature, 
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as noted above. For the purpose of this study, completion was defined at 6 months 
because the number of participants who remained in each of the studies at one year was 
too low (ClozHal (9), OlzHal (4), OlzQueRis (5) for analysis in this study. The actual 
length of the three studies varied, ClozHal two to five years (1996 – 2003), OlzHal two 
years (1997 – 2001), and OlzQueRis one year (2002 – 2004). In the ClozHal and OlzHal 
studies, lack of efficacy was the most common reason for study withdrawal (24% and 
50% respectively), followed by withdrawal of consent (24% and 15% respectively). Only 
a small percentage of the non-attrition group received haloperidol (ClozHal 18% and 
OlzHal 33%). In the OlzQueRis study, withdrawal of consent and loss to follow-up (33% 
each) were the most common causes of attrition. OlzQueRis was an outpatient study and 
loss to follow-up could be considered a form of patient withdrawal of consent. Thus, 
these findings suggest that lack of efficacy and withdrawal of consent is a common 
reason for attrition across studies involving both typical and atypical antipsychotics. 
 In the individual studies, analysis of between-group differences, which is rarely 
done in the literature, found a significant difference between the attrition and non-
attrition groups for several variables but the significant variable varied from study to 
study. For example, the ClozHal study found the attrition group to be significantly older 
(23.9 years old vs 20.1 for the non-attrition group p = .002) at study entry. But, the 
OlzHal and the OlzQueRis study did not find a significant difference in age between the 
attrition (22.3 and 21.9 years old respectively), and non-attrition group (25.4 and 22 years 
old respectively). Other significant variables varied between the individual studies as 
well. In the ClozHal study, the attrition group had more years of education (12.7 versus 
10.8 in the non-attrition group p = .03), but, the attrition group in the OlzQueRis study 
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had fewer years of education (10 versus 12.5 in the non-attrition group p = .051). There 
was no significant difference in number of years of education in the OlzHal study. The 
attrition group was older at the onset of psychosis (22.6 versus 18.9 for the non-attrition 
group), but non-significant for the two other studies. Clinically, the difference between 
the attrition and non-attrition groups are non-significant and require a larger study sample 
to better answer the questions raised in this study.  
Implication of Findings for Design of Clinical Trials 
 The studies in this sample were traditional double-blind, randomized clinical 
trials. Despite not being able to use detailed data in this study, it is important to note that 
participants were dropped from these studies for a variety of reasons such as needing an 
antidepressant, and missing more than one week of study medication. In the past ten 
years an increasing number of articles have called for more practical clinical trials 
(Glasgow, Magid, Beck, Ritzwoller, & Estabrooks, 2005; March et al., 2005; Tansella, 
Thornicroft, Barbui, Cipriani, & Saraceno, 2006; Tunis, Stryer, & Clancy, 2003). The 
purpose of these trials is to go beyond the usual randomized clinical trial used to obtain 
registration approval by the FDA. Practical clinical trials, based on an effectiveness 
model, take place in a wide range of clinic settings with diverse populations. The research 
questions are designed to evaluate real world clinical and treatment issues, and to provide 
more relevant information for evidence-based practice guidelines. Practical effectiveness 
trials are more flexible and participant friendly, without, for example, the strict inclusion 
and exclusion criteria, limits on allowable concomitant medications, and a low tolerance 
for missed doses. All of these issues can contribute to the high attrition rates in usual 
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clinical trials. The goal is a more clinician and patient friendly clinical trial and, it is 
hoped, in a real world setting the attrition rates would decrease.  
 The CATIE trial, the largest effectiveness study in the treatment of schizophrenia 
to date, followed many of the practical clinical trials guidelines (Lieberman et al., 2005b). 
Despite this, it had a large (74%) all-cause discontinuation of randomized medication rate 
by 18 months. This effectiveness study allowed for switching of the antipsychotic 
medication. Weiden (2007) reports this high rate of medication-switching and non-
adherence are poorly understood from the patient’s perspective (data was not collected 
for patient reason for study withdrawal). Clearly, the issue of high attrition rates is poorly 
understood, in both standard clinical trials, as well as, the more lenient effectiveness 
trials.  
 The use of Last Observation Carried Forward (LOCF) continues to be a common 
method of handling missing data in many of the first episode studies despite the identified 
weaknesses of this method. One basic assumption of LOCF is that no further change in a 
participant’s response would have taken place if they had not dropped from a study, 
regardless of when they drop (Mazumdar et al., 2007; Streiner, 2008; Wood et al., 2004).  
LOCF fails to make use of all prior data points that could be used to show the direction of 
change (getting better, worse or no change) (Streiner, 2002). Bias may be introduced 
when there are different drop-out rates between treatment groups (Barnes et al., 2006a; 
Gueorguieva & Krystal, 2004; Mazumdar et al., 1999) and when missing data is not 
random but related to the medication, such as side effects and lack of efficacy, or to the 
study procedures such as subject burden (Leon et al., 2006; Mazumdar et al., 2007; 
Sheiner, 2002). Currently, there is no best way to handle attrition without it having some 
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impact on study results. Comparison of data using LOCF to different methods of multiple 
imputation and regression models have found significant differences in the results calling 
into question the validity of the LOCF method (Gueorguieva & Krystal, 2004; Houck et 
al., 2004; Lavorie, Dawson, & Shera, 1995; Mazumdar et al., 2007). 
The results of this study of attrition in three double-blind randomized treatment 
studies were similar to the results found by  Leucht, Engel, Bauml, and Davis (2007) in a 
reanalysis of several large clinical trials of atypical antipsychotic medication as compared 
to a typical antipsychotic. Leucht et al. (2007) compared results for their four models for 
handling missing data under two different conditions: (a) data pooled across multiple 
studies; and (b) data analyzed separately for each study. When data were pooled across 
studies, the researchers did not find a difference in effect size between the various 
models. However, when they analyzed the data separately, the use of the first LOCF 
model (similar to the approach most frequently used in FE SSD research) resulted in 
higher effect sizes in favor of the atypical antipsychotic medications in 50% of the study 
data sets. The authors concluded further study comparing results using other statistical 
methods was needed. The point to be made here is not the finding regarding atypical 
antipsychotic medication, but the lack of findings in pooled samples and positive findings 
in the individual studies. This is similar to the lack of findings in the merged data for the 
three first episode studies and positive findings (effect sizes) for each of the individual 
studies. Further study is needed to better understand why this has occurred in the larger 
sample studies of Leucht et al. (2007) and the smaller samples found in this present 
study. 
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 In the last five years, some data analysis plans include comparison of newer 
sophisticated statistical modeling methods to the LOCF method (Green et al., 2006; 
Lieberman et al., 2003b; McEvoy et al., 2007).  Green et al., (2006), Lieberman et al., 
(2003b), and McEvoy et al. (2007) participated in two of the studies discussed in chapter 
2. Only one of the studies (Lieberman et al., 2003b) reported on differences between the 
results of the LOCF analysis and more sophisticated statistical methods (random 
regression analysis).  
 The newer, more sophisticated statistical methods of structural equation modeling 
include latent growth curve analysis, random effects regression, mixed effects regression, 
and hierarchical linear modeling. Each is used for longitudinal treatment data but the use 
of a specific method is dependent on the type of question asked, type of data collected, 
and the number of time points. These methods are dependent on having a minimum of 
three available data points for each participant. For example, latent growth curve analysis 
allows for the inclusion of missing and irregularly collected data and can analyze the 
relationship between many different types of variables that may mediate, moderate or in 
other ways influence the process of change for each subject (Hser, Shen, Chou, Messer, 
& Anglin, 2001; Llabre, Spitzer, Siegel, Saab, & Schneiderman, 2004). Many of these 
types of regression models create a slope of the line and its intercept (baseline severity 
level) for each person. Taken together, the slope of each group and each individual will 
indicate differences in treatment response (Streiner, 2008).  The newer modeling methods 
vary from fairly simple to very complex. These techniques address some of the problems 
encountered with LOCF as they use all available data on each person and can model 
effects over time when there is missing data. Understanding the dropout mechanism is 
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critical. However, the problem of an inability to identify if missing data is random 
(ignorable) or non-random (non-ignorable) continues. Randomness is assessed by the use 
of sensitivity tests, such as Little’s test or the index of sensitivity to ignorability (ISNI), 
which should be employed to assess the impact of non-random missing data (dropouts) 
on outcome (Houck et al., 2004; Mazumdar et al., 2007). Non-random missing data can 
affect the reliability of the modeled data. Overall, the use of statistical modeling methods 
to analyze data and deal with non-random missing data is very complex and requires 
statistical sophistication and a sufficiently large sample size.  
   
Question 3:  
What is the effect size in analyses comparing those who withdraw and those who 
remain in terms of their demographic profiles, illness and treatment characteristics 
in: (a) each of the three double-blind randomized drug trials; and, (b) a merged 
data set combining all three double-blind randomized drug trials?   
 
 Statistical significance conveys a degree of confidence or reliability in the 
difference between groups, but is very dependent on the sample size. A very large sample 
can easily achieve a stringent level of statistical significance that is much more difficult 
for a small sample. The purpose of effect size calculations is to provide additional 
information about the magnitude of the difference between two groups, usually two 
different treatment groups (Coe, 2002; Cohen, 1988; Faraone, 2008). In this study, effect 
size is utilized to better explore the magnitude of the difference between those who 
remain in a study and those who leave. Because this study had small sample sizes, the 
calculated effect sizes helps us understand the degree of difference between the groups. 
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In the individual studies there were several large effect sizes, but in the merged data the 
effect seem to have washed out. This may possibly be due to the heterogeneous nature of 
the course and severity of schizophrenia (Huber, 1997) which leads to differences in 
patient characteristics in each study or to the heterogeneous nature of the studies. Two of 
the studies compared haloperidol against an atypical medication and one study compared 
three atypical medications. One of these studies was conducted as an outpatient, while the 
other two were conducted on a dedicated inpatient research unit where participants were 
discharged to outpatient status when they were clinically stable. There were also 
differences between the studies on allowable concomitant medication. 
 A review of the literature found no published studies on the effect sizes for the 
differences between those who remain in a double-blind randomized treatment study and 
those who leave. To better understand the magnitude of the findings in this study, effect 
sizes published in the literature on schizophrenia were reviewed including three treatment 
studies (Haas et al., 2009; Hodge et al., 2008; Joffe et al., 2009), one review of twenty 
studies on the effects of atypical antipsychotic medication on cognition (Harvey & Keefe, 
2001), and three meta-analyses including the neurocognition in the first episode 
(Mesholam-Gately et al., 2009), cognitive behavioral therapy (Wykes, Steel, Everitt, & 
Tarrier, 2008), and social skill training (Kurtz & Mueser, 2008). 
 Effect sizes (Cohen’s d) found in treatment studies have varied widely depending 
upon the dependent variable and study design. One randomized treatment study evaluated 
the effectiveness of cognitive remediation in schizophrenia (Hodge et al., 2008). The 
authors found significant improvement with small (d =.18) to medium (d = .65) effect 
sizes in memory, attention and executive functioning that persisted for four months after 
  
119
 
  
the end of training. The change in cognition resulted in clinically significant 
improvement in psychosocial functioning as measured by clinical ratings. 
 Joffe et al., (2009) reported an effect size of 1.0 for differences in symptom 
severity as measured by the Positive and Negative Symptom Scale in a randomized 
placebo controlled study of the addition of mirtazapine, an antidepressant, to typical 
antipsychotic medication. This report suggests the antidepressant may enhance the 
antipsychotic effect of typical antipsychotics.  
 Haas et al., (2009) in their study, compared two dosing regimens (1.5 to 6 mg/day 
as compared to 0.15 to 0.6mg/day) of risperidone in the treatment of adolescent 
schizophrenia. A small to medium effect size of .49 (Cohen’s d) was found. There was a 
significant improvement in mean Positive and Negative Symptom Scale (PANSS) 
positive and negative subscales for 1.5 to 6mg/day treatment group. 
 Meta-analyses report effect size, using standard deviation units as a way to 
standardize various statistical tests, allowing for comparison of many different research 
studies, including studies with a small sample size (Lipsey & Wilson, 2001). Although 
not a meta-analysis, the next report is a methodological assessment of twenty studies on 
the effect of atypical antipsychotic medications on cognition found a mix of open label, 
randomized open label and randomized double-blind treatment studies (Harvey & Keefe, 
2001). This review found effect sizes for these novel atypical antipsychotics ranging from 
very small (.13) to medium small (.43) (Harvey & Keefe, 2001). When compared with 
the effect sizes for the cognitive deficits in the first episode of schizophrenia (-1.59 to -
.28) (Mesholam-Gately et al., 2009), the effect of atypical antipsychotic medications on 
cognition is very small. Harvey and Keefe (2001) assert that the effect sizes obtained may 
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have reached statistical significance but may not be clinically significant based on the 
magnitude of the underlying cognitive deficit. The effect size for the difference in 
cognitive deficits between the attrition and non-attrition groups in the merged data for the 
present study was small (.08. to 34) similar to that observed in Harvey and Keefe’s 
(2001) estimate for the novel atypical antipsychotics. (See Table 26 for details on effect 
size for the individual studies).  
 The first meta-analysis, conducted by Mesholam-Gately et al., (2009), found a 
large difference in neurocognition (d = -.28 to -1.59) in a comparison of healthy controls 
and people in a first episode of schizophrenia. They also noted a significant difference 
between and within neuropsychological tests and domains, providing further evidence 
that neurocognitive deficits in first episode schizophrenia are heterogeneous with wide 
individual variation.  
 A second meta-analysis of cognitive behavioral therapy in schizophrenia explored 
the effect sizes (Cohen’s d) in thirty-four treatment trials (Wykes et al., 2008). They 
found an effect size of .40 for positive symptoms. This meta-analysis identified 
methodological issues that can result in inflated effect sizes such as lack of randomization 
and a lack of masking of treatment assignment for the clinical raters. Both of these issues, 
randomization and masking of treatment assignment, were controlled for in the three 
combined studies of FE SSD. Each was a randomized, double-blind study and the clinical 
raters did not conduct the assessments for side effects to further protect the blind and 
prevent any potential inflation of the effect sizes from these methodological issues.  In 
the last meta-analysis, Kurtz & Mueser (2008) evaluated 22 randomized controlled trials 
of social skill training. The mean effect sizes ranged from the largest (d = 1.20) for 
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content mastery to the smallest (d = .15) for the effect of social skill training on overall 
psychiatric symptoms.   
 It is difficult to compare the effect sizes found in this study of attrition and non-
attrition to those obtained in the literature for two reasons. First, treatment response was 
not analyzed and second, the sample was divided by attrition, not by treatment 
assignment. The usefulness of this review of effect sizes is in their ability to provide a 
sense of the magnitude of change for different types of treatments (medication, cognitive 
behavioral therapy, cognitive remediation and social skills training) and the magnitude of 
the cognitive deficits found in schizophrenia. Cognitive deficits in schizophrenia are large 
and the treatment effect sizes are only small to medium. Additionally, statistically 
significant results can be associated with a small effect size (Haas et al., 2009; Hodge et 
al., 2008; Kurtz & Mueser, 2008; Wykes et al., 2008). 
 The effect sizes found in this study fall within the ranges observed in the 
literature. In this study of attrition, the individual studies each had some large effect sizes, 
but within any one variable there was great variation between studies. In addition, not all 
of the large effect sizes reached statistical significance. It remains unclear why, in the 
merged database, many of these large effect sizes decreased in size from the effect size 
found in each individual study. It may be that the large effect sizes and statistical 
significance in the individual studies truly reflects the wide variation in demographic and 
illness characteristics seen in first episode schizophrenia or the effect sizes could be 
inflated by the small sample size. Further study is required to better understand the 
relationship between demographic, illness and treatment characteristics and attrition and 
non-attrition in first episode SSD.  
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Limitations 
 This secondary analysis of data has four major limitations. First, as noted earlier, 
this study is underpowered, and significant tests of differences between the attrition and 
non-attrition group may be misleading. However, effect size analysis was conducted to 
offset this limitation and provide readers with effect sizes for attrition/non-attrition group 
differences that can be used to inform their interpretation of the results reported here. 
Moreover, as an exploratory study, these data on differences between those who remain 
in a study and those who leave may begin to identify those who are at high risk for 
attrition.  
 A second limitation is the small number of females in this study, which did not 
allow for analysis of gender differences in the variables of interest, limiting its 
generalizability to women. This is a serious limitation, identified in many different areas 
of clinical research, which results in an inability to analyze data for gender differences. In 
1994, the National Institute of Health issued guidelines for the inclusion of women and 
minorities in clinical research studies (Federal Registry, 1994). Since that time, two 
reports were published (Geller, Adams, & Carnes, 2006; Vidaver, Lafleur, Tong, 
Bradshaw, & Marts, 2000) on compliance with this guideline. In 2000, 20% of the studies 
reviewed did not include women, and of those who did include women, only one quarter 
to one third of the studies included analysis of the results by gender (Vidaver et al., 
2000). There was little improvement by 2006; 37% of the sample, in the studies 
evaluated, were women, and when only drug trials were evaluated, the number of women 
decreased to 24%. In addition, 87% of the studies evaluated did not include analysis by 
  
123
 
  
gender or with the use of gender as a covariate (Geller et al., 2006). Qualitative studies 
can help identify barriers to enrolling women in FE SSD studies.  
 Howard, de Salis, Tomlin, Thornicroft and Donovan (2009) studied barriers to 
enrollment for a randomized clinical trial of supported employment in people with a 
serious mental illness and found several areas of concern expressed by the clinical care 
coordinators that impacted on referral to the study. Barriers to enrollment included a lack 
of understanding about the trial, especially the need for randomization and a control 
group. Treatment as usual (control) was viewed as less than adequate care, when 
compared to the treatment arm, and lead to a sense of inequality between the treatments 
offered. Individual clinicians interpreted inclusion criteria differently thus effecting who 
was referred. Lastly, care coordinators had a paternalistic attitude, wanting to protect the 
patient from stress and the potential for failure in the study which may result in a relapse 
of symptoms. Potential strategies to improve the participation of women in FE SSD 
studies could include in depth discussions with potential participants, their clinicians and 
care givers about barriers to participation. Discussions with women who participate in FE 
SSD studies may help to identify reasons for willingness to join a clinical research study. 
People with a serious mental illness, who are involved in the recovery and peer assistance 
movements, may further identify barriers and help to build pathways to research.  
 A third limitation is created by the inherent problems of combining three 
randomized double-blind treatment studies. There were variations in data collection 
where the same information was collected categorically in one study and continuously in 
another, resulting in the use of a lower level of measurement for the variables being 
assessed (e.g., substance use and functional measures). This may have limited our effect 
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sizes for differences involving such variables. Additionally, the length of the three studies 
and when they were conducted varied: ClozHal up to 5 years (1996 – 2003); OlzHal 2 
years (1997 – 2001); and OlzQueRis for 1 year (2002 – 2004). Due to the high number of 
people in the attrition group, this study limited the focus to an analysis of attrition at 6 
months.  
A fourth limitation is the potential for inflation of alpha (galloping alpha). The 
exploratory nature of this study allowed for multiple analyses even though there is 
concern about a Type I error (when the null hypothesis of no difference between the 
groups is rejected, when it is in fact true) (Burns & Grove, 2001). A Bonferroni 
correction was used to adjust for multiple comparisons which corrects the p value for 
multiple comparisons by preventing the inflation of Type I errors, but at the same time 
increases the risk for Type II errors, potentially missing differences that really are 
significant.  
Implications for Future Research 
 Further evaluation of the potential differences in demographic, illness and 
treatment characteristics in those who remain in studies and those who leave needs to be 
conducted with a larger sample size. Pharmaceutical companies who own the large first 
episode, randomized, double-blind treatment data could evaluate the data for differences 
between the attrition and non-attrition groups. A re-analysis of the pharmaceutical 
company data using the more sophisticated modeling methods could also identify 
mediators or moderators for risk of attrition (Holroyd et al., 2005). This is important 
because the utility of using statistical methods like LOCF has been questioned in the 
literature, especially when there are high attrition rates and a failure to evaluate the data 
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for randomness of missing data (Houck et al., 2004; Lavorie et al., 1995; Leon et al., 
2006; Mazumdar et al., 2007; Streiner, 2008). If a re-analysis of past FE studies is not 
possible, then a meta-analysis of key demographic, illness and treatment variables, as 
related to attrition, would be useful. Results might identify which medications are most 
often associated with attrition. 
 Further study is needed to better understand why there are so few females in 
research studies on first episode SSD. Does an older age at onset for women and/or 
decreased substance use play a role? Identifying pathways to care and barriers to early 
identification and treatment in people, not just women, in a FE SSD clinical population 
may help to identify potential differences between men and women.  
 The present study had a high number of participants who withdrew consent (22%) 
similar to that found in studies of schizophrenia (see Table 5). Attrition due to withdrawal 
of consent in FE studies (see Table 3) varied from 2% to 42%. Understanding the rates of 
attrition due to patient withdrawal of consent, is further complicated by variations in the 
definition and classification of attrition. The reasons for patient withdrawal are unknown, 
but stigma-related hypotheses, such as fear of a diagnosis of a psychotic disorder, denial 
of the need for treatment, and a desire to return to home or school with the hope for a 
return to normal daily functioning, are common in the experience of the author. It would 
be helpful to conduct a qualitative study to better understand the participants’ subjective 
experience of psychiatric care within a double-blind psychopharmacology research study.  
 The use of cannabis by participants in this study was high and the role of the 
neurobiological mechanisms by which cannabis affects the development of schizophrenia 
and long-term outcomes is poorly understood. Cannabis, via the cannabinoid-1 (CB-1) 
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receptors, affects the regulation of dopamine and serotonin (known to play a role in 
psychosis) and in particular, raises dopamine levels in the limbic system and neocortex 
(Fergusson et al., 2006). Additional evidence is found in the catechol-o-methyltransferase 
(COMT) gene which encodes dopamine. Individuals who were homozygous for the 
Val/Val (valine) polymorphism of COMT and used cannabis are at higher risk (odds ratio 
10.9, 95% CI 2.2 – 54.1) for developing a schizophreniform psychosis. People without 
this polymorphism, who used cannabis, had a much lower risk for developing psychosis 
(Odds ratio 1.1, 95% CI 0.2 – 5.3) (Caspi et al., 2005). Additional genetic research is 
needed to better characterize the role of COMT in cannabis users and non-users and 
clinical outcome. 
 CB-1 has been found to affect electrophysiological functioning in the limbic 
system by interfering with neuronal oscillations and impairing sensory gating (Hajós, 
Hoffmann, & Kocsis, 2008). People in a first episode of schizophrenia who use cannabis 
have been found to have a greater increase in brain volume loss in the right posterior 
cingulate cortex, an area rich in CB-1 receptors (Bangalore et al., 2008), anterior 
cingulate (Szeszko et al., 2007) and over time to have greater brain volume reduction 
(Rais et al., 2008) than in those who do not use cannabis. Overall, researchers continue to 
try to better understand the role of cannabis in brain structure and function and its 
potential influence on the onset and course of schizophrenia. 
 Insel (2009) recently published a report on the priorities of the National Institute 
of Mental Health, including the need for early detection of mental illness and for 
individualized care. In order to achieve these goals further research is needed to 
understand the trajectory of the illness, the barriers that prevent optimal treatment 
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response, and disparities in mental health care. In addition, new, more individualized 
interventions are needed. Moreover, better methods to disseminate research findings in a 
more timely and effective manner are essential. These are all important goals, but before 
these goals can be attained researchers must gain a better understanding of why so many 
people with this illness drop out of studies and standard treatment.  
Implications for Practice 
            Attrition 
 There are several important implications for practice that are highlighted by this 
study. In this research study, based on effect sizes, the attrition group was older, had 
more years of education, was less likely to be diagnosed with abuse or dependence of 
cannabis or other drugs, and was higher functioning with a history of working in the year 
prior to entry into the study. These characteristics may have played a role in the high 
attrition rate in this research study. Participants may become anxious to get back to their 
usual level of functioning, once they start to feel better. This group also had lower scores 
on executive functioning, which may have an impact on problem solving and future 
planning. The researcher team needs to provide psychoeducation to study participants and 
their families about the importance of intensive treatment and relapse prevention in the 
early phase of schizophrenia. 
 The high attrition rate associated with research studies is troubling, but there is 
also a high rate of dropping out of standard treatment, which is even more troubling. 
What constitutes standard treatment is variable ranging from individual and/or group 
treatment, psychosocial rehabilitation, or receiving only a minimal amount of treatment 
such as medication appointments only. The type of available treatment is often dependent 
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on several factors, including federal and state funding for mental health care, rural or 
urban area of the country, and perceived need for treatment. The availability of intensive 
treatment programs for people in a first episode of psychosis as described in this study 
are limited.  
 In a review of epidemiological surveys (Mojtabai et al., 2009), about 40% of 
people with a diagnosis of schizophrenia reported receiving no treatment in the preceding 
6 to 12 months. In a longitudinal study, the Suffolk County Mental Health Project 
followed people with a first hospital admission for schizophrenia and found 20% were 
not receiving medication treatment and another 40% were not receiving any form of 
psychosocial treatment. This longitudinal study identified people who dropped out of 
treatment, or had minimal treatment, as less likely to achieve remission of psychotic 
symptoms, and more likely to have an increased number of hospitalizations, than those 
fully engaged in treatment (Mojtabai et al., 2005).  
 In another review of treatment non-adherence, Nose, Barbui and Tansella (2003) 
found 26% of clients had medication and treatment non-adherence. Those at highest risk 
for non-adherence included young males in the first episode with positive symptoms, a 
lack of insight, unemployed, and a history of substance abuse and poor social 
functioning. These findings are not consistent with the findings in this study of attrition 
from three double-blind drug studies, because dropping out of a study, while in the initial 
treatment phase, may be different from dropping out of non-research outpatient 
treatment. Understanding this difference requires further study. 
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 Antipsychotic Medication   
 This study of attrition from three double-blind research studies found typical 
antipsychotic medication to be associated with a high attrition rate, but atypical 
antipsychotic medications also had high attrition rates as noted in the CATIE study 
(Lieberman et al., 2005a). The two most common reasons for attrition, in the present 
study, were lack of efficacy and withdrawal of consent. Clearly, these reasons highlight 
patient dissatisfaction with current medications, and are similar to the reasons for the high 
rate of medication turnover in the CATIE study (Weiden, 2007). Research methodologies 
(randomized controlled trials) include careful observation and measurement of 
symptoms, cognitive functioning, psychosocial and vocational/educational functioning 
(to name only a few of the areas studied in first episode of schizophrenia) along with the 
provision of clinical care. Developing a partnership, where an ongoing dialogue with 
active listening and responding to participants’ concerns, fears and descriptions of the 
effects of medication, along with the participants’ experience of research, are crucial. Of 
course, the level of psychosis and cognitive disorganization will influence the ability of 
the participant to engage with the researcher/clinicians, who must adjust their approach, 
as appropriate, to the situation.  
 Cognitive deficits may be also associated with non-adherence (Perkins, 1999, 
2002) and are associated with a poor outcome and a low levels of psychosocial and 
vocational functioning (Green, 2006; Robinson et al., 2004). But, cognition is not 
affected by antipsychotic medication and a misunderstanding of the expected effects of 
medication may play a role in patient dissatisfaction with medication, with resultant non-
adherence.  
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Advances in Treatment for First Episode SSD 
 The factors identified in this study on attrition in FE SSD clinical trials can help 
inform nursing practice about potential risk factors that may contribute to treatment non-
adherence in this vulnerable population. Early identification of psychosis and treatment 
adherence has been demonstrated to significantly decrease the morbidity associated with 
schizophrenia. Subsequently, many countries have developed large networks of 
specialized first episode treatment centers. England has over 50 clinic sites, Australia, a 
national early intervention program, and Canada has many sites ranging from Nova 
Scotia to British Columbia. Other European and Scandinavian countries have been in the 
forefront of early intervention and also have many specialized treatment programs.  
 All of these countries have moved much further along than the United States in the 
development of combined early identification and intervention with intensive specialized 
treatment for first episode SSD. The United States has lagged behind, with too few clinics 
providing intensive specialized care early on in treatment, providing less than what is 
now considered the standard of care worldwide (Falloon et al., 1998b; McGorry, 2005). 
Often, in the US, these specialized treatment centers only exist in academic settings, often 
associated with research in first episode of psychosis, as opposed to the nationally funded 
treatment centers found in many parts of the world. Additionally, the American 
Psychiatric Association practice guidelines (2006) for the treatment of schizophrenia 
includes a very brief, cursory mention of the first episode. In contrast, the Royal 
Australian and New Zealand College of Psychiatrists (2005) published very detailed 
guidelines for people in a first episode of psychosis calling this a critical period in the 
treatment of schizophrenia. Ongoing evaluation is needed to better understand what types 
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of intensive treatment programs are most effective in the US. This is especially important 
due to the culturally diversity found in the US, with its very large urban population 
centers and large underserved rural areas. More research is needed to better understand 
culturally based views of mental illness, and culturally acceptable treatment strategies.  
 Nursing, psychology, social work, psychiatry and other mental health practitioners 
are part of a multidisciplinary team integral to the treatment of young people in a first 
episode of psychosis. First and foremost is the early identification of psychosis and rapid 
intervention to treat symptoms and prevent disability in a culturally acceptable manner. 
Early identification may occur in a variety of non mental health settings, such as schools, 
pediatrician and primary care offices, requiring outreach and education to providers about 
the identification of early psychosis. A survey (Etheridge, Yarrow, & Peet, 2004) of 
service users and their caregivers on their pathways to care reported frequent difficulty 
finding appropriate help, frustration at the service delivery system and unhelpful 
professionals. Etheridge, Yarrow and Peet (2004) also found a lack of recognition of 
psychotic symptoms by primary care, and delays in treatment due to substance misuse in 
these young people with psychosis. Most often, a primary care physician and school 
personnel were first approached for help with the psychotic symptoms. Lack of 
recognition of symptoms results in a longer duration of untreated psychosis, in the 
present study the average duration of untreated psychosis was 30 weeks (range 0 – 208 
weeks).  
 Prevention and early intervention include identification of young adults with early 
clinical symptoms and/or those who are at a high genetic risk (a first degree relative with 
a psychotic disorder). These symptoms, indicators of clinical high risk for psychosis, are 
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usually identified retrospectively, after the onset of psychosis and are known as 
prodromal symptoms (Yung & McGorry, 2007). Prodromal symptoms often include 
educational difficulties, ineffective social behavior and/or withdrawal, and affective 
instability such as depression, anxiety and emotional turmoil. Early identification and 
intervention requires the development of prevention and treatment strategies to address 
early symptoms, and the ongoing assessment of the effectiveness of these strategies 
(Cannon et al., 2008; Cornblatt & Auther, 2005). Early identification of psychosis results 
in a shorter duration of untreated psychosis which is associated with improved outcomes 
(Norman et al., 2007; Schimmelmann et al., 2008) 
 Service users have described their experience in a specialized first episode 
treatment program as a more humane approach to their illness, with involvement in 
decision making, and improvement in symptoms and quality of life, as well as higher 
treatment adherence in specialized treatment programs (O'Toole et al., 2004). Additional 
positive outcomes in specialized or integrated clinics have included fewer inpatient days 
(Agius, Shah, Ramkisson, Murphy, & Zaman, 2007; Cullberg et al., 2002; Cullberg et al., 
2006), a decrease in the frequency of psychotic episodes (Agius et al., 2007; Falloon et 
al., 1998a), a decrease in positive and negatives symptoms, less substance misuse, better 
adherence and satisfaction with treatment (Agius et al., 2007; Petersen et al., 2005).   
 In addition to early identification, Hamilton Wilson, Hobbs, and Archie (2005) 
describe an effective approach used by one early intervention clinic to assist young 
people in the recovery from a first episode of psychosis. In this model, clinicians must 
first examine their own beliefs about psychosis, beliefs often associated with a loss of 
hope for future functioning. Clinicians need to become more knowledgeable about the 
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effectiveness of early intervention clinics. A collaborative alliance between the staff, 
client and family focuses on the prevention of demoralization and provision of hope with 
a focus on recovery. Clinicians must be comfortable with a model that emphasizes shared 
power, is recovery oriented, and involves a participatory treatment style. Intensive 
support to the client and family is often required, ranging from daily contact to once or 
twice a week as needed. Ongoing psychoeducation, psychotherapeutic support, 
medication, family treatment, recovery oriented psychosocial rehabilitation and self-care 
relapse prevention are critical.   
 Taking a proactive approach to relapse prevention is another important issue in the 
treatment of psychosis. Nurse researchers van Meijel, van der Gaag, Kahn and 
Grypdonck (2003) have reported on nursing implementation issues to prevent relapse. A 
randomized controlled trial of usual care or a relapse prevention plan included the nurse, 
social network members and the patient. The prevention plan included four phases. The 
first phase consists of developing a working relationship and providing information about 
relapse prevention, as well as identifying network related factors that could hinder or 
assist in the implementation of a relapse prevention plan. The second phase is the 
identification of early warning signs, based on past symptoms and behaviors. The third 
monitoring phase develops a plan to evaluate early warning signs by the nurse, social 
network and patient, and requires agreement and cooperation by all for effective 
implementation. The final phase is the development of an action plan to be implemented 
when early signs and symptoms emerge and includes stress reduction, medication 
adjustment, enhancement of coping skills, and attention to safety issues with inpatient 
treatment an option, if necessary.  
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Evidence-based treatment modalities, such as cognitive remediation (McGurk, 
Twamley, Sitzer, McHugo, & Mueser, 2007) and cognitive behavioral therapy 
(Waldheter et al., 2008; Wykes et al., 2008), with a focus on symptomatic and functional 
recovery, have been found to be effective, and when given early enough in the course of a 
psychotic disorder, may lessen the deterioration common in SSD (Grossman et al., 2003). 
Vocational rehabilitation involving individual placement with supportive services is 
effective in improving rates of employment in people with FE SSD (Killackey, Jackson, 
& McGorry, 2008). Overall, psychosocial treatment is helpful but more stringent 
evaluation of their effectiveness is needed (Penn et al., 2005).  
 As one member of the treatment team, psychiatric nurses play an important role in 
addressing the health care priorities of people in a first episode. Self-management of 
symptoms in a client centered recovery model is a priority according to the National 
Institute of Nursing Research, The Institute of Medicine (IOM), and The President’s New 
Freedom Commission on Mental Health (Committee on Quality of Health Care in 
America, 2001; New Freedom Commission on Mental Health, 2003; NINR, 2006).  The 
stated priorities for managing symptoms include understanding the causes of symptoms; 
symptom recognition by patient, family and care givers; and interventions to improve 
response to symptoms over the phases of an illness. Self-management includes early self-
detection of symptoms and early reporting; strategies for decision making in healthy life 
style choices; and defining behavior that supports adherence to treatment (NINR, 2006). 
Both the Institute of Medicine and The President’s New Freedom Commission on Mental 
Health emphasize a change in the mental health care systems to client centered and 
recovery oriented. In the recovery model, the individual defines treatment goals and 
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outcomes. The treatment team uses evidence based practice as the cornerstone of 
treatment.  
 These standards of care rely on two different models, one based on the best 
evidence to date for treatment and another based on consumer identified principles of 
recovery oriented treatment (Bellack, 2006). Implementation of evidence based practice 
within a recovery oriented treatment model is still in its infancy. In the past, treatment of 
schizophrenia was based on a model of achieving stability, not of forward movement 
toward recovery. More recently, advances have been made in developing a description or 
roadmap toward evidence based individualized treatment (Weiden et al., 2009). Much 
work needs to be done to identify ways to better integrate the evidence based and 
recovery models with the experiences of the specialized treatment centers into usual care 
settings. 
 A psychiatric nurse, as a member of an early intervention treatment team, works 
collaboratively to provide comprehensive care and promote optimal health based on an 
understanding of the neurobiology of schizophrenia, its core cognitive deficits, the 
subjective experience of a client, psychosocial rehabilitation and psychopharmacology. 
Working with the individual collaboratively to identify treatment goals is essential in 
order to provide a level of care that will promote recovery. Treatment needs to be 
individualized, foster decision making and autonomy, include medication adherence, 
psychoeducation and encouragement of healthy alternative behaviors (Spear & Kulbok, 
2004). Both short and long term goals need to be identified, including issues of illness 
management and functional recovery. Psychoeducation about recovery from psychosis 
focuses on improving social and role functioning, decreasing the use of substances, and 
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includes information about time needed for healing from the effects of a psychotic 
episode. Psychosocial withdrawal and post-psychotic depression are not uncommon 
occurrences requiring treatment. The development of a relapse prevention plan includes 
recognition of the triggers of symptoms, such as stress or substance abuse, and a plan for 
a rapid respond to early warning signs of relapse (E. Waldheter, personal communication, 
June 12, 2009).  
Young adults often have their education interrupted by psychosis. In this study, of 
those in school, 40% had to leave school due to psychiatric symptoms. Twenty seven 
percent never completed high school and of those who attended college only 7% 
graduated. Young adults frequently identify a return to school as an important goal, but 
we do not know the outcome for those who did return to school as there is no available 
data. Discussions of how to maximize the young adult’s strengths, while anticipating 
what components of classroom work will be difficult or easy are essential. Options 
include taking one class, a limited class load or a return to full time school. Young adults 
need guidance in developing supports at school, often available through a school’s 
disability center. Clinicians need to have active discussions with each college based 
disability center, as their degree of comfort with working with people with a psychotic 
disorder varies greatly (M. Friedman-Yakoobian, personal communication, June 12, 
2009).  
 A collaborative model supports self-control and self-determination over time. The 
provision of early intervention needs to take place in a non-stigmatizing location such as 
store fronts that are youth oriented and easily accessible. Health classes need to promote 
a better understanding of the role of stress and drugs of abuse in depression, anxiety, 
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eating disorders, substance misuse and psychosis. Teaching effective coping skills are 
essential, as well as helping young people learn ways to assist their friends in obtaining 
help. Schools need to work in conjunction with community mental health providers to 
provide early identification and treatment of at risk youth.  
Conclusion  
 Other than this study, there is no data on the effect size of the demographic, 
illness and treatment characteristics of the people who drop out of psychopharmacology 
research studies. The effect sizes generated for the small individual studies do vary 
markedly between the studies and reflect the magnitude of difference between those who 
stayed in a study and those who left. This variability may reflect the wide range seen in 
severity of illness and levels of psychosocial functioning.  
 The aim of this study was to evaluate the difference between those who withdraw 
and those who remain in a study on demographic profiles and illness and treatment 
characteristics of participants in three double-blind randomized drug trials. The 
participants were all young adults, in a first episode of a schizophrenia spectrum disorder, 
initially treated either in an inpatient research unit or as an outpatient. The group was 
representative of a wide range of socioeconomic groups, had an average age of 22.8 
years, was predominately male, and never married. The average age at onset of psychosis 
was 21 years old. The participants were moderately to markedly ill with a range of 
neurocognitive deficits ranging from above average to well below average. The majority 
had a history of marijuana and alcohol use and misuse with almost half having used LSD 
and a third used cocaine.  
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 Attrition was a major problem with 66% attrition rate from the three combined 
studies. The two most common reasons people left these studies were lack of efficacy and 
withdrawal of consent, the next most frequent reasons were due to side effects and loss to 
follow-up. It is important to understand not just the reason for attrition, but also if there is 
a difference between the attrition and non-attrition groups. This study highlighted some 
potential differences between the attrition and non-attrition groups such as a medium 
effect size for higher rates of attrition with typical antipsychotics. Small effect sizes were 
found for the attrition group, which was more likely to be Caucasian, slightly older, with 
more years of education, but not in school in the previous year. The attrition group had a 
higher level of functioning and was more likely to be either working or a student with a 
lower household median income. This group also was less likely to have a history of 
substance abuse or dependence for drugs other than alcohol and marijuana. These results 
are based on a small sample size, analysis of larger studies is needed. In addition, more 
work is needed to better understand the reasons for attrition from both research studies 
and standard psychiatric care.  
 There is currently enough evidence in the literature to question the continued use 
of Last Observation Carrier Forward, especially when there are differences in attrition 
rates between treatment groups. Further study, of these differences as well as differences 
between attrition and non-attrition groups is needed. One potential method is the use of a 
meta-analysis with the use of effect sizes to quantify the magnitude of difference between 
those who stay in a study or in treatment and those who do not. Exploration of the 
differences between pooled samples and individual studies of people in a first episode of 
schizophrenia spectrum disorders is also needed.  
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 Psychiatric nurses and other mental health practitioners are in a key position to 
advocate for early identification, intervention and treatment in the first episode of a 
schizophrenia spectrum disorder. The incorporation of recovery oriented client centered 
care models into usual care will require learning and understanding the philosophy of 
these models and newer treatments and their methods. Ongoing research is needed to 
better understand the lived experience of people in a first episode, especially why they 
drop out of treatment in such high numbers, as well as to assess the effectiveness of 
different treatment methods. Reasons for attrition may be better understood when we 
have a clearer understanding of the barriers to care and those factors affecting alliance 
development with mental health practitioners. Existing mental health systems will need to 
be modified, to better meet the needs of young adults, as they move along a path toward 
recovery. Major goals include promoting skill development to enhance autonomy, 
symptom management and relapse prevention, along with promoting good healthy habits, 
and the prevention of disability, can lead to positive outcomes. Finding better ways to 
manage factors that result in poor outcomes, such as substance use, is critical. It is clear 
that recovery from a first episode SSD is enhanced by early intervention and adherence to 
treatment.  
 Early identification and intensive treatment may help improve treatment 
outcomes, but we can not forget that with over fifty years of modern 
psychopharmacology, more than half of the people with schizophrenia drop out of 
treatment and are not receiving medication or other forms of treatment.  Medication used 
in the treatment of schizophrenia does not treat all dimensions of this illness, most 
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notable the neurocognitive deficits. Clearly, developing comprehensive treatment is 
complicated, and medication is only one piece of the puzzle. 
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Appendix B. Combined Studies Entry and Attrition 
 
 
Phase I 
UConsented 
    Withdrew Consent 
     Lost to Follow-up 
     Fail Inclusion Criteria 
UEvaluable 
   Withdrew too Psychotic 
   Withdrew Consent 
   Fail Inclusion Criteria 
Phase II 
URandomization 
UStudy Medication (wk 1-24) 
   Withdrew Consent  
   Lack of Efficacy  
   Adverse Events  
   Moved  
   Medication Non-adherence 
  Require Disallowed Medication 
UComplete 24 Weeks 
ClozHal 
UN 
U44 
1 
 
         7 
       U36 
         2 
2 
         5 
 
   
 
       U27 
 
2 
6 
         4 
         4 
 
 
 
       U12 
OlzHal 
UN 
U32 
        2 
 
1 
      U29 
 
       2 
       3 
 
 
 
     U24 
 
1 
      10 
1 
         
1 
        2 
 
9 
OlzQueRis 
UN 
U19 
 
         2 
 
       U17 
 
         2 
         3 
 
 
 
       U12 
 
         1 
1 
1 
1 
 
 
 
         8 
Combined 
UN 
U95 
 3 
 2 
        8 
      U82 
        2   
6 
      11 
       
 
      U63 
 
        4 
17 
6 
5 
1 
2 
      U29 
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Appendix C.  
Demographic Characteristics From Each Study and Final Variables  
 
Independent or grouping variables: 
Attrition    
     did not complete study (no) = 0 
     completed study (yes)  = 1 
Research study: 
      ClozHal = 1 
      OlzHal = 2 
      OlzQueRis = 3 
Dependent Variables: 
UVariable U                    UClozHalU                                 UOlzHal U                               UOlzQueRis U                      UFinal Variable       
1. Age                     date of birth                          date of birth                         date of birth                    age in years at             
                                                                                                                                                                       baseline 
2. Gender                    male=1, female=2                male, female                       male, female                   male=0, female=1 
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Appendix C (continued).  
Demographic Characteristics From Each Study and Final Variables  
 
UVariable U                    UClozHalU                                       UOlzHal U                            UOlzQueRis U                      UFinal Variable       
3. Race/Ethnicity                                       
                                    1 = White                                  Caucasian                          White                               1= Caucasian 
                                    2 = Black, not Hispanic            African Descent                 Black or                          2 = African               
                                                                                                                                                                              American 
 
                                    3 = East/SE Asian or                East/SE Asian                   African American            3 = Asian 
                                          Pacific Islander                   Western Asian                  American Indian or          4 = Hispanic 
                                    4 = Western Asian                    Hispanic                            Alaskan Native              
                                           (India and Pakistan)                                                     Asian                                       
                                    5 = Hispanic                                                                       Native Hawaiian or            
                                                                                                                               other Pacific Islander             
4. Marital Status          1 = single/never married          From record review          married                   1 = single/never married    
                                     2 = married/common law                                                  widowed                 2 = married/common law 
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Appendix C (continued).  
Demographic Characteristics From Each Study and Final Variables  
 
UVariable U                    UClozHalU                                  UOlzHal U                                UOlzQueRis U                          UFinal Variable      
                                    3 = separated                                                                      divorced                              3 = separated 
                                    4 = divorced                                                                       separated                             4 = divorced 
                                    5 = widowed                                                                      never married                
5. Marital Status (collapsed) 
                                                                                                                                                                         0 = never married 
                                                                                                                                                                         1 = ever married 
6.  School attendance in past 12 months prior to baseline _____, 
                                     If student,                              Level of school               Level completed           Highest level of school 
                                     current education level          past 12 months                                                     in past year 
                                    1 = high school                      1 = GED                          GED/ high school        0 = not in school 
                                    2 = GED                                2 = secondary                   some college, did        1 = in GED/HS classes 
                                                            
                                    3 = technical school              3 = adult education           not graduate                2 = in college/graduate     
                                                                                                                                                                      school 
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Appendix C (continued).  
 
Demographic Characteristics From Each Study and Final Variables  
 
UVariable U                     UClozHal U                                  UOlzHal U                                 UOlzQueRis U                          UFinal Variable      
                                   4 = non-degree college          4 = community college        community college/        
                                         program                           5 = vocational/                     technical school         
                                   5 = two-year                                technical center              degree                       
 
                                          college                            6 = trade school                    college graduate                   
                                           
                                    6 = four-year                        7 = 4 year college                 college graduate and      
 
                                          college                            8 = college/university          some master’s level    
                                  
                                    7 = graduate School                   graduate level                 courses                            
 
                                    8 = Doctoral Level               9 = other                              Master’s degree               
                                                                                                                                                                                      
                                    97 = Other _____                                                              completed                           
                     
                                                                                                                              Advanced degree                  
                                                                                                                              courses, not graduated      
                                                                                                                                          
                                                                                                                             Advanced degree completed     
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Appendix C (continued).  
 
Demographic Characteristics From Each Study and Final Variables  
 
 
UVariable U                    UClozHalU                                  UOlzHal U                                 UOlzQueRis U                      UFinal Variable       
7. Number of years of completed education (HS/GED = 12) 
                                     From above item                   From above item                  From above item     # of years education___  
8. Left school due to symptoms from research record and admission history                                     
                                     Admission History                Admission History               Admission History          no = 0, yes = 1 
ULiving situation 
9.  Highest level in the previous year and  
10. Highest level in the month prior to baseline 
                                   1 = Independent                      1 = Independent                  1 = Independent            1 = Independent          
 
                                   2 = Sheltered apartment          2 = Apartment -                  2 = Apartment -            2 = Dormitory  
 
                                   3 = Halfway house                        supervised                           supervised              3 = Family shelter        
                                                                                                                
                                   4 = Quarterway house             3 = Apartment -                  3 = Apartment -            4 = Homeless, street 
                              
                                   5 = Foster home                            therapeutic                           therapeutic                  
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Appendix C (continued).  
 
Demographic Characteristics From Each Study and Final Variables  
 
 
UVariable U                    UClozHalU                                    UOlzHal U                                  UOlzQueRis U                      UFinal Variable      
                                   6 = Live with family in            4 = Apartment -                     4 = Apartment -                  
                                                                                                                         
                                        dependent status                       association                            association                           
                                                                                                                                         
                                   7 = Street or shelter                  5 = Apartment -                    5 = Apartment -                  
                                   
                                   8 = Inpatient                                   therapeutic family               therapeutic family                                      
                                                                                                                                                                                                           
                                 97 = Other:________                 6 = Group home                   6 = Group home                 
                                                                                                                                                          
                                 98 = Refused to answer              7 = Family                           7 = Family                                 
 
                                                                                    8 = Hospital or institution    8 = Hospital or institution   
                          
                                                                                    9 = Homeless                        9 = Homeless                            
                                                                                                                                          
                                                                                  99 = Other________            99 = Other________           
                             
11. The highest level of employment in the year prior to baseline and 
12.  the month prior to baseline 
                            Is patient currently                Work status (majority of        Work status (majority     Work status as defined   
                            employed (no = 0,                 time during the 12 months     time since last visit or      above 
  
153
 
  
Appendix C (continued).  
Demographic Characteristics From Each Study and Final Variables  
 
UVariable U               UClozHalU                                UOlzHal U                                      UOlzQueRis U                        UFinal Variable       
                        yes = 1) and  from detailed        prior to entering study)         past month for baseline      
                       chart of employment history      and from admission history  visit and history)                                    
                       as per final variable                  1 = working for pay               1 = working for pay        0 = Unemployed, due to   
                                                                         2 = full-time sheltered           2 = full-time sheltered       study disease disability 
                                                                               program                                program                     1 = working for pay 
                                                                         3 = part-time sheltered          3 = part-time sheltered    2 = student                         
                                                                               program                                 program                             
                                                                        4 = student (full or part-time)  4 = student – full-time      
                                                                        5 = retired                                5 = student – part-time            
                                                                        6 = keeping house                   6 = retired                         
                                                                        7 = volunteer work                  7 = housekeeping              
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Appendix C (continued).  
Demographic Characteristics From Each Study and Final Variables  
 
UVariable U                    UClozHalU                             UOlzHal U                                       UOlzQueRis U                      UFinal Variable       
                                                                              8 = unemployed, not due           8 = volunteer work                                           
 
                                                                                    to study disease disability    9 = Unemployed, not         
                                                                             9 = Unemployed, due to                    due to study disease disability                   
                                                                                study disease disability          10 = Unemployed, due 
                                                                                                                                        to study disease disability                         
13. highest number of hours of work per week in the year prior to baseline                                                                                   
                              # of hours per week__    # of hours per week__          # of hours per week__        # of hours per week__ 
14. Level of functioning (includes working for pay, student, and housekeeping) majority of time in the year prior to baseline 
                              From admission             1 = no useful functioning     1 = no useful functioning   1 = no useful functioning 
                               history, NPQST,           2 = >0 to <25% of time        2 = >0 to <25% of time      2 = >0 to <25% of time 
                             & Heinrich QOL            3 = >25% to <50% of time   3 = >25% to <50%            3 = >25% to <50% 
                                                                    4 = >50% to <75% of time   4 = >50% to <75%             4 = >50% to <75% 
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Appendix C (continued).  
Demographic Characteristics From Each Study and Final Variables  
 
UVariable U                    UClozHalU                                       UOlzHal U                             UOlzQueRis U                      UFinal Variable       
                                                                         5 = >75% to <100% of time        5 = >75% to <100%         5 = >75% to <100% 
 
15. Median household income                                                                                                                                           
                                                                                                                                                                         $_____________ 
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Appendix D.  
 
Variables for Illness Characteristics From Each Study and Final Variables  
 
Variable                     ClozHal                             OlzHal                               OlzQueRis                         Final Variable       
16. Psychiatric Axis I diagnosis 
 
                                    SADS interview                SCID interview                  SCID interview                 
                                     
                                    Schizophrenia                   Schizophrenia                     Schizophrenia                  Schizophrenia 
 
                                                                              Schizophreniform               Schizophreniform            Schizophreniform 
 
                                                                              Schizoaffective                   Schizoaffective                Schizoaffective 
 
                                                                              Depressed type                   Depressed type                Depressed type 
 
17. Age at onset of psychosis                                                                                                                   age in years______ 
 
18. Severity of psychiatric symptoms at screening,  
 
19. Severity of psychiatric symptoms at baseline,  
                      
                    Clinical Global Impression (CGI) (CGI) Severity              (CGI) Severity                    (CGI) Severity                   
 
                        1 = Normal, not at all ill      1 = Normal, not at all ill     1 = Normal, not at all ill        1 = Normal, not at all ill 
 
                          2 = Borderline mentally ill   2 = Borderline mentally ill 2 = Borderline mentally ill   2 = Borderline           
                                                                                                                                                                              mentally  ill         
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Appendix D (continued). 
 
Variables for Illness Characteristics From Each Study and Final Variables  
 
 
Variable                     ClozHal                                OlzHal                               OlzQueRis                       Final Variable       
   
                                    3 = Mildly ill          3 = Mildly ill                       3 = Mildly ill           3 = Mildly ill 
 
                                    4 = Moderately ill               4 = Moderately ill               4 = Moderately ill           4 = Moderately ill 
 
                                    5 = Markedly ill                  5 = Markedly ill                  5 = Markedly ill                5 = Markedly ill 
 
                                    6 = Severely ill                   6 = Severely ill                    6 = Severely ill       6 = Severely ill 
 
                                    7 = Among the most        7 = Among the most            7 = Among the most     7 = Among the most 
 
                                   extremely ill patients        extremely ill patients         extremely ill patients          extremely ill patients 
 
20. Duration of untreated psychosis (DUP) – difference in the dates in weeks between the date (month/year) of onset of the 
first psychotic symptom and the date (month/year) of onset of first antipsychotic drug use:  DUP weeks_____                           
 
21. Number of psychiatric hospitalizations prior to the study _____                                                                                              
 
Lifetime History of Alcohol and Drug Use – for the following substance use variables (plus the use of weekly visit 
questionnaires). 
 
                                   SADS                                     SCID                                    SCID                           
 
                                   Lifetime history                    Lifetime history                  Lifetime history                Lifetime history  
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Appendix D (continued).  
 
Variables for Illness Characteristics From Each Study and Final Variables  
 
 
 Variable                     ClozHal                                    OlzHal                               OlzQueRis                           Final Variable      
 
 
                                  Absent                                     Absent                                  Absent       
 
                                  Abuse                                      Abuse                                   Abuse 
 
                                  Dependence                            Dependence                          Dependence     
 
Variable                                                                                                                                                            Final Variable       
 
22. Lifetime history of alcohol misuse                                                                                                               
 
23. Lifetime history of marijuana use                                                                                                                 
 
24. Lifetime history of cocaine                                                                                                                          0 = no use 
                                                                                                                                                                           
25. Lifetime history of opiates                                                                                                                           1 = use                    
 
26. Lifetime history of PCP                                                                                                                              2 = abuse                
 
27. Lifetime history of LSD                                                                                                                               3 = dependence   
 
28. Lifetime history of Amphetamines 
 
29. Lifetime use of other drugs (combines cocaine, opiates, PCP, LSD, and amphetamine)                      
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Appendix D (continued).  
 
Variables for Illness Characteristics From Each Study and Final Variables  
 
 
Variable                     ClozHal                                    OlzHal                             OlzQueRis                             Final Variable      
 
Alcohol - Alcohol Use Scale/Drug Use Scale (AUS/DUS)                                                                             1 = abstinent 
 
30 - 31. Alcohol use during month before baseline and during double-blind study                                        2 = use                     
.                                                                                                                                                                                                          
Marijuana - Alcohol Use Scale/Drug Use Scale (AUS/DUS)                                                                         3 = abuse 
 
32 - 33. marijuana use during month before baseline and during double-blind study                                     4 = dependence      
 
                                                                                                                                                                          5 = dependence w/  
                                                                                                                                                                                hosp 
34. Age at first alcohol use 
 
                                 Age in years                              Age in years                     Age in years                        Age in years 
 
35. Age at first marijuana use 
 
                                 Age in years                              Age in years                     Age in years                       Age in years 
 
Cognitive Functioning                                      
 
Estimated premorbid IQ - Wide Range Achievement Test (WRAT III) or National Adult Reading Test (NART)                 
                         WRAT III                                   NART                              WRAT III                          WRAT III or              
                                                                                                                                                                       NART 
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Appendix D (continued).  
 
Variables for Illness Characteristics From Each Study and Final Variables  
 
 
Variable                     ClozHal                                    OlzHal                               OlzQueRis                           Final Variable      
                                 
                                     Standard Score                       Standard Score                   Standard Score                Standard Score ___ 
36.                                Percentile                               Percentile                            Percentile                        Percentile_____ 
Executive Functioning 
 
             Wisconsin Card Sort (WCST-64)                                                       
                                   WCST-64                              WCST-64                             WCST-64 (computer)       WCST-64 
                                   percentile rank for                 percentile rank for                 percentile rank for           percentile rank for 
37.                              perseverative responses        perseverative responses          perseverative responses  perseverative  
                                                                                                                                                                         responses___            
38.                             # categories completed          # categories completed          # categories completed    # categories        
                                                                                                                                                                         completed ___ 
 
Language Functioning  
Controlled Word Association Test (COWAT - FAS) ______ 
                            Total # words                         Total # words                        Total # words             Total # words_______ 
39.                             Percentile score                      Percentile score                     Percentile score          Percentile score_____    
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Appendix D (continued).  
Variables for Illness Characteristics From Each Study and Final Variables  
____________________________________________________________________________________________________ 
 
Variable                     ClozHal                                    OlzHal                            OlzQueRis                           Final Variable       
 
Memory Functioning 
Wechsler Memory Scale – Revised (WMS-R) Logical Memory (LM) or Hopkins Verbal Learning Test (HVLT) 
                                  WMS-R LM                         WMS-R LM                       HVLT                                WMS-R or HVLT 
        Immediate        Standardized Scores             Standardized Scores            Standardized Scores          Standardized Scores   
40.                            Percentile                              Percentile                            Percentile                            Percentile 
Motor Functioning  
Finger Tapping or Grooved Pegboard Dominant hand 
                        Finger Tapping                    Finger Tapping                Grooved Pegboard (GP)     Finger Tapping  or GP 
                              Standardized T scores          Standardized T scores     Standardized T scores        Standardized T scores___  
41.                         and percentile rank              and percentile rank          and percentile rank             and percentile rank____ 
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Appendix D (continued).  
 
Variables for Illness Characteristics From Each Study and Final Variables  
 
 
Variable                     ClozHal                                    OlzHal                               OlzQueRis                           Final Variable      
 
Attention (visual attention) 
 
Cancellation Test (CT) will use the organizational score and time to complete task to yield a score of normal or abnormal. 
Visual CPT-IP (identical pairs version) standard score and percentile rank will be converted to a score of no impairment  
(<-1.5 standard deviation), mild to moderate impairment (>1.5 - < 3.0 standard deviation), and severe impairment (>3.0 
standard deviation). 
                                  Cancellation Test                Visual CPT-IP                    Visual CPT-IP              CT or Visual CPT-IP   
                                  Organizational score           d-prime score                      d’prime score                       
                                        Time to completion                                                                                                                                  
42.                                                                                                                                                               normal or abnormal      
 
 
____________________________________________________________________________________________________ 
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Appendix E.  
 
Variables for Treatment Characteristics From Each Study and Final Variables 
 
 
Variable                     ClozHal                               OlzHal                           OlzQueRis                      Final Variable       
43. Participation is the timing of withdrawal – early = screening to baseline; double-blind = weeks 1- 24. 
 
                                                                                                                                                            1 = early withdrawal 
                                                                                                                                                       
                                                                                                                                                            2 = double-blind withdrawal 
 
44. Number of weeks completed in the double-blind phase from study book. 
 
                                 # of weeks                           # of weeks                      # of weeks                      # of weeks _________ 
 
 
45. Reason for study termination obtained from study book 
  
                        1.  adverse event                     1. protocol complete           1. adverse event                 1. adverse event 
 
                        2. lack of efficacy (LOE)        2. adverse event                  2. (LOE)                           2. (LOE) 
                            patient perception               3. satisfactory  response          patient perception               patient perception 
                                
                       3. LOE – MD perception         4. LOE – MD perception    3. LOE – MD perception   3. LOE - MD perception  
 
                       4. LOE  patient & MD             5. LOE – patient & MD      4. LOE – patient & MD     4. LOE – patient & MD       
                           agree                                         agree                                    agree                                  agree 
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Appendix E (continued).  
 
Variables for Treatment Characteristics From Each Study and Final Variables 
 
 
Variable               ClozHal                                    OlzHal                               OlzQueRis                         Final Variable       
                     5. patient withdrew consent   6. patient withdrew consent  5. patient withdrew consent  5. patient withdrew            
                                                                                                                                                                    consent 
                     6. lost to follow-up                7. lost to follow-up                6. lost to follow-up                6. lost to follow-up 
                     7. patient moved                    8. patient moved                    7. patient moved                   7. patient moved 
 
                     8. inclusion/exclusion           9. inclusion/exclusion            8. inclusion/exclusion           8. inclusion/exclusion 
                         criteria not met                      criteria not met                      criteria not met                      criteria not met 
                     9. protocol violation             10. protocol violation             9. protocol violation              9. too psychotic for             
                                                                                                                                                                     procedures                    
   
                                                                                                                                                             10. requires disallowed         
                                                                                                                                                                    medication 
                                                                                                                                                                                                            
                                                                                                                                                              11. patient stopped study  
                                                                                                                                                                    medication 
                                                                                                                                                                                
                                                                                                                                                             12. severity criteria not met  
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Appendix E (continued).  
 
Variables for Treatment Characteristics From Each Study and Final Variables 
 
 
Variable                     ClozHal                                    OlzHal                       OlzQueRis                 Final Variable       
46. Study termination collapsed into 3 groups                                                                               1. Patient related issues 
                                                                                                                                                            (withdraw consent, move,  
                                                                                                                                                            lost to follow-up) 
 
                                                                                                                                                       2.  Medication related issues 
                                                                                                                                                           (lack of efficacy, adverse        
                                                                                                                                                            events)                                     
      
                                                                                                                                                     3.  Protocol related issues              
                                                                                                                                                          (entry severity criteria,              
                                                                                                                                                          disallowed medication) 
 
47. Washout classified as either having a antipsychotic medication washout or not 
 
                            Had washout                           Had washout                       No washout                      0. no washout 
            
                                                                                                                                                                 1. washout 
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Appendix E (continued).  
 
Variables for Treatment Characteristics From Each Study and Final Variables 
 
 
Variable                     ClozHal                                    OlzHal                           OlzQueRis                       Final Variable       
48. Number of days in washout phase of study (OLZQUERIS did not have a washout phase) from study book 
                                
                                   # of days                               # of days                           No washout phase             # of days_____ 
 
49. Randomized Antipsychotic Medication                                                                                                  0 = not randomized     
 
                                 Haloperidol                             Haloperidol                      Quetiapine                         1 = Clozapine 
  
                                 Clozapine                                Olanzapine                       Olanzapine                        2 = Olanzapine 
 
                                                                                                                             Risperidone                      3 = Haloperidol  
                                                                                                           
                                                                                                                                                                       4 = Quetiapine 
                                                                                                                                                         
                                                                                                                                                                       5 = Risperidone 
 
50. Randomized Antipsychotic medication as typical and atypical                                                              0 = typical 
 
                                                                                                                                                                       1 = atypical 
            
_____________________________________________________________________________________________________   
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Appendix F. Data Collection Tool 
 
 
CLOZHAL______   OLZHAL_____   OLZQUERIS_____ 
 
Subject ID :________________ 
 
School attendance: 
 
              In the 12 months prior to baseline________   
              Number of years of completed education__________ (GED/HS = 12) 
 
              Left school due to symptoms from research record and admission                 
              history_________  
Living situation 
            highest level in the year prior to baseline________  
                         1 = Independent  
                         2 = Family 
                         3 = Apartment – off site supervised 
                         4 = Apartment – live in supervision/therapeutic family 
                         5 = Group home (halfway house, quarterway house     
                         6 = Hospital or institution (inpatient) 
                         7 = Homeless, shelter or on the street 
                         8 = Other_____________ 
Level of employment:  
            highest level in the year prior to baseline________   
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Appendix F (continued).  Data Collection Tool 
__________________________________________________________________ 
                     1 = working for pay 
                        2 = student - full-time 
             3 = student - part-time 
             4 = sheltered program full-time 
             5 = sheltered program part-time 
            6 = volunteer work                                 
             7 = retired  
       8 = housekeeping              
  9 = Unemployed, not due to study disease disability 
                      10 = Unemployed, due to study disease disability                      
Number of hours worked/week  
             highest level in the year prior to baseline________  
Level of functioning (includes working for pay, student, housekeeping, and 
volunteer work) (CLOZHAL from admission history, NPQST & Heinrich QOL)      
 month prior to baseline________   
            highest level in the year prior to baseline________   
                                   1 = no useful functioning             
                                   2 = >0 to <25% of time                
                                   3 = >25% to <50% of time           
                                   4 = >50% to <75% of time           
                                   5 = >75% to <100% of time         
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Appendix F (continued).  Data Collection Tool 
__________________________________________________________________ 
 
Duration of untreated psychosis (DUP) – difference in the dates in weeks between 
the date (month/year) of onset of the first psychotic symptom and the date 
(month/year) of  onset of first antipsychotic drug use      DUP weeks __________     
 
Lifetime history of alcohol use______                                                                          
 
Lifetime history of marijuana use______ 
 
Lifetime history of cocaine use______ 
 
Lifetime history of opiate use______   
 
Lifetime history of PCP use______ 
 
Lifetime history of LSD use______ 
 
Lifetime history of Amphetamine use______ 
0 = no use          1 = use        2 =  abuse       3 = dependence                             
Alcohol - Alcohol Use Scale/Drug Use Scale (AUS/DUS) during  
month before baseline______                 
Marijuana - Alcohol Use Scale/Drug Use Scale (AUS/DUS) during 
month before baseline______                 
Cocaine - Alcohol Use Scale/Drug Use Scale (AUS/DUS) during 
month before baseline______                 
Opiates - Alcohol Use Scale/Drug Use Scale (AUS/DUS) during 
month before baseline______                 
PCP - Alcohol Use Scale/Drug Use Scale (AUS/DUS) during                                     
month before baseline______                 
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Appendix F (continued).  Data Collection Tool 
___________________________________________________ 
LSD - Alcohol Use Scale/Drug Use Scale (AUS/DUS) during 
month before baseline______                 
Amphetamines - Alcohol Use Scale/Drug Use Scale (AUS/DUS) during 
month before baseline______                 
 
1 = abstinent  
 
2 = use  
 
3 = abuse 
                                                                                                               
4 = dependence 
                                                                                                               
5 = dependence w/ hosp 
 
Age at first alcohol use_______________ 
 
Age at first marijuana use_____________ 
 
Number of days in washout phase_____________ 
 
Did participant complete study?  0 = no, 1 = yes__________ 
 
What phase did participant leave study?  
 
                      1 = screening 
                   
                      2 = drug taper 
 
                      3 = washout 
 
                      4 = double-blind treatment 
 
Timing of withdrawal  
 
                      1 = early (screening to baseline)   
              
                      2 = double-blind weeks 1-24  
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Appendix F (continued).  Data Collection Tool 
__________________________________________________________________ 
Number of weeks completed double-blind phase_________ 
 
 
Reason for termination from study_____________ 
  
                      0 = completed 
                 
                      1 = adverse event 
 
                      2 = lack of efficacy (LOE) patient perception 
 
                      3 = LOE MD perception   
  
                      4 = LOE patient and MD agree 
 
                      5 = patient withdrew consent 
 
                      6 = lost to follow-up 
 
                      7 = patient moved 
 
                      8 = inclusion/exclusion criteria not met 
 
                      9 = protocol violation  
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Appendix G. Study Variables by Type of Proposed Analysis 
 
 
Chi Square t-test (Mann-Whitney U) 
  
Demographic Variables (variable number as listed in Appendix C): 
 
Gender (2) 
Race, Ethnicity (3) 
 
Marital Status (4, 5) 
 
Level of School Attendance (6) 
 
Left school due to symptoms (8) 
 
Living Situation (9, 10) 
 
Level of Employment (11, 12) 
 
Level of Functioning (14) 
 
 
Age (1) 
 
 
 
 
 
Total number of years of education (7) 
 
 
 
 
Employment # of hours (13) 
 
Median Household Income (15) 
Illness Characteristics (variable number as listed in Appendix D):  
 
                   Chi Square                                                    t-test (Mann Whitney U) 
 
Major Diagnostic Group (16) 
 
Substance Use (22 - 33) 
 
Visual Attention Functioning (42) 
 
 
 
 
 
 
 
 
 
 
Age at onset of psychosis (17) 
 
Symptom Severity – CGI (18 -19)  
 
Duration of Untreated Psychosis (20) 
 
Number of Previous Hospitalizations (21) 
 
Age at First Alcohol Use (34) 
 
Age at First Marijuana Use (35) 
 
Cognitive Functioning (36 - 41) 
 
 
 
 
 
 
  
173
 
  
Appendix G (continued). Study Variables by Type of Proposed Analysis 
 
 
Treatment Characteristics (variable number as listed in Appendix E): 
 
                   Chi Square                                                    t-test (Mann Whitney U) 
 
Timing of Withdrawal (43) 
 
Reason for Study Withdrawal (45 - 46) 
Washout (47) 
Antipsychotic Medication (49 - 50) 
 
 
 
 
 
Double-blind Completion in Weeks (44) 
 
Antipsychotic Drug Washout (days) (48) 
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Appendix H: Effect Size Calculator Used for Continuous Variables 
 
Retrieved from on May 15, 2009: http://web.uccs.edu/lbecker/Psy590/escalc3.htm 
 
 
 
0BEffect Size Calculators 
Calculate Cohen's d and the effect-size correlation, rY, using -- 
 Hmeans and standard deviations 
 Hindependent groups  t test values and df 
For a discussion of these effect size measures see HEffect Size Lecture Notes 
 
1BCalculate d and r using means and standard deviations 
  
Calculate the value of Cohen's d and the effect-size 
correlation, rY, using the means and standard deviations of 
two groups (treatment and control).  
Cohen's d = M1 - M2 / pooled  
    where pooled = [( 1²+  2²) / 2] 
rY = d / (d² + 4) 
Note: d and rYare positive if the mean difference is in the 
predicted direction. 
Group 1 Group 2 
M1  M2  
SD1  SD2 
Reset
 
Cohen's d 
 
effect-size r
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Appendix I.  Question 1  
 
Table 11.  
 
Demographic Characteristics - Comparison of the Three Double-blind, Randomized 
Studies 
 
Table 12. 
 
Illness Characteristics - Comparison of the Three Double-blind, Randomized Studies   
 
Table 13. 
 
Treatment Characteristics - Comparison of the Three Double-blind, Randomized Studies  
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Appendix I.   
 
Table 11.  
 
Demographic Characteristics - Comparison of the Three Double-blind, Randomized Studies1  
  
           ClozHal                                  OlzHal                         OlzQueRis                             
Dependent Variables              pa  
          
Age                            (N) 
Mean
(SD)
Median
(Range)  
         (36) 
22.72 
 (4.25) 
          21.5 
  (18 - 34)       
         (29) 
          23.28   
           (4.72)  
          20.3      
  (17 - 34)  
         (17) 
 21.94 
  (4.59) 
          20.0        
  (18 - 36)  
.648 
          
Education (years)      (N) 
Mean
(SD)
Median
                           (Range)  
        (36) 
         12.11  
          (2.40)  
         12.0             
          (3 - 16)  
          (29) 
   12.48   
     (2.42)  
12.0            
      (8 - 19)  
         (16) 
  11.26  
   (2.52)  
12.0         
      (6 - 16)  
.296 
Employment              (N)
(hours/week)          Mean 
(SD)
Median
                           (Range)  
         (29) 
15.62  
         (17.7)  
            0          
     (0 - 40)  
          (29) 
   23.45  
  (18.71)  
           30.0        
       (0 - 50)  
         (12) 
 14.17    
(21.9)  
             0            
       (0 - 50)  
 
.217 
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Table 11 (continued).  
 
Demographic Characteristics - Comparison of the Three Double-blind, Randomized Studies1  
  
 
 
      ClozHal                OlzHal                            OlzQueRis                        
 
Dependent Variables        
 
     pa  
Median Income         (N) 
                             Mean  
                              (SD)  
                         Median  
                           (Range)  
 
         (33) 
 $49,722         
($18,975)  
 $45,984      
  (11 - 97k)  
 
          (17) 
  $36,362 
 ($14,491)  
$32,022 
 (11 - 66k)  
 
          (17) 
   $41,295  
  ($20,933)  
   $41,186                 
    (11 - 98k)  
 
.031* 
 
 
 
 
 
 
          
 
                                  (N) %       (N) %  (N)   %     pb 
            
Gender                              (n = 36)   (n = 29)    (n = 17)    .678 
   Male                             (31) 86.1%  (26) 89.7%  (16) 94.1%   
   Female                            (5) 13.9%   (3) 10.3%   (1)   5.9%   
          
Race                                  (n = 36)   (n = 29)   (n = 17)    .695 
   Non-Caucasian        (18) 50%  (12) 41.4%  (9) 52.9%   
   Caucasian                       (18) 50%  (17) 58.6%  (8) 47.1%   
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Table 11 (continued).  
 
Demographic Characteristics - Comparison of the Three Double-blind, Randomized Studies  
  
                             
 
     ClozHal                OlzHal                  OlzQueRis              
Dependent Variables          pb 
 
School Attendance                       (n = 34)   (n = 28)   (n = 14)  .930  
   not in school                (20) 58.8%   (18) 62.1%  (9) 64.3%   
   in school                       (14) 41.2%  (11) 37.9%   (5) 35.7%   
            
Left school                                    (n = 30)   (n = 27)   (n = 15)  .361  
   no                              (16)  53.3%  (19)  70.4%  (8)  53.3%   
   yes                             (14)  46.7%   (8)  29.6%  (7)  46.7%   
            
Living situation (past year)          (n = 34)   (n = 29)   (n = 14)  .760  
   independent/dorm     (10) 29.4%   (9) 31%     (4) 28.6%   
   Family                       (22) 64.7%  (17) 58.6%       (10) 71.4%   
   Homeless                     (2)   5.9%   (3) 10.3%      (0)    
            
Employment Status (past year)    (n = 34)   (n = 29)   (n = 15)  .01**  
   not working                 (9) 26.5%   (2)   6.9%  (7) 46.7%   
   working/student        (25) 73.5%  (27) 93.1%  (8) 53.3%   
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Table 11 (continued).  
 
Demographic Characteristics - Comparison of the Three Double-blind, Randomized Studies  
  
                    
                          ClozHal                            OlzHal                            OlzQueRis             
Dependent Variables                  
                                 (N) %  (N) %  (N)   % pb 
 
Functional Level (past year)          (n = 31)  (n = 29)   
   
(n = 13)     .033*  
   no useful functioning to 25%      (9)  29%  (2)   6.9%  (5) 38.5%   
   25 to 100%             (22) 71% (27) 93.1%  (8) 61.5%   
           
           
1 p values are reported without Bonferroni correction 
a Welch Test 
b Chi Square 
* p < .05  ** p < .01  *** p < .001     
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Table 12. 
 
 Illness Characteristics - Comparison of the Three Double-blind, Randomized Studies1   
 
     ClozHal 
 
OlzHal  
  
OlzQueRis    
 
Dependent Variables                         pa  
        
Age at onset                      (N) 
                                    Mean  
                                      (SD) 
                                 Median  
                                   (Range) 
        (36) 
21.4  
   (4.14)  
         20        
  (16 - 33) 
         (28) 
22.3  
   (4.67)  
          21           
    (16 - 33)  
          (17) 
21.5    
   (4.78) 
           20        
 (17 - 36)  
.747 
 
 
Severity of illness  - 
Screening                          (N) 
                                      Mean  
                                        (SD) 
                                   Median 
                                   (Range) 
 
        (34) 
    4.62    
    (0.82)  
           5         
          (2 – 6) 
        (24) 
   4.54   
   (0.66)  
           4             
   (4 – 6)  
         (14) 
            5.36  
  (0.74)   
            5      
           (4 – 7)  
 
 
.005** 
 
 
Severity of illness –    
Baseline                            (N) 
                                      Mean  
                                        (SD) 
                                   Median 
                                   (Range) 
 
        (31) 
   4.52    
   (0.99)  
           5          
    (2 – 6) 
        (23) 
   4.39    
   (0.99)  
           4              
   (2 – 6)  
          (14) 
   4.29   
   (0.99)  
             5           
    (2 – 5)  
 
         
.761 
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Table 12 (continued). 
 
 Illness Characteristics - Comparison of the Three Double-blind, Randomized Studies1   
 
 
   
    ClozHal  OlzHal  OlzQueRis    
Dependent Variables                       pa  
 
Alcohol                            (N) 
(Age 1st use)                Mean   
                                       (SD)  
Median 
(Range) 
        (12) 
14.5  
    (2.07) 
         15       
    (10 - 17) 
         (12) 
  14.58 
    (1.15) 
 15.5         
       (7 - 19)  
          (11) 
  14.45     
    (2.25)  
           14         
    (12 - 18)  
 
.994 
 
 
Marijuana                        (N) 
(Age 1st use)                 Mean 
                                   (SD)  
Median 
(Range) 
 
       (19) 
15.11  
  (2.28) 
        15          
   (8 - 19) 
         (11) 
15.6  
    (1.84)  
          16         
     (13 - 19)  
          (12) 
  14.75     
    (1.96)  
14.5       
    (12 -18)  
 
.621 
 
 
Intellectual Functioning  (N) 
Mean 
                                   (SD)  
Median 
(Range)  
 
       (30) 
      101.5  
       (11.64)        
      101     
  (70 - 116)  
          (15) 
106.6 
      (7.79)  
         106         
         (92 - 118)   
          (11) 
107.36    
    (9.70)  
         109         
      (92 - 119)  
 
.033* 
 
 
 
 
 
 
 
 
  
182
 
  
Table 12 (continued). 
 
 Illness Characteristics - Comparison of the Three Double-blind, Randomized Studies1   
 
 
   
    ClozHal  OlzHal  OlzQueRis    
Dependent Variables                            pa  
 
Executive Functioning -    (N) 
Perseverative            Mean 
(SD)  
Median  
(Range) 
 
      (31) 
       49.48  
      (34.89)  
       42          
       (0.5 - 99.9)  
       (23) 
        52.08  
       (33.94)  
        50           
    (1 –  99)   
         (11) 
45.36   
 (28.63)  
           50    
            (1 –  82)  
 
.838 
 
 
Executive Functioning  - (N) 
Categories                     Mean 
(SD)  
Median  
(Range) 
       (31) 
 2.23 
 (1.56)  
          2            
  (0 - 6)  
       (22) 
2.41      
         (1.7)  
          2           
         (0 - 5)   
        (11) 
2.82    
(1.66)  
           3           
 (0 - 5)  
 
.599 
 
 
Language Functioning     (N)  
Mean 
(SD)  
Median  
(Range) 
 
       (30) 
46.37  
(23.13)  
        44.5          
    (4 - 84)  
        (24) 
37.58  
(30.83)  
         34.5       
     (2 - 96)   
         (11) 
43.27  
(33.49)  
          38          
    (3 - 99)  
 
.528 
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Table 12 (continued). 
 
 Illness Characteristics - Comparison of the Three Double-blind, Randomized Studies1   
 
 
   
    ClozHal  OlzHal  OlzQueRis   
Dependent Variables                        pa  
 
Memory Functioning        (N) 
Mean  
(SD)  
Median  
(Range) 
        (30) 
27.5        
(29.8) 
         14        
      (1 - 94)  
         (23) 
19.57   
(18.94) 
          16         
     (1 - 74)   
        (12) 
           0.59    
          (1.10)  
           0.15             
          (0.1-4) 
 
.000*** 
 
 
Motor Functioning           (N) 
Mean  
(SD)  
Median  
(Range) 
 
        (31) 
 26.84  
 (22.07) 
         24           
     (2 - 76)  
         (23) 
          27.7 
         (31.35) 
          16     
          (0.06 - 97)   
         (11) 
45.27 
         (27.94)  
          47         
    (4 - 85) 
 
.161 
 
           
 
 
(N) %    (N) %  (N)   % pb  
 
Visual Attention Functioning      (n = 29)   (n = 18)   (n = 10)  .007**  
  normal                      (11) 37.9%   (1)   5.6%  (6)      60%   
  abnormal                  (18)  62.1%  (17)  94.4%  (4)      40%   
           
Duration of Untreated  
Psychosis                                    (n = 32)   (n = 28)   (n = 16)  .291  
   <13 weeks                        (15)  46.9% (13)  46.4%  (11)  68.8%   
   >13 weeks                        (17 ) 53.1% (15)  53.6%    (5)  31.2%   
  
184
 
  
 
Table 12 (continued).  
 
Illness Characteristics - Comparison of the Three Double-blind, Randomized Studies  
 
                             
        ClozHal              OlzHal                  OlzQueRis            pb  
 Dependent Variables              
                                        
Psychiatric Hospitalizations     (n = 36)   (n = 29)       (n = 15)  .350  
     <1                                             (23)  63.9%  (14)  48.3%  (7)  46.7% .  
     >2                                             (13)  36.1%  (15)  51.7%  (8)  53.3%   
            
  Lifetime Alcohol               (n = 32)   (n = 29)   (n = 15)  .235  
    no use and use             (19)  59.4%  (16)  55.2%    (5) 33.3%   
    abuse and dependence (13)  40.6%  (13) 44.8%  (10)  66.7%   
           
 
  Lifetime Marijuana            (n = 33)   (n = 29)   (n = 15)  .107  
     no use and use            (16)  48.5%  (15)  51.7%    (3)     20%   
     abuse and dependence (17)  51.5%  (14)  48.3%  (12)  80%   
           
Lifetime other drugs      (n = 32)   (n = 29)   (n = 14)  .225  
    no use and us               (30)  93.8%  (27)  93.1%  (11) 78.6%   
    abuse and dependence   (2)    6.2%    (2)    6.9%    (3)  21.4%   
           
1 p values are reported without Bonferroni correction 
a Welch Test  
b Chi Square 
* p < .05  ** p < .01  *** p < .001     
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Table 13. 
 
Treatment Characteristics - Comparison of the Three Double-blind, Randomized Studies1  
 
 
 
                                       
          ClozHal                   OlzHal                  OlzQueRis   
Dependent Variables       
                                     
 
       pa  
Double-Blind (weeks)           (27) 
  14.8  
    (9.1)  
        15    
        (1 - 24)  
(24) 
  14.8  
    (8.9) 
         17        
       (1 - 24)  
(12) 
   19.3 
     (7.1)  
24         
         (6 - 24) 
.189 
 
         
            
    
                          (N) %     (N) %  (N)   % pb  
 
Termination Phase                    (n = 25)   (n = 20)   (n = 9)  .279  
   screening to baseline                   (9) 36%    (5) 25%   (5) 55.6%   
   double-blind              (16) 64%  (15) 75%   (4) 44.4%   
            
Study Completion                  (n = 36)   (n = 29)   (n = 17)  .451  
   No                           (25) 69.4%  (20) 69%   (9) 52.9%   
   Yes                           (11) 30.6%     (9) 31%  (8) 47.1%   
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Table 13 (continued).  
 
Treatment Characteristics - Comparison of the Three Double-blind, Randomized Studies   
 
 
 
     ClozHal     OlzHal              OlzQueRis   
           
Termination Reason2             (n = 25)   (n = 20)   (n = 9)    
Lack of efficacy        (6) 24%  (10) 50%  (1) 11.1% n/a2  
Patient withdrew consent       (6) 24%    (3) 15%  (3) 33.3%   
  Adverse event             (4) 16%    (1)   5%  (1) 11.1%   
  Patient moved             (4) 16%     (1) 11.1%   
Inclusion criteria not met       (2)   8%    (2) 10%      
  Lost to follow-up              (3) 33.3%   
Severity criteria not met        (2)   8%    (1)   5%      
Requires disallowed              
medication                       (2) 10%      
Patient stopped  medication        (1)   5%      
Too psychotic for 
procedures             (1)   4%         
           
 
Termination (collapsed)         (n = 25)   (n = 20)   (n = 9)  .058  
 research design                 (5) 20%     (5) 25%  (0)    
 patient related                  (10) 40%    (4) 20%  (7) 77.8%   
 medication related           (10) 40%  (11) 55%  (2) 22.2%   
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Table 13 (continued). 
 
 Treatment  Characteristics - Comparison of the Three Double-blind, Randomized Studies  
 
 
 
ClozHal OlzHal OlzQueRis   
Dependent Variables                   
     (N) %    (N) %  (N)   % p  
            
Washout (days) 
(ClozHal & OlzHal only)             (n = 30)   (n = 27)     .008**  
         < 3 days            (21) 70%    (9) 33.3%      
         > 4 days              (9) 30%  (18) 66.7%      
            
Randomized Medication              (n = 27)   (n = 24)   (n = 12)  -  
   Typical (n = 22)                         (11) 40.7%  (11) 45.8%    (0)    
   Atypical (n = 41)                       (16) 59.3%  (13) 54.2%  (12) 100%   
            
1 p values are reported without Bonferroni correction 
a Welch  
b Chi Square/Fisher’s Exact        
2  Provided for descriptive purposes only. 
* p < .05  ** p < .01  *** p < .001  
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Appendix J. Question 2 
 
Table 14.  
 
Demographic Characteristics – Comparison of Attrition versus Non-Attrition in Merged 
Group 
 
Table 15. 
 
Illness Characteristics – Comparison of Attrition versus Non-Attrition in Merged Group  
 
Table 16. 
 
Treatment Characteristics – Comparison of Attrition versus Non-Attrition in Merged 
Group   
  
189
 
  
Appendix J. 
 
Table 14.  
 
Demographic Characteristics – Comparison of Attrition versus Non-Attrition in Merged 
Group   
  
      
  Attrition Group                Non-Attrition Group  
Dependent Variables    
                                      
 
      pc      
Age                        (N) 
Mean 
(SD) 
Median 
(Range)
(54)  
     22.96  
       (4.45) 
   22.5 
        (17 – 36)   
(28)  
     22.36  
      (4.55) 
20 
       (18 – 34)   
 
.563 
 
 
Education (years)   (N) 
Mean 
(SD) 
Median 
(Range)
 
(53) 
     12.36  
       (4.45) 
12 
          (6 – 19)   
(28)  
     11.54  
       (2.38) 
12 
          (3 – 16)   
 
.150 
 
         
Employment  
(hours/week)          (N) 
                            Mean 
(SD) 
Median 
                        (Range) 
          (45)  
    18.07  
    (18.41) 
           18 
         (0 – 50)   
(25)  
   19.6  
    (20.1) 
 20 
           (0 – 50)   
 
.748 
 
 
Median Income    (N)   
Mean 
(SD) 
Median 
(range)
             (42) 
     $41,765 
    ($21,499) 
     $39,507 
($11 – 98k)   
              (25) 
$48,275 
     ($13,787) 
$44,260 
    ($27 – 84k)   
 
.136 
 
         
                                      
                                   (N) %  (N) %  pb  
         
Gender                          (n = 54)   (n = 28)   .711  
   Male                          (47)  87%  (26)  92.9%    
   Female                         (7)  13%    (2)  7.1%    
         
Race                              (n = 54)   (n = 28)   .249  
   Non-Caucasian          (23)  42.6%  (16)  57.1%    
   Caucasian                  (31) 57.4%  (12) 42.9%    
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Table 14 (continued).  
 
Demographic Characteristics – Comparison of Attrition versus Non-Attrition in 
Merged Group  
  
                                        
                                      Attrition Group Non-Attrition Group     
Dependent Variables    
                                   (N) % (N) %  pb   
         
School Attendance  (n = 49)  (n = 28)   .809   
   not in school             (29)  59.2% (18)  64.3%     
   in school                    (20)  40.8% (10)  35.7%     
         
Left school                    (n = 45)  (n = 27)   .805   
   no                               (26)  57.8% (17) 63%     
   yes                              (19)  42.2% (10)  37%     
        
Living situation  
(past year) (n = 49)  (n = 28)   .304  
   independent/dorm      (17)  34.7%  (6)  21.4%    
   Family                        (30)  61.2% (19)  67.9%    
   Homeless                     (2)    4.1%   (3)  10.7%    
        
Employment Status 
(past year)                     (n = 50)  (n = 28)   .413  
   not working               (10)  20%   (8)  28.6%    
   working/student         (40) 80% (20)  71.4%    
        
Functional Level 
(past year)                     (n = 54)  (n = 28)   .249  
  no useful       
functioning to 25%         (8)  17%   (8)  30.8%    
   25 to 100%                (39)  83% (18)  69.2%    
        
b Chi Square/Fisher’s Exact   
 c  t-tests
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Table 15.  
 
Illness Characteristics – Comparison of Attrition versus Non-Attrition in Merged 
Group  
 
     
 Attrition Group        Non- Attrition Group         
Dependent Variables                   
                                                         pc 
Age at onset                          (N)
Mean  
(SD) 
Median  
(Range)
(53) 
           22 
      (4.49) 
21 
        (16 – 36) 
(28)  
     21.29  
       (4.35) 
   19.5 
        (16 – 33)   
 
.493
 
 
Severity of illness –             (N)  
Screening                         Mean 
                                          (SD)  
Median  
                                     (Range) 
 
(47)  
      4.72  
      (0.85) 
5 
      (2 – 7) 
(25) 
      4.76  
      (0.72) 
 5 
      (4 – 6)   
 
.856
       
Severity of illness -             (N) 
Baseline                           Mean   
                                          (SD) 
                                      Median   
                                     (Range)   
(43)  
      4.49 
      (0.94) 
 5 
      (2 – 6)  
          (25)  
      4.32  
      (1.07) 
 4 
       (2 – 6)   
 
.500
 
Alcohol                                (N) 
(Age 1st use)                     Mean 
                                   (SD) 
Median 
(Range)
(19)  
    14.58  
      (2.87) 
           16 
         (7 – 19)  
(16) 
     14.44  
       (1.97) 
14 
        (12 – 18)   
 
.869
 
 
 Marijuana                           (N) 
(Age 1st use)                     Mean 
                                   (SD) 
Median 
(Range)
 
(25)  
  15.2  
      (2.22) 
           15 
         (8 – 19)  
(17)  
15  
       (1.87) 
15 
        (12 – 18)   
 
.762
 
Intellectual Functioning      (N) 
Mean 
                                   (SD) 
Median 
(Range)  
 
(29)  
 101.9  
       (9.53) 
         103 
         (77 – 118)  
(27)  
 103.8  
    (12.32) 
         108 
         (70 – 119)   
 
.516
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Table 15 (continued). 
 
 Illness Characteristics – Comparison of Attrition versus Non-Attrition in Merged 
Group  
 
     
    Attrition Group Non-Attrition Group  
 
Dependent Variables                     pc 
 
Executive Functioning -      (N)
Perseverative                    Mean
(SD) 
Median 
(Range) 
        (38)  
         47.06 
        (32.16) 
         42 
          (0.5 – 99.9) 
     (27)  
      53.43 
     (34.79) 
      50 
       (1 – 99.9)  
 
.449 
 
Executive Functioning  -     (N)
Categories                         Mean
 (SD)
  Median
 (Range)
        (37)  
           2.16  
          (1.57) 
           2 
          (0 – 6) 
      (27)  
         2.7  
        (1.6) 
         2 
        (0 – 5)  
 
.183 
 
Language Functioning         (N) 
Mean
(SD)
Median
 (Range)
        (38)  
         43.53  
        (29.27) 
         39.5 
          (2 – 99) 
      (27)  
       41.3   
      (29.19) 
       37 
        (2 – 96)  
 
.753 
 
Memory Functioning           (N)
Mean  
(SD) 
Median  
(Range) 
         
         (38)  
          22.87  
         (26.28) 
          11 
           (0.10 – 81) 
 
      (27)  
       15.34 
      (22.8) 
         4 
        (0.10 – 94)  
 
.234 
 
Motor Functioning               (N)
Mean  
(SD) 
Median  
(Range) 
        
         (37)  
          34.03 
         (29.16) 
          27 
         (0.06 – 97) 
 
      (28)  
       25.3  
      (23.72) 
       17 
        (0.5 – 73)  
 
.198 
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Table 15 (continued). 
 
 Illness Characteristics – Comparison of Attrition versus Non-Attrition in Merged 
Group   
 
 
                                                 Attrition Group  Non-Attrition Group  
Dependent Variables          
 (N)  % (N)  %  pb 
       
Visual Attention  
Functioning              (n = 34)  (n = 23)   .774 
  normal                              (10)  29.4%   (8)  34.8%   
  abnormal                          (24)  70.6% (15)  65.2%   
       
Duration of Untreated  
Psychosis (n = 50)   (n = 26)   .630 
   <13 weeks                       (27)  54%   (12)  46.2%   
   >13 weeks                       (23)  46% (14)  53.8%   
       
Psychiatric  
Hospitalizations                  (n = 52)  (n = 28)   .488 
   <1                                    (27)  51.9% (17)  60.7%   
   >2                                    (25)  48.1% (11)  39.3%   
       
Lifetime Alcohol                (n = 48)  (n = 28)   .479.
   no use and use                 (27)  56.2% (13)  46.4%   
   abuse and dependence     (21)  43.8% (15)  53.6%   
       
Lifetime Marijuana            (n = 49)  (n = 28)   .341 
    no use and use                (24)  49% (10)  35.7%   
    abuse and dependence    (25)  51% (18)  64.3%   
       
Lifetime use of other 
drugs             (n = 47)  (n = 28)   .413 
    no use and use                (44)  93.6% (24)  85.7%   
    abuse and dependence           (3)    6.4%   (4)  14.3%   
       
b Chi Square/Fisher’s Exact  
c  t-test
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Table 16.  
 
Treatment Characteristics – Comparison of Attrition versus Non-Attrition in Merged 
Group   
 
   
 Attrition Group  
Non-Attrition 
Group   
 
Dependent Variables                   (N)  %  (N)  %  pb 
        
Termination Reason2                         - 
   Lack of efficacy        (17) 31.5%      
   Patient withdrew consent         (12) 22.2%      
   Adverse event               (6) 11.1%      
   Patient moved               (5)   9.3%      
   Inclusion criteria not met   (4)   7.4%      
   Lost to follow-up   (3)   5.6%      
   Severity criteria not met        (3)   5.6%      
   Requires disallowed     
   medication   (2)   3.7%      
   Patient stopped medication   (1)   1.9%      
   Too psychotic for procedures   (1)   1.9%      
        
Washout (days) 
(ClozHal & OlzHal only)                 (n = 44)   (n = 28)   .808 
         < 3 days           (28) 63.6%  (17) 60.7%   
         > 4 days           (16) 36.4%  (11) 39.3%   
        
Study Medication         
(ClozHal & OlzHal only)            (n = 31)   (n = 20)   .034* 
  Typical                             (17) 54.8%    (5) 25%   
  Atypical                      (14) 45.2%  (15) 75%   
        
Individual Study Medications (n = 35)   (n = 28)   .125 
Clozapine  (6)  17.1%    (9)  32.1%      
Olanzapine (8) 22.9%     (10) 35.7%   
Seroquel (1)   2.9%  (2)   7.1%   
Risperidone (3)   8.6%  (2)   7.1%   
Haloperidol    (17) 48.6%  (5) 17.9%   
        
 b Chi Square/Fisher’s Exact 
2 Provided for descriptive purposes only 
* p < .05  ** p < .01  *** p < .001       
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Appendix K. Question 3a 
 
Table 17. 
 
ClozHal Study Demographic Characteristics – Comparison of Attrition versus Non-
Attrition Groups 
 
Table 18.  
 
ClozHal Study Illness Characteristics – Comparison of Attrition versus Non-Attrition 
Groups  
 
Table 19. 
 
ClozHal Study Treatment Characteristics – Comparison of Attrition versus Non-Attrition 
Group
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Appendix K. 
 
Table 17.  
 
ClozHal – Demographic Characteristics – Comparison of Attrition versus  
Non-Attrition Groups 
  
     
  Attrition Group Non-Attrition Group  
Dependent Variables       
                                         
 
           pc 
        
Age                            (N) 
Mean
(SD)
Median
(Range)
        (25)  
   23.88  
     (4.45) 
         23 
      (18 - 34)   
(11)  
     20.09  
       (2.21) 
19 
        (18 – 26)   
.002a** 
 
Education (years)      (N) 
Mean
(SD)
Median
(Range)
 
(25)  
    12.68  
      (1.68) 
12 
          (8 – 16)   
(11)  
     10.81  
       (3.38) 
12 
          (3 – 15)   
.030* 
 
Employment 
(hours/week)             (N) 
                               Mean 
(SD)
Median
                           (Range) 
 
(20)  
     15.65 
   (17.4) 
 9 
         (0 – 40)   
(9)  
 15.6  
 (19.4) 
           0 
        (0 – 40)   
 
  .990 
 
Median Income  
   
 
        (22) 
     $48,813  
    ($20.066) 
     $48,617 
    ($11 – 97k)   
 
        (11)  
$51,541  
($17,354) 
$44,260 
   ($29 – 84k)   
 
  .704 
        
 
                                 (N)  %  (N)  %  pb 
Gender                             (n = 25)   (n = 11)   1.0 
   Male                            (21)  84%  (10)  90.9%   
   Female                            (4)  16%    (1)    9.1%   
        
Race                                 (n = 25)   (n = 11)   1.0 
   Non-Caucasian            (12) 48%  (6)  54.5%   
   Caucasian                    (13)  52%  (5)  45.5%   
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Table 17 (continued). 
 
ClozHal Demographic Characteristics - Comparison of Attrition versus  
Non-Attrition Groups 
  
   
    Attrition Group  
     Non-Attrition      
           Group   
 
Dependent Variables    (N)  %  (N)  %  pb 
        
School Attendance  (n = 23)   (n = 11)   .458 
   not in school            (15)  65.2%  (5)  45.5%   
   in school                    (8)  34.8%  (6)  54.5%   
        
Left school                  (n = 20)   (n = 10)     1.0 
   no                               (11)  55%  (5)  50%   
   yes                               (9)  45%  (5)  50%   
        
Living situation 
(past year) (n = 23)   (n = 11)      .084 
   independent/dorm        (9)  39.1%   (1)    9.1%   
   Family                        (12)  52.2%  (10)  90.9%   
   Homeless                     (2)    8.7%    (0)    
        
Employment Status 
(past year)  (n = 23)   (n = 11)     1.0 
   not working                (6)  26.1%        (3)  27.3%   
   working/student         (17)  73.9%  (8)  72.7%   
        
Functional Level 
(past year)                    (n = 22)    (n = 9)     1.0 
   no useful 
functioning to 25%         (6)  27.3%   (3)  27.3%   
  25 to 100%                (16)        72.7%   (6)  66.7%   
        
b Chi Square/Fisher’s Exact        
 c t-test 
* p < .05  ** p < .01  *** p < .001    
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Table 18.   
 
ClozHal - Illness Characteristics - Comparison of Attrition versus Non-Attrition Groups 
 
   
    Attrition Group  
Non-Attrition      
       Group    
 
Dependent Variables    
 
           pc 
         
Age at onset           (N) 
Mean
(SD)
Median
(Range)
(25) 
     22.56  
       (4.32) 
          22 
        (16 – 33)   
(11)  
     18.91  
       (2.21) 
19 
        (16 – 24)    
     .002a**
 
Severity of illness -       
Screening               (N) 
                            Mean 
                             (SD) 
Median
(Range)
 
(23)  
       4.65  
       (0.88) 
  5 
        (2 – 6)   
(11)  
      4.55  
      (0.69) 
 4 
       (4 – 6)    
    .727 
 
Severity of illness -       
Baseline                  (N) 
                            Mean 
                             (SD) 
                         Median 
                        (Range) 
 
(20)  
     4.5  
       (0.94) 
  5 
       (2 – 6)   
(11)  
       4.55  
       (1.13) 
  5 
       (2 - 6)    
    .906 
 
Alcohol                  (N)  
(Age 1st use)       Mean 
                             (SD)
Median
(Range)
 
(8)  
   14.75 
     (2.25) 
 15.5 
      (10 – 17)   
(4)  
 14.0  
     (1.83) 
         14 
       (12 – 16)    
 
   .579 
 
Marijuana               (N) 
 (Age 1st use)      Mean 
                             (SD) 
Median
                        (Range) 
 
(13)  
     15.38  
       (2.53) 
16 
          (8 – 19)   
(6)  
 14.5  
     (1.64) 
         15 
       (12 – 16)    
 
   .448 
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Table 18 (continued). 
 
ClozHal - Illness Characteristics - Comparison of Attrition versus Non-Attrition Groups 
 
 
     
Attrition Group   Non-Attrition Group   
 
Dependent Variables             
 
        pc 
 
Intellectual Functioning  (N) 
    Mean
                                   (SD)
Median
                                 (Range) 
       (19)  
       100.47  
        (10.22) 
       100 
   (77 – 116)  
          (11)  
    97.18  
   (14.06) 
         105 
        (70 – 109) 
 
.465 
 
Executive Functioning -  (N) 
Perseverative               Mean 
                                   (SD)
Median
                                 (Range) 
                         
 
       (20) 
        48.76  
       (34.73) 
        48 
         (0.5 – 99.9) 
  
 
         (11)  
          50.79   
         (36.83) 
          42 
           (4 – 99.9) 
 
.880 
 
Executive Functioning -  (N) 
Categories                    Mean 
                                   (SD)
Median
                                 (Range) 
 
       (20)  
          2.2  
         (1.64) 
          2 
         (0 – 6) 
(11)  
      2.27  
      (1.49) 
 2 
       (1 – 5) 
 
.904 
    
Language Functioning    (N) 
    Mean
                                   (SD)
Median
                                 (Range) 
       (20)  
        48.8  
       (24.0) 
        50.5 
       (12 – 84) 
(10)  
   41.5  
     (21.63) 
42 
          (4 – 80) 
.425 
 
Memory Functioning      (N) 
    Mean
                                   (SD)
Median
                                 (Range) 
       (19)  
        27.79            
       (30.31) 
        16 
  (1 – 81) 
(11)  
     27.09   
     (30.49) 
            12 
          (1 – 94)  
 
.952 
 
Motor Functioning          (N) 
    Mean
                                   (SD)
Median
                                 (Range) 
 
       (20)  
        28.35  
       (20.86) 
        24 
  (2 – 76) 
(11)  
   24.1   
     (24.93) 
14 
          (2 – 73)  
 
.616 
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Table 18 (continued).  
 
ClozHal  - Illness Characteristics – Comparison of Attrition versus Non-Attrition Groups 
 
       
     Attrition Group                  Non-Attrition Group  
 Dependent Variables   
                                      (N)  %  (N)  %      pb  
          
Visual Attention 
Functioning                   (n = 19)   (n = 10)   1.0  
   normal                          (7)  36.8%   (4)  40%    
   abnormal                    (12) 63.2%   (6)  60%    
          
Duration of untreated 
Psychosis                      (n = 23)   (n = 9)   1.0   
   <13 weeks                  (11) 47.8%  (4) 44.4%     
   >13 weeks                      (12) 52.2%  (5) 55.6%     
          
Psychiatric 
Hospitalizations  (n = 25)   (n = 11)   .137   
   <1 (14) 56%  (9) 81.8%     
   >2                               (11) 44%        (2) 18.2%     
          
Lifetime Alcohol          (n = 21)   (n = 11)   1.0  
   no use and use           (12)  57.1%  (7)  63.6%    
   abuse and    
   dependence    
  (9)  43.8%  (4)  36.4% 
   
         
Lifetime Marijuana       (n = 22)   (n = 11)   .141  
   no use and use           (13)  59.1%  (3)  27.3%    
   abuse and      
   dependence   
  (9)  40.9%  (8)  72.7% 
   
         
Lifetime Other Drugs   (n = 21)   (n = 11)   .631  
   no use and use           (20)  95.2%  (10)  90.9%    
   abuse and     
   dependence     
      (1)    4.8%    (1)    9.1% 
   
         
b Chi Square/Fisher’s Exact 
c t-test 
* p < .05  ** p < .01  *** p < .001     
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Table 19.  
 
ClozHal - Treatment Characteristics - Comparison of Attrition versus Non-Attrition 
Groups 
 
 
 
Attrition Group  
Non-Attrition 
Group   
 
Dependent Variables                   (N)     (%)  (N)  (%)  pb 
        
Termination Reason2                          - 
   Lack of efficacy        (6) 24%      
   Patient withdrew Consent        (6) 24%      
   Adverse event             (4) 16%      
   Patient moved             (4) 16%      
   Severity criteria not met      (2)   8%      
   Inclusion criteria not met (2)   8%      
   Too psychotic for procedures (1)   4%      
        
Termination (collapsed)2                  - 
  Patient related (10) 40%           
  Medication related (10) 40%      
  Research design   (5) 20%      
        
Washout (days)    (n = 19)   (n = 11)   .225 
   < 3 days                            (15) 78.9%  (6) 54.5%   
   > 4 days                              (4) 21.1%  (5) 45.5%   
        
Study Medication                        (n = 16)   (n = 11)   .109 
   Typical (Haldol)    (9) 56.2%  (2)    18.2%   
   Atypical  (Clozapine)               (7)  43.8%  (9)  81.8%   
  
 
         
2 provided for descriptive purposes only  
b Chi Square/Fisher’s Exact 
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Appendix L. Question 3a 
 
 
Table 20. 
 
OlzHal - Demographic Characteristics – Comparison of Attrition versus Non-Attrition 
Groups 
 
 
Table 21.  
 
OlzHal - Illness Characteristics – Comparison of Attrition versus Non-Attrition Groups  
 
 
Table 22. 
 
OlzHal - Treatment Characteristics – Comparison of Attrition versus Non-Attrition Groups   
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Appendix L. 
 
Table 20.  
 
OlzHal - Demographic Characteristics – Comparison of Attrition versus Non-Attrition 
Groups 
  
      
     Attrition Group Non-Attrition Group  
 
Dependent Variables                pc  
        
Age                               (N) 
Mean
(SD)
Median
(Range)
(20)  
   22.3  
       (3.88) 
           23 
       (17 – 30)   
(9)  
   25.44 
     (5.88) 
         26 
      (19 – 34)  
.170 
 
 
Education (years)         (N) 
Mean
(SD)
Median
                              (Range) 
 
(20)  
   12.9  
       (2.75) 
           12 
         (8 – 19)   
(9)  
   11.55  
     (1.01) 
         12 
      (10 – 13)  
  
.066 
 
 
Employment                 (N) 
(hours/week)             Mean 
(SD)
Median
                              (Range) 
 
(20)  
   20.5  
    (18.42) 
           25 
         (0 – 40)   
(9)  
         30  
   (18.71) 
         40 
        (0 – 50)  
 
.212 
 
 
Median Income  
 
           (11)  
        $31,613  
       ($13,596) 
        $29,072 
       ($11 – 52k)   
                
               (6)  
     $45,066  
    ($12,718) 
     $43,751 
    ($27 – 66k)  
 
.065 
 
        
 
                                            (N)     %  (N)     % pb  
        
Gender                                (n = 20)   (n = 9)  1.0  
   Male                                 (18)  90%         (8)  88.9%   
   Female                               (2)  10%         (1)  11.1%   
        
Race                                    (n = 20)   (n = 9)       .422  
   Non-Caucasian                  (7)  35%  (5)  55.6%   
   Caucasian                         (13)  65%  (4)  44.4%   
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Table 20 (continued).  
 
OlzHal - Demographic Characteristics – Comparison of Attrition versus Non-Attrition 
Groups  
  
 
          Attrition Group   Non-Attrition Group  
Dependent 
Variables                    (N)     % (N)     %  pb 
       
School Attendance    (n = 20)  (n = 9)    .005 
   not in school             (9)  45% (9) 100%   
   in school                 (11) 55% (0)     
       
Left School  (n = 18)  (n = 9)   .026* 
   no                            (10)  55.6% (9)  100%   
   yes                            (8)  44.4% (0)    
       
Living situation 
(past year)                  (n = 20)  (n = 9)   .017* 
   independent/dorm     (6)  30% (3)  33.3%   
   Family                     (14)  70% (3)  33.3%   
   Homeless                  (0)  (3)  33.3%   
       
Employment Status 
(past year)                  (n = 20)  (n = 9)    .089 
   not working              (0)   (2)  22.2%   
   working/student      (20)  100%  (7)  77.8%   
       
Functional Level 
(past year)                  (n = 20)  (n = 9)   .089 
   no useful 
functioning to 25%      (0)   (2)  22.2%   
   25 to 100%             (20) 100%  (7)  77.8%   
       
b Chi Square/Fisher’s Exact     
c t-tests           
* p < .05  ** p < .01  *** p < .001     
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Table 21.   
 
OlzHal - Illness Characteristics – Comparison of Attrition versus Non-Attrition Groups 
 
 
          
    Attrition 
Group  
Non-Attrition 
Group   
                                       
Dependent Variables                     pc 
       
Age at onset                       (N) 
                                       Mean 
                                         (SD) 
                                     Median
                                    (Range) 
(19)  
   21.5  
      (4.17) 
20 
       (16 – 30)  
(9) 
   23.89  
     (5.51) 
         22 
     (18 – 33)   
.218 
 
Severity of illness -            (N) 
Screening                        Mean 
                                         (SD) 
                                    Median 
                                    (Range) 
 
(18)  
    4.6 
          (0.70) 
   4.5 
     (4 - 6)  
(6)  
   4.3 
     (0.52) 
4 
      (4 – 5)   
 
.382 
       
Severity of illness -            (N) 
Baseline                          Mean 
                                         (SD) 
                                     Median 
                                    (Range) 
(17)  
      4.35  
      (1.06) 
4 
      (2 – 6)  
        (6)  
4.5  
  (0.84) 
         4 
   (4 – 6)   
.762 
 
 
Alcohol                               (N)
(Age 1st use)                   Mean 
                                         (SD) 
                                     Median 
                                    (Range) 
(8)  
   14.88  
     (3.72) 
         16 
        (7 – 19)  
(4)  
         14  
     (1.83) 
         14 
       (12 – 16)   
.671 
 
 
Marijuana                           (N) 
(Age 1st use)                   Mean 
                                         (SD) 
                                     Median 
                                    (Range) 
(8)  
 15.5  
     (1.85) 
         15 
      (14 – 19)  
        (3)  
15.67  
  (2.31) 
       17 
      (13 – 17)   
 
.903 
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Table 21 (continued). 
 
OlzHal - Illness Characteristics – Comparison of Attrition versus Non-Attrition Groups  
 
 
          
 Attrition 
Group 
  Non-Attrition     
       Group    
                                       
Dependent Variables                       pc 
 
Intellectual  Functioning       (N)
                                           Mean 
                                           (SD)
                                       Median
                                       (Range) 
        (7)  
     106.14  
        (6.2) 
     104 
    (100 – 118) 
         (8)  
      107.0  
         (9.38) 
      109.5 
   (92 – 116)   
 
.841 
 
Executive Functioning -        (N)
Perseverative                     Mean 
                                            (SD)
                                        Median
                                       (Range) 
      (15)  
       45.67  
      (30.16) 
       34 
   (1 – 98) 
        (8)  
       64.11  
      (39.33) 
       80 
        (4 – 99.9)   
 
.222 
      
Executive Functioning -        (N)
Categories                          Mean
                                            (SD)
                                        Median
                                       (Range)
      (14)  
         2.0  
        (1.47) 
         2 
        (0 – 4) 
         (8)  
          3.12  
         (1.81) 
          3 
         (1 – 5)   
.127 
 
Language Functioning          (N)
                                           Mean 
                                            (SD)
                                        Median
                                       (Range) 
 
      (14) 
       34.3 
      (36.43) 
       29 
   (2 – 96) 
 
         (9) 
        17.33  
       (18.67) 
        37 
         (2 – 94) 
   
.743 
 
Memory Functioning            (N)
                                           Mean 
                                            (SD) 
                                        Median
                                       (Range)
      (15)  
        22.6            
       (21.63) 
        16 
         (1 – 74) 
        (8) 
        13.88  
       (11.63) 
        13.5 
    (2 – 31)   
 
.304 
 
Motor Functioning                (N)
                                           Mean 
                                            (SD)
                                        Median
                                       (Range)
 
      (14)  
       34.3  
      (36.43) 
       27 
       (0.06 – 97) 
 
 
        (9)  
       17.33  
      (18.67) 
       10 
     (0.5 – 58) 
 
 
  
.157  
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Table 21 (continued).  
 
OlzHal - Illness Characteristics -  Comparison of Attrition versus Non-Attrition Groups 
 
 
 
Attrition Group 
Non-Attrition 
Group   
       
 Dependent Variables      (N)     % (N)     %  pb 
       
Visual Attention 
Functioning         (n = 11)  (n = 7)   1.0 
   normal                             (1)    9.1%  (0)     
   abnormal                       (10)  90.9%  (7)  100%   
       
Duration of Untreated 
Psychosis                         (n = 19)   (n = 9)   .435 
   <13 weeks                     (10)  52.6%   (3) 33.3%   
   >13 weeks                       (9)  47.2%   (6)  66.7%   
       
Psychiatric 
Hospitalizations  (n = 20)  (n = 9)   .427 
   <1                                  (11)  55% (3)  33.3%   
   >2                                    (9)  45% (6)  66.7%   
       
Lifetime Alcohol             (n = 20)  (n = 9)   .688 
 no use and use                (12)  60% (4)  44.4%   
 abuse and dependence      (8)  40% (5)  55.6%   
       
Lifetime Marijuana          (n = 20)  (n = 9)   1.0 
  no use and use               (10)  50% (5)  55.6%   
  abuse and dependence   (10)  50% (4)  44.4%    
        
Lifetime Other Drugs      (n = 20)  (n = 9)   .532  
  no use and use               (19)  95% (8)  88.9%    
  abuse and dependence     (1)    5% (1)  11.1%    
        
b Chi Square/Fisher’s Exact 
c  t-tests 
d Mann Whitney 
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Table 22.  
 
OlzHal - Treatment Characteristics – Comparison of Attrition versus Non-Attrition 
groups 
  
 
 
Attrition Group  
Non-Attrition 
Group    
 
Dependent Variables             (N)     %  (N)    %  pb  
         
Termination Reason2                   -  
Lack of efficacy        (10) 50%       
Patient withdrew Consent        (3) 15%       
Adverse event               (1)   5%       
Inclusion criteria not met   (2) 10%       
Requires disallowed 
medication   (2) 10%       
Patient stopped medication   (1)   5%       
Severity criteria not met   (1)   5%       
         
Termination2        -  
Patient related   (4) 20%       
Medication related (11) 55%       
  Research design   (5) 25%       
         
Washout (days) (n = 18)   (n = 9)     
   < 3 days                                (6) 33.3%  (3) 33.3%    1.0  
 > 4 days                             (12) 66.7%  (6) 66.7%    
         
Study Medication                  (n = 14)   (n = 9)   .400  
   Typical (Haldol)        (8) 53.3%  (3)     33.3%    
   Atypical (Olanzapine)        (7)  46.7%  (6)  66.7%    
         
2 provided for descriptive purposes only;  
b Chi Square/Fisher’s Exact 
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Appendix M. Question 3a 
 
 
Table 23.  
 
OlzQueRis  - Demographic Characteristics – Comparison of Attrition versus Non-Attrition 
Groups   
  
 
Table 24.  
 
OlzQueRis  - Illness Characteristics - Comparison of the Attrition versus Non-Attrition 
Groups   
 
 
Table 25.  
 
OlzQueRis  - Treatment Characteristics - Comparison of the Attrition versus Non-Attrition 
Groups   
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Appendix M 
 
Table 23.  
 
OlzQueRis  -Demographic Characteristics – Comparison of Attrition versus Non-
Attrition Groups   
  
 
 
  Attrition Group Non-Attrition Group    
 
Dependent Variables              pc   
        
Age                               (N) 
                                  Mean 
                                   (SD) 
                               Median 
                              (Range) 
(9) 
   21.89  
    (5.56) 
       20 
    (18 – 36)  
(8) 
         22  
      (3.59) 
  21.5 
       (18 – 27)  
.962 
  
 
Education (years)         (N) 
                                 Mean 
                                   (SD) 
                               Median 
                              (Range) 
(8) 
       10  
    (2.56) 
       12 
       (6 – 13)  
(8)  
         12.5  
     (1.85) 
         12 
      (10 – 16)  
 
.051* 
  
 
Employment                 (N) 
(hours/week)             Mean 
                                   (SD) 
                              Median 
                              (Range) 
(5)  
       18  
(24.9) 
         0 
       (0 – 50)  
(7)  
   11.43  
 (19.5) 
0 
        (0 – 40)  
 
.618 
  
 
Median Income            (N) 
                                 Mean 
                                   (SD) 
                               Median 
                              (Range) 
 
        (9)  
  $36,944  
 ($27,663) 
  $35,874 
 ($11 – 98k)  
         (8)  
     $46,190  
      ($8,680) 
     $43,751 
    ($35 – 59k)  
 
.380 
  
        
 
                                           (N)     % (N)     % pc   
        
Gender                               (n = 9)  (n = 8)  1.0   
   Male                      (8)  88.9% (8)  100%    
   Female                       (1)  11.1% (0)     
        
Race                                    (n = 9)  (n = 8)  .637   
   Non-Caucasian        (4)  44.4% (5)  62.5%    
   Caucasian                (5)  55.6% (3)  37.5%    
 .        
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Table 23 (continued). 
 
OlzQueRis  - Demographic Characteristics – Comparison of the Attrition versus 
Non-Attrition Groups  
 
 
 
Attrition Group Non-Attrition Group    
 
Dependent 
Variables                    (N)     % (N)     %  pc 
       
School Attendance  (n = 6)  (n = 8)   .301 
   not in school           (5) 83.3% (4)  50%   
   in school                 (1)  16.7% (4)  50%   
       
Left School  (n = 7)  (n = 8)   .315 
   no                            (5)  71.4% (3)  37.5%   
   yes                          (2)  28.6% (5)  62.5%   
        
Living Situation 
(past year) (n = 6)  (n = 8)   1.0  
   independent/dorm   (2)  33.3% (2)  25%    
   Family                   (4)  66.7% (6)  75%    
   Homeless                     (0)  (0)     
        
Employment Status 
(past year)  (n = 7)  (n = 8)   .619  
   not working            (4)  57.1%  (3)  37.5%    
   working/student      (3)  42.9%  (5)  62.5%    
        
Functional Level 
(past year)                  (n = 5)  (n = 8)   1.0  
   no useful 
functioning to 25%          (2)  40%  (3) 37.5%    
   25 to 100%             (3)  60%  (5)  62.5%    
        
b Chi Square/Fisher’s Exact 
  
212
 
  
Table 24.  
 
OlzQueRis  -  Illness Characteristics - Comparison of the Attrition versus  
Non-Attrition Groups   
  
 
 
     Attrition 
Group 
Non-Attrition 
Group   
 
Dependent Variables                  pd 
 
Age at onset                       (N) 
Mean
(SD)
  Median
                                    (Range) 
(9)  
   21.44  
     (5.81) 
          19 
      (17 – 36) 
(8)  
   21.63  
        (3.7) 
       20.5 
     (18 – 27) 
 
 
 
.941 
 
Severity of illness -            (N) 
Screening                        Mean 
  (SD)
Median
                                    (Range) 
(6)  
     5.33  
         (1.03) 
          5 
     (4 – 7) 
(8)  
     5.38 
     (0.52) 
5 
      (5 – 6)  
 
.922 
     
Severity of illness -            (N) 
Baseline                          Mean 
 (SD)
   Median
                                    (Range) 
(6)  
     4.83  
     (0.41) 
5 
     (4 – 5) 
(8)  
     3.88   
     (1.13) 
4 
      (2 – 5)  
.053*  
      
Alcohol                               (N)
(Age 1st use)                   Mean 
(SD)
Median
                                    (Range) 
         (3)  
        13.33  
         (2.31) 
        12 
     (12 – 16) 
(8)  
   14.88  
     (2.23) 
       14 
     (12 – 18)  
.338  
      
Marijuana                           (N) 
(Age 1st use)                   Mean 
(SD)
Median
                                    (Range) 
(4)  
         14  
     (1.83) 
         14 
      (12 – 16) 
(8)  
   15.12 
     (2.03) 
       14.5 
     (13 – 18)  
.373  
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Table 24 (continued).  
 
OlzQueRis - Illness Characteristics – Comparison of the Attrition versus Non-Attrition 
Groups 
 
 
 
     Attrition Group  
 Non-Attrition 
Group   
 
Dependent Variables                
 
    
 
 pd 
       
Intellectual Functioning     (N) 
 Mean
(SD)
Median
                                    (Range) 
(3)  
        101  
  (11.53) 
          97 
       (92 – 114) 
         (8)  
      109.75 
         (8.51) 
      111.5 
      (92 – 119)   
.197 
 
Executive Functioning -    (N)  
Perseverative                  Mean 
(SD)
Median
                                    (Range) 
          (3)  
         42.67  
        (35.23) 
         32 
    (14 – 82)  
         (8)  
  46.38  
       (28.5) 
        54 
       (1 – 79)   
 
.860 
       
Executive Functioning -     (N) 
Categories                       Mean 
(SD)
Median
                                    (Range) 
          (3)  
   2.67  
          (2.08) 
           2 
   (1 - 5) 
 (8) 
     2.88  
     (1.64) 
3 
      (0 – 5)   
.864 
       
Language Functioning       (N) 
 Mean
(SD)
Median
                                    (Range) 
          (3)  
         46.33  
        (46.49) 
         29 
    (11 – 99) 
 (8)  
   42.13 
   (31.29) 
         42.5 
        (3 – 96)   
.864 
       
Memory Functioning         (N) 
 Mean
(SD)
Median
                                    (Range) 
          (4)  
           0.50   
          (0.29) 
           0.55 
          (0.1 - 0.8)  
(8)  
     0.64   
     (1.36) 
   0.1 
         (0.1 – 4)   
.849 
 
Motor Functioning             (N) 
 Mean
(SD)
Median
                                    (Range) 
  
          (3)  
         70.67  
        (14.5) 
         71 
    (56 – 85) 
  
         (8)  
  35.75  
       (25.98) 
        25.5 
      (4 – 73)   
 
.059 
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Table 24 (continued).  
 
OlzQueRis  - Illness Characteristics - Comparison of the Attrition versus  
Non-Attrition Groups 
  
 
 
Attrition Group  Non-Attrition Group   
Dependent Variables    
 (N)     % (N)     %  pb 
       
Visual Attention 
Functioning                  (n = 4)  (n = 6)   1.000 
   normal                        (2)  50%  (4) 66.7%   
   abnormal                    (2)  50%  (2)  33.3%   
       
Duration of untreated 
Psychosis                      (n = 8)   (n = 8)   1.0 
   <13 weeks                  (6)  75%   (5)  62.5%   
   >13 weeks                  (2)  25%   (3)  37.5%   
       
Psychiatric 
Hospitalizations  (n = 7)  (n = 8)   .189 
   0, 1                             (2)  28.6%  (5)  62.5%   
   2+                               (5)  71.4%  (3)  37.5%   
       
Lifetime Alcohol          (n = 7)  (n = 8)   .608 
 no use and use             (3)  42.9% (2)  25%   
 abuse and 
dependence      (4)  57.1% (6)  75%   
       
Lifetime Marijuana       (n = 7)  (n = 8)   1.0 
 no use and use             (1) 14.3% (2)  25%   
 abuse and    
 dependence        (6)  87.5% (6)  75%    
        
Lifetime Other Drugs   (n = 6)  (n = 8)   1.0  
 no use and use             (5)  83.3% (6)  75%    
 abuse and    
 dependence    (1) 16.7%       (2) 25%    
        
b Chi Square/Fisher’s Exact 
d Mann Whitney U 
* p < .05  ** p < .01  *** p < .001     
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Table 25.  
 
OlzQueRis  - Treatment Characteristics - Comparison of the Attrition versus  
Non-Attrition Groups   
 
 
 Attrition Group  
Non-Attrition 
Group   
 
Dependent Variables             (N) %  (N) %  pb 
        
Termination Reason2        
   Lack of efficacy        (1) 11.1%      
   Patient withdrew Consent  (3) 33.3%      
   Adverse event             (1) 11.1%      
   Patient moved             (1) 11.1%      
   Lost to follow-up        (3) 33.3%      
        
Termination2        
  Patient related (7) 77.8%      
  Medication related (2) 22.2%      
        
Washout (days)             
none        
        
Study Medication2        
 olanzapine (0)   (4) 50%   
 quetiapine                            (1) 25%  (2) 25%   
 risperidone (3) 75%  (2) 25%   
        
        
b Chi Square/Fisher’s Exact 
2 Provided for descriptive purposes only
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